1 | ( L ) ASCORBATO DI CALCIO | 1件: Calcium Calcium | - | - | - | 2件: 96 96, 97 💬 |
2 | (-)-trans-delta-9-Tetrahydrocannabinol | 1件: Dronabinol Dronabinol | 1件: Dronabinol
Dronabinol
💬 | 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 13 13 💬 |
3 | (1-3)-beta-D-Glucan (BDG) assay (Fungitell) | - | - | - | - | 1件: 107 107 💬 |
4 | (1-3)-ß-D-Glucan (BDG) assay (Fungitell) | - | - | - | - | 1件: 107 107 💬 |
5 | (1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide | - | - | - | - | 1件: 11 11 💬 |
6 | (2-chloro-5-[11C]methoxy-N-(((3s,5s,7s)-3,5,7-trifluoroadamantan-1-yl)methyl) benzamide) | - | - | - | - | 1件: 6 6 💬 |
7 | (3R,4R)-4-methyl-3-(methyl-1H-pyrrolo [2,3-d]pyrimidin-4-ylamino)-beta-oxo-1- | - | - | - | - | 1件: 46 46 💬 |
8 | (3R,4R)-4-methyl-3-(methyl-1H-pyrrolo [2,3-d]pyrimidin-4-ylamino)-beta-oxo-1-piperidinepropanenitrile, | - | - | - | - | 1件: 46 46 💬 |
9 | (3R,4R)-4-methyl-3-(methyl-1H-pyrrolo [2,3-d]pyrimidin-4-ylamino)-ß-oxo-1- | - | - | - | - | 1件: 46 46 💬 |
10 | (3R,4R)-4-methyl-3-(methyl-1H-pyrrolo [2,3-d]pyrimidin-4-ylamino)-ß-oxo-1-piperidinepropanenitrile, | - | - | - | - | 1件: 46 46 💬 |
11 | (3R,4R)-4-metil-3-(metil-1H-pirrolo [2,3-d]pirimidin-4-ilamino)-beta-oxo-1- | - | - | - | - | 1件: 46 46 💬 |
12 | (3R,4R)-4-metil-3-(metil-1H-pirrolo [2,3-d]pirimidin-4-ilamino)-ß-oxo-1- | - | - | - | - | 1件: 46 46 💬 |
13 | (4S)-4-[4-cyano-2-(methylsulfonyl)phenyl]-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carbonitrile | - | - | - | - | 1件: 231 231 💬 |
14 | (6R)-4, 5, 6, 7 - tetrahydro-N6-propyl-2,6-benzothiazolidiamine dihydrochloride monohydrate | - | - | - | - | 1件: 2 2 💬 |
15 | (6S)-6-{propyl-[2-[2-thienyl]ethyl]amino}-5,6,7,8-tetrahydro-1-naphtalenol | - | - | - | - | 1件: 6 6 💬 |
16 | (7R,8R,9R)-2.3-Dimethyl-8-hydroxy-7(2-methoxyethoxy)- 9-phenyl-7.8.9.10-tetrahydro-imidazo-[1.2-h].[1.7].- naphthyridine | - | - | - | - | 1件: 301 301 💬 |
17 | (minus)-L-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid monohydrate | - | - | - | - | 1件: 6 6 💬 |
18 | (R) 3-(5-Dimethylcarbamoyl-pent-1-enyl)-N-(2-hydroxy-1- methylethyl) benzamide | - | - | - | - | 1件: 13 13 💬 |
19 | (R)-3-(1-oxo-propoxy)-4-(N,N,N-trimethyl amonium chloride)-butanoic acid | 2件: Butyric Acid Butyric Acid, Chloride ion | - | - | - | 1件: 97 97 💬 |
20 | (R)-[N-metil-11C1-PK11195(PK) | - | - | - | - | 1件: 127 127 💬 |
21 | (R)-N-(5-(5-ETHYL-1,2,4-OXADIAZOL-3-YL)-2,3-DIHYDRO-1H-INDEN-1-YL)-1-METHYL-1H-PYRAZOLE-4-CARBOXAMIDE | 1件: Pyrazole Pyrazole | - | - | - | 1件: 58 58 💬 |
22 | (R)-N-(5-(5-ETHYL-1,2,4-OXADIAZOL-3-YL)-2,3-DIHYDRO-1H-INDEN-1-YL)-1METHYL-1H-PYRAZOLE-4-CARBOXAMIDE | 1件: Pyrazole Pyrazole | - | - | - | 1件: 58 58 💬 |
23 | (R)-N-(5-(5-ETHYL-1,2,4-OXADIAZOL-3-YL)-2,3-DIHYDRO-1H-INDEN-1-YL)-1METHYL-1HPYRAZOLE-4-CARBOXAMIDE | - | - | - | - | 1件: 58 58 💬 |
24 | (RS)-baclofen, naltrexone hydrochloride and D-sorbitol | 3件: Baclofen Baclofen, Naltrexone, Sorbitol | 3件: Sorbitol solution
Sorbitol solution
,
Baclofen
,
Naltrexone
💬 | 5件: GABBR1 GABBR1, GABBR2, OPRD1, OPRK1, OPRM1 💬 | 9件: Estrogen signaling pathway Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, Taste transduction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 10 10 💬 |
25 | (S)-2-(4,6-dimethylpyrimidin-2-yloxy)-3-methoxy-3,3-diphenylpropanoic acid | - | - | - | - | 1件: 86 86 💬 |
26 | (S)-2-amino-6-(2-hydroxypropanoyl)-7,8-dihydropteridin-4(3H)-one | - | - | - | - | 1件: 240 240 💬 |
27 | (S)-3-((3-(1-((6-(3,4-DIMETHOXYPHENYL)PRYAZIN-2- YL)AMINO)ETHYL)PHENYL)CARBAMOYL)-5-METHYLPRIDIN-1-IUM | - | - | - | - | 1件: 86 86 💬 |
28 | (S)-3-((3-(1-((6-(3,4-DIMETHOXYPHENYL)PRYAZIN-2-YL)AMINO)ETHYL)PHENYL)CARBAMOYL)-5-METHYLPRIDIN-1-IUM | - | - | - | - | 1件: 86 86 💬 |
29 | (S)-4,5-dihydro-2-[2-hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-methyl-4-thiazo | - | - | - | - | 1件: 284 284 💬 |
30 | (S)-4,5-dihydro-2-[2-hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-methyl-4-thiazolecarboxylate magnesium hydroxide | 3件: Hydroxide ion Hydroxide ion, Magnesium, Magnesium hydroxide | 1件: Magnesium hydroxide
Magnesium hydroxide
💬 | - | - | 1件: 284 284 💬 |
31 | (S)-4,5-dihydro-2[hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-m | - | - | - | - | 1件: 284 284 💬 |
32 | (S)-4,5-dihydro-2[hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-methyl-4-thiazolecarboxylate magnesium hydroxide | 3件: Hydroxide ion Hydroxide ion, Magnesium, Magnesium hydroxide | 1件: Magnesium hydroxide
Magnesium hydroxide
💬 | - | - | 1件: 284 284 💬 |
33 | (S)-5-(3-(1-((2-hydroxyethyl)amino)-2,3-dihydro-1H-inden-4-yl)-1,2,4-oxadiazol-5- yl)-2-isopropoxybenzonitrile hydrochloride | - | - | - | - | 1件: 97 97 💬 |
34 | (S)-5-(3-(1-((2-hydroxyethyl)amino)-2,3-dihydro-1H-inden-4-yl)-1,2,4-oxadiazol-5-yl)-2-isopropoxyben | - | - | - | - | 1件: 97 97 💬 |
35 | (S)-5-(3-(1-((2-hydroxyethyl)amino)-2,3-dihydro-1H-inden-4-yl)-1,2,4-oxadiazol-5-yl)-2-isopropoxybenzonitrile hydrochloride | - | - | - | - | 1件: 97 97 💬 |
36 | * D.3.4 Solution for infusion in pre-filled syringe | - | - | - | - | 1件: 97 97 💬 |
37 | * D.3.4 Solution for injection in pre-filled syringe | - | - | - | - | 1件: 97 97 💬 |
38 | * D.3.4 Solution for injection/infusion in pre-filled syringe | - | - | - | - | 1件: 97 97 💬 |
39 | * D.3.6.2.1 - valore : Every 4 weeks dosing of 200 mg | - | - | - | - | 1件: 41 41 💬 |
40 | * D.3.6.2.1 - valore :Every 4 weeks dosing of 400 mg | - | - | - | - | 1件: 41 41 💬 |
41 | **Comment**- IMP inhalation solution identical to ventavis inhalation solution, but IMP is in a different volume presentation. Please see covering letter. | 1件: Iloprost Iloprost | 1件: Iloprost
Iloprost
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 💬 |
42 | .Nusinersen | 1件: Nusinersen Nusinersen | 1件: Nusinersen
Nusinersen
💬 | 1件: SMN2 SMN2 💬 | - | 1件: 3 3 💬 |
43 | 0.05%cyclosporin eye drop | 1件: Cyclosporine Cyclosporine | 1件: Cyclosporine
Cyclosporine
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 38 38 💬 |
44 | 0.15mg KPG-818 dose | - | - | - | - | 1件: 49 49 💬 |
45 | 0.6mg KPG-818 dose | - | - | - | - | 1件: 49 49 💬 |
46 | 0.9% normal saline (control) | - | - | - | - | 1件: 299 299 💬 |
47 | 0.9% sodium chloride (normal saline) | 2件: Chloride ion Chloride ion, Sodium chloride | 1件: Sodium chloride
Sodium chloride
💬 | - | - | 1件: 6 6 💬 |
48 | 1 mg QD to 7 mg QD PF-06649751 (if de-escalated in parent study) | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
49 | 1 ml 0.9 % NaCl | - | - | - | - | 1件: 46 46 💬 |
50 | 1,2-Dihexadecanoyl-sn-Glycero-3-Phospho-(1-raac-glycerol) | 1件: Glycerin Glycerin | 1件: Glycerin
Glycerin
💬 | - | - | 1件: 79 79 💬 |
51 | 1,5 (Butylimino)-1,5-dideoxy-D-glucitol | 1件: Sorbitol Sorbitol | 1件: Sorbitol solution
Sorbitol solution
💬 | - | - | 1件: 299 299 💬 |
52 | 1,5-anhydro-2,3-dideoxy-3-[[(1R,3S)-3-[[7,8-dihydro-3- (trifluoromethyl)-1,6-naphthyridin-6(5H)-yl]c | - | - | - | - | 1件: 46 46 💬 |
53 | 1- Deoxygalactonojirimycin | - | - | - | - | 1件: 19 19 💬 |
54 | 1-(2,3,4-Trimethoxybenzyl)piperazine dihydrochloride | 1件: Piperazine Piperazine | 1件: Piperazine
Piperazine
💬 | - | - | 1件: 58 58 💬 |
55 | 1-(2-Isopropoxyethyl)-2-thioxo-1,2,3,5-tetrahydro-pyrrolo[3,2-d] pyrimidin-4-one | - | - | - | - | 1件: 17 17 💬 |
56 | 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-[1-piperazinyl]-3-quinoline carboxylic acid | - | - | - | - | 1件: 299 299 💬 |
57 | 1-Deoxygalactonojirimycin | 1件: Migalastat Migalastat | 1件: Migalastat
Migalastat
💬 | - | - | 1件: 19 19 💬 |
58 | 1-deoxygalactonojirimycin hydrochloride | 1件: Migalastat Migalastat | 1件: Migalastat
Migalastat
💬 | - | - | 1件: 19 19 💬 |
59 | 1-deoxynojirimycin | 1件: Duvoglustat Duvoglustat | 1件: Duvoglustat
Duvoglustat
💬 | 1件: GAA GAA 💬 | 4件: Galactose metabolism Galactose metabolism, Lysosome, Metabolic pathways, Starch and sucrose metabolism 💬 | 1件: 256 256 💬 |
60 | 1-deoxynojirimycin hydrochloride | 1件: Duvoglustat Duvoglustat | 1件: Duvoglustat
Duvoglustat
💬 | 1件: GAA GAA 💬 | 4件: Galactose metabolism Galactose metabolism, Lysosome, Metabolic pathways, Starch and sucrose metabolism 💬 | 1件: 256 256 💬 |
61 | 1. Tesofensine (NS 2330) | 1件: Tesofensine Tesofensine | - | - | - | 1件: 6 6 💬 |
62 | 1.0 MIU IL-2 per day | 1件: Human interleukin-2 Human interleukin-2 | - | - | - | 1件: 2 2 💬 |
63 | 10 mg Natura-alpha capsule | - | - | - | - | 1件: 97 97 💬 |
64 | 10% nifedipine cream | 1件: Nifedipine Nifedipine | 1件: Nifedipine
Nifedipine
💬 | 4件: CACNA1C CACNA1C, CACNA1D, CACNA1F, CACNA1S 💬 | 37件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy, Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy, Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 50 50 💬 |
65 | 10% Nitroglycerine in Propylene Glycol, USP | 2件: Nitroglycerin Nitroglycerin, Propylene glycol | 2件: Propylene glycol
Propylene glycol
,
Nitroglycerin
💬 | - | - | 1件: 51 51 💬 |
66 | 10-mg dose of E5501 2G tablet | - | - | - | - | 1件: 63 63 💬 |
67 | 10-mg dose of E5501 cyclodextrin oral solution | - | - | - | - | 1件: 63 63 💬 |
68 | 10-mg dose of E5501 lipid-based oral | - | - | - | - | 1件: 63 63 💬 |
69 | 10-mg dose of E5501-P21% powder | - | - | - | - | 1件: 63 63 💬 |
70 | 10-nitro-9(E)-octadec-9-enoic acid | - | - | - | - | 1件: 86 86 💬 |
71 | 100 mg ELX/50 mg TEZ/75 mg IVA fixed dose combination | - | - | - | - | 1件: 299 299 💬 |
72 | 100 mg/m2 dose | - | - | - | - | 1件: 299 299 💬 |
73 | 1000 IU D3 | - | - | - | - | 1件: 96 96 💬 |
74 | 10000IU vitamin D | 1件: Vitamin D Vitamin D | - | - | - | 1件: 13 13 💬 |
75 | 11-beta-hydroxysteroid dehydrogenase type 1 | - | - | - | - | 1件: 75 75 💬 |
76 | 11-ß-hydroxysteroid dehydrogenase type 1 | - | - | - | - | 1件: 75 75 💬 |
77 | 120 mg sodium nitrite inhalation solution | 1件: Nitrite Nitrite | - | - | - | 1件: 86 86 💬 |
78 | 13-15mg/kg/d Ursodeoxycholic | - | - | - | - | 1件: 93 93 💬 |
79 | 15 mg QD de-escalated to 7 mg QD PF-06649751 in parent study remain at 7 mg QD | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
80 | 15 mg sodium nitrite inhalation solution | 1件: Nitrite Nitrite | - | - | - | 1件: 86 86 💬 |
81 | 150 mg double-blinded secukinumab | 1件: Secukinumab Secukinumab | 1件: Secukinumab
Secukinumab
💬 | 1件: IL17A IL17A 💬 | 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 271 271 💬 |
82 | 17,21-Dihydroxypregna-1,4-diene-3,11,20-trione | - | - | - | - | 1件: 41 41 💬 |
83 | 17beta-hydroxy-11beta-(4-dimethylaminophenyl)17a-(prop-1-ynyl)estra-4,9-dien-3-one | - | - | - | - | 1件: 75 75 💬 |
84 | 17ß-hydroxy-11ß-(4-dimethylaminophenyl)17a-(prop-1-ynyl)estra-4,9-dien-3-one | - | - | - | - | 1件: 75 75 💬 |
85 | 18-22mg/kg/d Ursodeoxycholic | - | - | - | - | 1件: 93 93 💬 |
86 | 18-F]DPA-714 | - | - | - | - | 1件: 127 127 💬 |
87 | 18F- DTBZ | - | - | - | - | 1件: 6 6 💬 |
88 | 18F-DOPA | - | - | - | - | 2件: 6 6, 75 💬 |
89 | 18F-DOPA PET | - | - | - | - | 1件: 6 6 💬 |
90 | 18F-DPA-714 and 18F-FDG | 1件: Fludeoxyglucose (18F) Fludeoxyglucose (18F) | - | - | - | 1件: 13 13 💬 |
91 | 18F-DTBZ | - | - | - | - | 1件: 6 6 💬 |
92 | 18F-DTBZ AV-133 | - | - | - | - | 1件: 6 6 💬 |
93 | 18F-Fluoro-L-dopa | 1件: Levodopa Levodopa | 1件: Levodopa
Levodopa
💬 | 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
94 | 18F]-(E)-N-(3-iodoprop-2-enyl)-2b-carbofluoroethoxy-3b-(4'-methylphenyl)nortropane | - | - | - | - | 1件: 6 6 💬 |
95 | 18F]DPA-714 | - | - | - | - | 2件: 13 13, 127 💬 |
96 | 19 nor vitamin d | 1件: Vitamin D Vitamin D | - | - | - | 1件: 13 13 💬 |
97 | 1[(6- Allyl- 8beta- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]- | - | - | - | - | 1件: 6 6 💬 |
98 | 1[(6- Allyl- 8beta- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]- 3- ethylurea | - | - | - | - | 1件: 6 6 💬 |
99 | 1[(6- Allyl- 8ß- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]- | - | - | - | - | 1件: 6 6 💬 |
100 | 1[(6- Allyl- 8ß- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]- 3- ethylurea | - | - | - | - | 1件: 6 6 💬 |
101 | 2 x 10 mg Natura-alpha capsules | - | - | - | - | 1件: 97 97 💬 |
102 | 2',4'-difluoro-4-hydroxy-3-biphenylcarboxylic acid | 1件: Diflunisal Diflunisal | 1件: Diflunisal
Diflunisal
💬 | 1件: PTGS2 PTGS2 💬 | 22件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 28 28 💬 |
103 | 2'-O-(2-METHOXYETHYL)-D-RIBOSE ANTISENSE OLIGONUCLEOTIDE TARGETING | 1件: Ribose Ribose | - | - | - | 1件: 131 131 💬 |
104 | 2'-O-(2-METHOXYETHYL)-D-RIBOSE ANTISENSE OLIGONUCLEOTIDE TARGETING GLIAL FIBRILLARY ACIDIC PROTEIN MESSENGER RIBONUCLEIC ACID | 1件: Ribose Ribose | - | - | - | 1件: 131 131 💬 |
105 | 2,3-dihydroxybutanedioic acid | - | - | - | - | 1件: 299 299 💬 |
106 | 2,5-Dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4,6-dimethylpyridine-1-oxide | - | - | - | - | 1件: 6 6 💬 |
107 | 2-(2-(2-Amino-9H-purin-9-yl)ethyl)-1,3-propanediol diacetate ester | 1件: Famciclovir Famciclovir | 1件: Famciclovir
Famciclovir
💬 | - | - | 1件: 13 13 💬 |
108 | 2-(3,5-dichloro-phenyl)-benzoxazole-6-carboxylat | - | - | - | - | 1件: 28 28 💬 |
109 | 2-(3,5-dichloro-phenyl)-benzoxazole-6-carboxylate | - | - | - | - | 1件: 28 28 💬 |
110 | 2-(4-[5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy)-N-(methylsulfonyl)actamide | - | - | - | - | 1件: 86 86 💬 |
111 | 2-[[[(2R)-1-[1-[(4-CHLORO-3-METHYLPHENYL)METHYL]-4- PIPERIDINYL]-5-OXO-2-PYRROLIDINYL]CARBONYL]AMINO]- N,N,6-TRIMETHYL-4-PYRIDINECARBOXAMIDE,DIHYDROCHLORIDE | - | - | - | - | 2件: 6 6, 162 💬 |
112 | 2-CdA, 2-chloro-2'-deoxy-beta-D-adenosine | 2件: Adenosine Adenosine, Cladribine | 2件: Adenosine
Adenosine
,
Cladribine
💬 | 5件: ADORA1 ADORA1, ADORA2A, ADORA2B, ADORA3, RRM1 💬 | 18件: Alcoholism Alcoholism, Calcium signaling pathway, Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Nucleotide metabolism, Parkinson disease, Purine metabolism, Pyrimidine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 13 13 💬 |
113 | 2-CdA, 2-chloro-2'-deoxy-ß-D-adenosine | 2件: Adenosine Adenosine, Cladribine | 2件: Adenosine
Adenosine
,
Cladribine
💬 | 5件: ADORA1 ADORA1, ADORA2A, ADORA2B, ADORA3, RRM1 💬 | 18件: Alcoholism Alcoholism, Calcium signaling pathway, Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Nucleotide metabolism, Parkinson disease, Purine metabolism, Pyrimidine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 13 13 💬 |
114 | 2-CdA, 2-chloro-2?-deoxy-beta-D-adenosine | 2件: Adenosine Adenosine, Cladribine | 2件: Adenosine
Adenosine
,
Cladribine
💬 | 5件: ADORA1 ADORA1, ADORA2A, ADORA2B, ADORA3, RRM1 💬 | 18件: Alcoholism Alcoholism, Calcium signaling pathway, Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Nucleotide metabolism, Parkinson disease, Purine metabolism, Pyrimidine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 13 13 💬 |
115 | 2-CdA, 2-chloro-2?-deoxy-ß-D-adenosine | 2件: Adenosine Adenosine, Cladribine | 2件: Adenosine
Adenosine
,
Cladribine
💬 | 5件: ADORA1 ADORA1, ADORA2A, ADORA2B, ADORA3, RRM1 💬 | 18件: Alcoholism Alcoholism, Calcium signaling pathway, Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Nucleotide metabolism, Parkinson disease, Purine metabolism, Pyrimidine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 13 13 💬 |
116 | 2-CdA, 2-chloro-2’-deoxy-beta-D-adenosine | 2件: Adenosine Adenosine, Cladribine | 2件: Adenosine
Adenosine
,
Cladribine
💬 | 5件: ADORA1 ADORA1, ADORA2A, ADORA2B, ADORA3, RRM1 💬 | 18件: Alcoholism Alcoholism, Calcium signaling pathway, Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Nucleotide metabolism, Parkinson disease, Purine metabolism, Pyrimidine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 13 13 💬 |
117 | 2-CdA, 2-chloro-2’-deoxy-ß-D-adenosine | 2件: Adenosine Adenosine, Cladribine | 2件: Adenosine
Adenosine
,
Cladribine
💬 | 5件: ADORA1 ADORA1, ADORA2A, ADORA2B, ADORA3, RRM1 💬 | 18件: Alcoholism Alcoholism, Calcium signaling pathway, Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Nucleotide metabolism, Parkinson disease, Purine metabolism, Pyrimidine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 13 13 💬 |
118 | 2-chloro-2'-deoxy-beta-D-adenosine (2-CdA) | 2件: Adenosine Adenosine, Cladribine | 2件: Adenosine
Adenosine
,
Cladribine
💬 | 5件: ADORA1 ADORA1, ADORA2A, ADORA2B, ADORA3, RRM1 💬 | 18件: Alcoholism Alcoholism, Calcium signaling pathway, Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Nucleotide metabolism, Parkinson disease, Purine metabolism, Pyrimidine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 13 13 💬 |
119 | 2-chloro-2'-deoxy-ß-D-adenosine (2-CdA) | 2件: Adenosine Adenosine, Cladribine | 2件: Adenosine
Adenosine
,
Cladribine
💬 | 5件: ADORA1 ADORA1, ADORA2A, ADORA2B, ADORA3, RRM1 💬 | 18件: Alcoholism Alcoholism, Calcium signaling pathway, Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Nucleotide metabolism, Parkinson disease, Purine metabolism, Pyrimidine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 13 13 💬 |
120 | 2-chloro-2'-deoxyadenosine (2-CdA) | 1件: Cladribine Cladribine | 1件: Cladribine
Cladribine
💬 | 1件: RRM1 RRM1 💬 | 6件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Nucleotide metabolism, Purine metabolism, Pyrimidine metabolism 💬 | 1件: 13 13 💬 |
121 | 2-chloro-2'-deoxyadenosine, 2CdA | 1件: Cladribine Cladribine | 1件: Cladribine
Cladribine
💬 | 1件: RRM1 RRM1 💬 | 6件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Nucleotide metabolism, Purine metabolism, Pyrimidine metabolism 💬 | 1件: 13 13 💬 |
122 | 2-chloro-2?-deoxy-beta-D-adenosine | 1件: Adenosine Adenosine | 1件: Adenosine
Adenosine
💬 | 4件: ADORA1 ADORA1, ADORA2A, ADORA2B, ADORA3 💬 | 12件: Alcoholism Alcoholism, Calcium signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 13 13 💬 |
123 | 2-chloro-2?-deoxy-ß-D-adenosine | 1件: Adenosine Adenosine | 1件: Adenosine
Adenosine
💬 | 4件: ADORA1 ADORA1, ADORA2A, ADORA2B, ADORA3 💬 | 12件: Alcoholism Alcoholism, Calcium signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 13 13 💬 |
124 | 2-chloro-2’-deoxy-beta-D-adenosine | 1件: Adenosine Adenosine | 1件: Adenosine
Adenosine
💬 | 4件: ADORA1 ADORA1, ADORA2A, ADORA2B, ADORA3 💬 | 12件: Alcoholism Alcoholism, Calcium signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 13 13 💬 |
125 | 2-chloro-2’-deoxy-beta-D-adenosine (2-CdA) | 2件: Adenosine Adenosine, Cladribine | 2件: Adenosine
Adenosine
,
Cladribine
💬 | 5件: ADORA1 ADORA1, ADORA2A, ADORA2B, ADORA3, RRM1 💬 | 18件: Alcoholism Alcoholism, Calcium signaling pathway, Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Nucleotide metabolism, Parkinson disease, Purine metabolism, Pyrimidine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 13 13 💬 |
126 | 2-chloro-2’-deoxy-ß-D-adenosine | 1件: Adenosine Adenosine | 1件: Adenosine
Adenosine
💬 | 4件: ADORA1 ADORA1, ADORA2A, ADORA2B, ADORA3 💬 | 12件: Alcoholism Alcoholism, Calcium signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 13 13 💬 |
127 | 2-chloro-2’-deoxy-ß-D-adenosine (2-CdA) | 2件: Adenosine Adenosine, Cladribine | 2件: Adenosine
Adenosine
,
Cladribine
💬 | 5件: ADORA1 ADORA1, ADORA2A, ADORA2B, ADORA3, RRM1 💬 | 18件: Alcoholism Alcoholism, Calcium signaling pathway, Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Nucleotide metabolism, Parkinson disease, Purine metabolism, Pyrimidine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 13 13 💬 |
128 | 2-chloro-2’-deoxyadenosine (2-CdA) | 1件: Cladribine Cladribine | 1件: Cladribine
Cladribine
💬 | 1件: RRM1 RRM1 💬 | 6件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Nucleotide metabolism, Purine metabolism, Pyrimidine metabolism 💬 | 1件: 13 13 💬 |
129 | 2-deoxy-2 [F-18] fluoro-2-d-glucose | 2件: D-glucose D-glucose, Dextrose, unspecified form | 1件: Glucose
Glucose
💬 | - | - | 1件: 49 49 💬 |
130 | 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl) acetamide | 1件: Acetamide Acetamide | - | - | - | 1件: 86 86 💬 |
131 | 2-{7-[1,1-dimethyl-3-(4-sulfobutyl)-benz[e]indolin-2-ylidene]-1,3,5-heptatrienyl}-1,1-dimethyl-3-(sulfobutyl)-1H-benz[e]-indolium hydroxide,inner salt | 1件: Hydroxide ion Hydroxide ion | - | - | - | 1件: 46 46 💬 |
132 | 2.0 MIU IL-2 per day | 1件: Human interleukin-2 Human interleukin-2 | - | - | - | 1件: 2 2 💬 |
133 | 200 mg/m2 dose | - | - | - | - | 1件: 299 299 💬 |
134 | 200mg Cannabidiol by capsules twice daily | 1件: Cannabidiol Cannabidiol | 1件: Cannabidiol
Cannabidiol
💬 | 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 46 46 💬 |
135 | 20mg daily citalopram | 1件: Citalopram Citalopram | 1件: Citalopram
Citalopram
💬 | 1件: SLC6A4 SLC6A4 💬 | 2件: Serotonergic synapse Serotonergic synapse, Synaptic vesicle cycle 💬 | 1件: 8 8 💬 |
136 | 25% MTD sodium nitrite inhalation solution | 1件: Nitrite Nitrite | - | - | - | 1件: 86 86 💬 |
137 | 25(OH)D3 | - | - | - | - | 1件: 13 13 💬 |
138 | 25-Hydroxyvitamin D3 | 1件: Calcifediol Calcifediol | 1件: Calcifediol
Calcifediol
💬 | 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 299 299 💬 |
139 | 25OH-Vitamin D | 2件: Cholecalciferol Cholecalciferol, Vitamin D | 1件: Cholecalciferol
Cholecalciferol
💬 | 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 13 13 💬 |
140 | 2622U90 Duramycin | 1件: Lancovutide Lancovutide | - | - | - | 1件: 299 299 💬 |
141 | 2mg KPG-818 dose | - | - | - | - | 1件: 49 49 💬 |
142 | 3 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study) | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
143 | 3,4-DIAMINOPYRIDINE | - | - | - | - | 2件: 12 12, 13 💬 |
144 | 3,4-Diaminopyridine Phosphate | 2件: Amifampridine Amifampridine, Phosphate ion | 1件: Amifampridine
Amifampridine
💬 | 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 1件: 3 3 💬 |
145 | 3- (9,10- Didehydro- 6- methyl- 8?- ergolinyl)-1,1- diethylurea hydrogenmaleate | - | - | - | - | 1件: 6 6 💬 |
146 | 3-(3,4-Dihydroxyphenyl)-L-alanine | 1件: Alanine Alanine | 1件: Alanine
Alanine
💬 | - | - | 1件: 6 6 💬 |
147 | 3-(3-(3,5-DIMETHYL-1H-PYRAZOL-4-YL)PROPOXY)-4-FLUOROBENZOIC ACID | 1件: Pyrazole Pyrazole | - | - | - | 1件: 28 28 💬 |
148 | 3-({[(3R,5R)-3-butyl-3-ethyl-7-(methyloxy)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro- | - | - | - | - | 1件: 93 93 💬 |
149 | 3-({[(3R,5R)-3-butyl-3-ethyl-7-(methyloxy)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,4-benzothiazepin-8-yl]methyl}amino)pentanedioic acid | - | - | - | - | 1件: 93 93 💬 |
150 | 3-[4-(1H-imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)thiophene-2-[(N-butyloxylcarbamate)-sulphonamide] sodium salt | - | - | - | - | 2件: 51 51, 85 💬 |
151 | 3-methyl-1-phenyl-4, 5-dihydro-1H-pyrazol-5-one. | 1件: Pyrazole Pyrazole | - | - | - | 1件: 2 2 💬 |
152 | 300 mg double-blinded secukinumab | 1件: Secukinumab Secukinumab | 1件: Secukinumab
Secukinumab
💬 | 1件: IL17A IL17A 💬 | 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 271 271 💬 |
153 | 3a,7a-dihydroxy-6a-ethyl-5betacholan-24-oic acid | - | - | - | - | 1件: 93 93 💬 |
154 | 3a,7a-dihydroxy-6a-ethyl-5ßcholan-24-oic acid | - | - | - | - | 1件: 93 93 💬 |
155 | 4'-chloro-2'-cyano-N-(trans-4-hydroxy-4-methylcyclohexyl)-biphenyl-4-sulphonamide | - | - | - | - | 1件: 46 46 💬 |
156 | 4'-iodo-4'-deoxydoxorubicin | 1件: Iodine Iodine | 1件: Iodine
Iodine
💬 | - | - | 1件: 28 28 💬 |
157 | 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]-benzamide, methane sulphonic acid salt. AB1010base | 1件: Methane Methane | - | - | - | 1件: 2 2 💬 |
158 | 4-benzyl-2-naphtalen-1-yl-1,2,4-thiadiazolidine-3,5-dione | - | - | - | - | 1件: 5 5 💬 |
159 | 4-Benzyl-2-naphthalen-1-yl-1,2,4- thiadiazolidine-3,5-dione | - | - | - | - | 1件: 113 113 💬 |
160 | 4-benzyl-2-naphthalen-1-yl-1,2,4-thiadiazolidine-3,5-dione | - | - | - | - | 1件: 113 113 💬 |
161 | 4.2% NaCl/Inhalation solution | - | - | - | - | 1件: 299 299 💬 |
162 | 4.5 mg Naltrexone | 1件: Naltrexone Naltrexone | 1件: Naltrexone
Naltrexone
💬 | 3件: OPRD1 OPRD1, OPRK1, OPRM1 💬 | 5件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 13 13 💬 |
163 | 40 MG- SOLUZIONE INIETTABILE IN SIRINGHE PRE-RIEMPITE- USO SOTTOCUTANEO- SIRINGA PRERIEMPITA (0,4ML)- 2 SIRINGHE PRE-RIEMPITE + 2 TAMPONI IMBEVUTI DI ALCOOL | - | - | - | - | 1件: 107 107 💬 |
164 | 400mg Cannabidiol by capsules twice daily | 1件: Cannabidiol Cannabidiol | 1件: Cannabidiol
Cannabidiol
💬 | 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 46 46 💬 |
165 | 45 mg sodium nitrite inhalation solution | 1件: Nitrite Nitrite | - | - | - | 1件: 86 86 💬 |
166 | 4cc of lidocaïne® | - | - | - | - | 1件: 149 149 💬 |
167 | 5-(ethylsulfonyl)-2-(naphthalen-2-yl)benzo[d]oxazole | - | - | - | - | 1件: 113 113 💬 |
168 | 5-Chloro-1,2-dihydro-N-ethyl-4-hydroxy-1-methyl-2-oxo-N-phenyl-3-quinolinecarboxamide sodium | - | - | - | - | 1件: 8 8 💬 |
169 | 50 mg ELX/25 mg TEZ/37.5 mg IVA fixed dose combination | - | - | - | - | 1件: 299 299 💬 |
170 | 5000 IU D3 | - | - | - | - | 1件: 96 96 💬 |
171 | 5000IU vitamin D | 1件: Vitamin D Vitamin D | - | - | - | 1件: 13 13 💬 |
172 | 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine | - | - | - | - | 1件: 38 38 💬 |
173 | 6-(nitrooxy)hexyl(2Z)-4-(acetyloxy)-3-[4-(methylsulfonyl)phenyl]-2-phenylbut-2-enoate | - | - | - | - | 1件: 46 46 💬 |
174 | 6-[(methyl-4-nitro-1H-imidazol-5-yl)thio]-1H-purine | - | - | - | - | 1件: 96 96 💬 |
175 | 6-[2-(3,4-diethoxyphenyl)thiazol-4-yl] pyridine-2-carboxylic acid | - | - | - | - | 1件: 97 97 💬 |
176 | 6-Mercaptopurine (Puri-Nethol) | 1件: Mercaptopurine Mercaptopurine | 2件: Mercaptopurine
Mercaptopurine
,
Mercaptopurine
💬 | 1件: HPRT1 HPRT1 💬 | 4件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬 | 1件: 96 96 💬 |
177 | 68Ga-DOTANOC | - | - | - | - | 1件: 84 84 💬 |
178 | 68Ga-DOTATATE | 2件: Dotatate Dotatate, Dotatate gallium Ga-68 | - | - | - | 1件: 84 84 💬 |
179 | 68Ga-DOTATATE PET/CT | 2件: Dotatate Dotatate, Dotatate gallium Ga-68 | - | - | - | 1件: 84 84 💬 |
180 | 68Ga-NEB | - | - | - | - | 3件: 46 46, 89, 280 💬 |
181 | 6a-ethylchenodeoxycholic acid , 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5betacholan-24-o | 1件: Obeticholic acid Obeticholic acid | 1件: Obeticholic acid
Obeticholic acid
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
182 | 6a-ethylchenodeoxycholic acid , 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5betacholan-24-o, obeticholic acid (OCA) | 1件: Obeticholic acid Obeticholic acid | 1件: Obeticholic acid
Obeticholic acid
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
183 | 6a-ethylchenodeoxycholic acid , 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5ßcholan-24-o | 1件: Obeticholic acid Obeticholic acid | 1件: Obeticholic acid
Obeticholic acid
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
184 | 6a-ethylchenodeoxycholic acid , 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5ßcholan-24-o, obeticholic acid (OCA) | 1件: Obeticholic acid Obeticholic acid | 1件: Obeticholic acid
Obeticholic acid
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
185 | 6a-ethylchenodeoxycholic acid, 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5betacholan-24-o | 1件: Obeticholic acid Obeticholic acid | 1件: Obeticholic acid
Obeticholic acid
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
186 | 6a-ethylchenodeoxycholic acid, 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5betacholan-24-o , obeticholic acid (OCA) | 1件: Obeticholic acid Obeticholic acid | 1件: Obeticholic acid
Obeticholic acid
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
187 | 6a-ethylchenodeoxycholic acid, 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5ßcholan-24-o | 1件: Obeticholic acid Obeticholic acid | 1件: Obeticholic acid
Obeticholic acid
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
188 | 6a-ethylchenodeoxycholic acid, 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5ßcholan-24-o , obeticholic acid (OCA) | 1件: Obeticholic acid Obeticholic acid | 1件: Obeticholic acid
Obeticholic acid
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
189 | 6abeta - apomorphine-10,11-diol hydrochloride hemihydrate | 1件: Apomorphine Apomorphine | 1件: Apomorphine
Apomorphine
💬 | 2件: DRD1 DRD1, DRD2 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
190 | 6aß - apomorphine-10,11-diol hydrochloride hemihydrate | 1件: Apomorphine Apomorphine | 1件: Apomorphine
Apomorphine
💬 | 2件: DRD1 DRD1, DRD2 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
191 | 7 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study) | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
192 | 7% NaCl | - | - | - | - | 1件: 299 299 💬 |
193 | 750 mg metformin and 7.5 g L-citrulline daily p.o. | 2件: Citrulline Citrulline, Metformin | 1件: Metformin
Metformin
💬 | 2件: PRKAA1 PRKAA1, PRKAA2 💬 | 20件: AMPK signaling pathway AMPK signaling pathway, Adipocytokine signaling pathway, Alcoholic liver disease, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Hypertrophic cardiomyopathy, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease, Oxytocin signaling pathway, PI3K-Akt signaling pathway, Thermogenesis, Tight junction, mTOR signaling pathway 💬 | 1件: 113 113 💬 |
194 | 80 mg DR-6MP | - | - | - | - | 1件: 96 96 💬 |
195 | 89 Zirconium Recombinant Human Alpha-N-Acetylglucosaminidase (rhNAGLU) (radiolabeled) | - | - | - | - | 1件: 19 19 💬 |
196 | 89Zr-DFO-CZP | - | - | - | - | 1件: 46 46 💬 |
197 | 89Zr]Zr-Df-crefmirlimab berdoxam | - | - | - | - | 2件: 51 51, 53 💬 |
198 | 9-Chloro-2,3-dimethyl-6-(N,N-dimethylaminoethylamino-2-oxoethyl)-6H-indolo[2,3-b] quinoxaline | - | - | - | - | 1件: 46 46 💬 |
199 | 9-CIS, 12-CIS-11,11-D2-LINOLEIC ACID ETHYL ESTER | 1件: Linoleic acid Linoleic acid | - | - | - | 2件: 2 2, 5 💬 |
200 | 90 mg sodium nitrite inhalation solution | 1件: Nitrite Nitrite | - | - | - | 1件: 86 86 💬 |
201 | 98% dehydrated alcohol | 1件: Ethanol Ethanol | 1件: Ethanol
Ethanol
💬 | - | - | 1件: 298 298 💬 |
202 | : 2-{4-[(5,6-difenilpirazin-2-yl)(isopropil)amino]butoxi}-N- | - | - | - | - | 1件: 86 86 💬 |
203 | : immunoglobulina umana normale 10% per somministrazione endovenosa | - | - | - | - | 1件: 14 14 💬 |
204 | [123I] mZINT injection and serial dynamic SPECT imaging | - | - | - | - | 1件: 6 6 💬 |
205 | [18F]DPA-714 PET | - | - | - | - | 1件: 2 2 💬 |
206 | [18F]DPA-714 PET scan | - | - | - | - | 1件: 6 6 💬 |
207 | [18F]Fluoro-2-deoxy-2-D-glucose | 2件: D-glucose D-glucose, Dextrose, unspecified form | 1件: Glucose
Glucose
💬 | - | - | 2件: 86 86, 88 💬 |
208 | [21CFR640.30] Plasma from 18 - 25 year old volunteer donors | - | - | - | - | 1件: 6 6 💬 |
209 | A fixed-dose combination of 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine | 3件: Clarithromycin Clarithromycin, Clofazimine, Rifabutin | 3件: Clarithromycin
Clarithromycin
,
Clofazimine
,
Rifabutin
💬 | - | - | 1件: 96 96 💬 |
210 | A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) | - | - | - | - | 1件: 60 60 💬 |
211 | A multistrain probiotic product (DSF) | - | - | - | - | 1件: 97 97 💬 |
212 | A Natural Remedy for Rheumatoid Arthritis vs. Common Drugs | - | - | - | - | 1件: 46 46 💬 |
213 | A novel synthetic, orally-administered, non-peptide small molecule, which acts as | - | - | - | - | 1件: 254 254 💬 |
214 | A novel synthetic, orally-administered, non-peptide small molecule, which acts as an agonist of the melanocortin-1 receptor (MC1R) | - | - | - | - | 1件: 51 51 💬 |
215 | A-dopamine | 1件: Dopamine Dopamine | 1件: Dopamine
Dopamine
💬 | 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
216 | A-F-A-F (NovoRapid-FIASP-NovoRapid-FIASP) | - | - | - | - | 1件: 299 299 💬 |
217 | A-glucosidasi acida umana ricombinante coniugata con multiple copie di bis-mannosio-6- fosfato-tetra-mannosio glicano sintetico (NEOGAA) | 1件: Avalglucosidase alfa Avalglucosidase alfa | 1件: Avalglucosidase alfa
Avalglucosidase alfa
💬 | 1件: GAA GAA 💬 | 4件: Galactose metabolism Galactose metabolism, Lysosome, Metabolic pathways, Starch and sucrose metabolism 💬 | 1件: 256 256 💬 |
218 | A: 1 dosis | - | - | - | - | 1件: 97 97 💬 |
219 | Aadipose-Derived Mesenchymal Stem Cells | - | - | - | - | 1件: 6 6 💬 |
220 | AAV directed hLDLR gene therapy | - | - | - | - | 1件: 79 79 💬 |
221 | AAV-GAD Dose 1 | - | - | - | - | 1件: 6 6 💬 |
222 | AAV-GAD Dose 2 | - | - | - | - | 1件: 6 6 💬 |
223 | Abacavir 300mg twice daily | 1件: Abacavir Abacavir | 1件: Abacavir
Abacavir
💬 | - | - | 1件: 265 265 💬 |
224 | Abatacept (ABA) + Methotrexate (MTX), double-blind (DB) | 2件: Abatacept Abatacept, Methotrexate | 2件: Methotrexate
Methotrexate
,
Abatacept
💬 | 4件: CD80 CD80, CD86, DHFR, DHFR2 💬 | 18件: Allograft rejection Allograft rejection, Antifolate resistance, Autoimmune thyroid disease, Biosynthesis of cofactors, Cell adhesion molecules, Folate biosynthesis, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Metabolic pathways, One carbon pool by folate, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Virion - Adenovirus 💬 | 1件: 46 46 💬 |
225 | Abatacept Delayed-Onset Treatment | 1件: Abatacept Abatacept | 1件: Abatacept
Abatacept
💬 | 2件: CD80 CD80, CD86 💬 | 13件: Allograft rejection Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Virion - Adenovirus 💬 | 1件: 50 50 💬 |
226 | ABBV-323 Dose A | - | - | - | - | 1件: 97 97 💬 |
227 | ABBV-323 Dose B | - | - | - | - | 1件: 97 97 💬 |
228 | ABC/DTG/3TC STR - Tablet | - | - | - | - | 1件: 256 256 💬 |
229 | ACETATO DI AMMONIO | - | - | - | - | 1件: 97 97 💬 |
230 | Acetyl-L-carnitine 1000mg 2X per day for 3 months | 2件: Acetylcarnitine Acetylcarnitine, Levocarnitine | 1件: Levocarnitine
Levocarnitine
💬 | - | - | 1件: 298 298 💬 |
231 | ACIDO ASCORBICO DC.IT | - | - | - | - | 1件: 10 10 💬 |
232 | ACIDO DEOSSICOLICO | - | - | - | - | 1件: 94 94 💬 |
233 | ACIDUM ASCORBICUM D6 | 1件: Ascorbic acid Ascorbic acid | 1件: Ascorbic acid
Ascorbic acid
💬 | - | - | 1件: 206 206 💬 |
234 | ACT-128800 Dose 1 | - | - | - | - | 1件: 13 13 💬 |
235 | ACT-128800 Dose 2 | - | - | - | - | 1件: 13 13 💬 |
236 | ACT-128800 Dose 3 | - | - | - | - | 1件: 13 13 💬 |
237 | ACT-293987 (NS-304) | - | - | - | - | 1件: 86 86 💬 |
238 | Acthar high dose (80 U) | 1件: Corticotropin Corticotropin | 1件: Corticotropin
Corticotropin
💬 | 1件: MC2R MC2R 💬 | 5件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 49 49 💬 |
239 | Acthar low dose (40 U) | 1件: Corticotropin Corticotropin | 1件: Corticotropin
Corticotropin
💬 | 1件: MC2R MC2R 💬 | 5件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 49 49 💬 |
240 | Active BMN 111: Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily. | - | - | - | - | 1件: 276 276 💬 |
241 | Active drug (BIIB014) at 10, 30, 100, or 300 mg once daily. | - | - | - | - | 1件: 6 6 💬 |
242 | Active drug: pimavanserin 17mg (2 strength tablets) | 1件: Pimavanserin Pimavanserin | - | - | - | 1件: 6 6 💬 |
243 | Active topical NS2 1% dermatologic cream | - | - | - | - | 1件: 160 160 💬 |
244 | Acylated and unacylated ghrelin dosages | 1件: Lenomorelin Lenomorelin | - | - | - | 3件: 193 193, 201, 202 💬 |
245 | ACZ885 Drug Substance | - | - | - | - | 3件: 46 46, 106, 107 💬 |
246 | Adalimumab (D2E7) | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 2件: 96 96, 271 💬 |
247 | Adalimumab, new formulation | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
248 | ADENO-ASSOCIATED VIRAL (AAV) SEROTYPE 8 (AAV2/8) VECTOR WITH LIVER-SPECIFIC THYROXINE-BINDING GLOBULIN (TBG) PROMOTER, DRIVING THE EXPRESSION OF THE HUMAN ARSB GENE | 1件: Levothyroxine Levothyroxine | 1件: Levothyroxine
Levothyroxine
💬 | 2件: THRA THRA, THRB 💬 | 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Thyroid hormone signaling pathway 💬 | 1件: 19 19 💬 |
249 | Adeno-associated viral vector serotype 9 containing the human mini-dystrophin gene | - | - | - | - | 1件: 113 113 💬 |
250 | Adeno-associated viral vector serotype 9 containing the human N-acetyl-alpha-glucosaminidase gene | - | - | - | - | 1件: 19 19 💬 |
251 | Adeno-associated virus serotype 2/6 encoding Human Iduronate 2-sulfatase (hIDS) gene donor vector, SB-A6P-HNT Donor Vector | 1件: Idursulfase Idursulfase | 1件: Idursulfase
Idursulfase
💬 | 1件: IDS IDS 💬 | 3件: Glycosaminoglycan degradation Glycosaminoglycan degradation, Lysosome, Metabolic pathways 💬 | 1件: 19 19 💬 |
252 | Adeno-associated virus serotype 2/6 encoding human iduronidase (hIDUA) gene donor vector, SB-A6P-HRL Donor Vector | - | - | - | - | 1件: 19 19 💬 |
253 | Adeno-associated virus serotype 2/6 encoding Left side-zinc finger nuclease (ZFN1), SB-A6P-ZLEFT Vector | - | - | - | - | 1件: 19 19 💬 |
254 | Adeno-associated virus serotype 2/6 encoding Right side-zinc finger nuclease (ZFN2), SB-A6P-ZRIGHT Vector | - | - | - | - | 1件: 19 19 💬 |
255 | ADENO-ASSOCIATED VIRUS SEROTYPE RH74 CONTAINING THE HUMAN MICRO-DYSTROPHIN GENE | - | - | - | - | 1件: 113 113 💬 |
256 | Adipose derived allogenic mesenchymal stem cells (adAMSC) | - | - | - | - | 1件: 96 96 💬 |
257 | Adipose derived mesenchymal stem cell | - | - | - | - | 1件: 3 3 💬 |
258 | Adipose derived mesenchymal stem cells | - | - | - | - | 1件: 86 86 💬 |
259 | Adipose derived stromal cells intravenously injected | - | - | - | - | 1件: 39 39 💬 |
260 | Adipose derived, autologous mesenchymal stem cells | - | - | - | - | 1件: 97 97 💬 |
261 | Adipose tissue-derived mesenchymal stem cells | - | - | - | - | 1件: 97 97 💬 |
262 | Adipose-derived stromal vascular fraction cells | - | - | - | - | 1件: 6 6 💬 |
263 | Adjunctive anti-depressants | - | - | - | - | 1件: 70 70 💬 |
264 | Administration of a high dose of desipramine | 1件: Desipramine Desipramine | 1件: Desipramine
Desipramine
💬 | 2件: SLC6A2 SLC6A2, SLC6A4 💬 | 2件: Serotonergic synapse Serotonergic synapse, Synaptic vesicle cycle 💬 | 1件: 156 156 💬 |
265 | Administration of a low dose of desipramine | 1件: Desipramine Desipramine | 1件: Desipramine
Desipramine
💬 | 2件: SLC6A2 SLC6A2, SLC6A4 💬 | 2件: Serotonergic synapse Serotonergic synapse, Synaptic vesicle cycle 💬 | 1件: 156 156 💬 |
266 | Administration of an ACE-inhibitor or not | - | - | - | - | 1件: 210 210 💬 |
267 | Administration of drug (Interferon-gamma 1-b) subcutaneously | - | - | - | - | 1件: 65 65 💬 |
268 | Administration of methylprednisolone, paracetamol and dexchlorpheniramine | 3件: Acetaminophen Acetaminophen, Dexchlorpheniramine, Methylprednisolone | 3件: Acetaminophen
Acetaminophen
,
Methylprednisolone
,
Dexchlorpheniramine
💬 | 4件: HRH1 HRH1, NR3C1, PTGS1, PTGS2 💬 | 26件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Calcium signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Inflammatory mediator regulation of TRP channels, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Neuroactive ligand-receptor interaction, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 49 49 💬 |
269 | ADX-102 1% Topical Dermal Cream (reproxalap) | 1件: Reproxalap Reproxalap | 1件: Reproxalap
Reproxalap
💬 | - | - | 1件: 160 160 💬 |
270 | AER-901 Solution for Nebulization | - | - | - | - | 1件: 86 86 💬 |
271 | Aerosolized, human, plasma-derived Alpha-1 Antitrypsin | - | - | - | - | 1件: 299 299 💬 |
272 | AFQ056 with L-dopa | 1件: Levodopa Levodopa | 1件: Levodopa
Levodopa
💬 | 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
273 | AIR DNase | - | - | - | - | 1件: 299 299 💬 |
274 | AIR DNase™ | - | - | - | - | 1件: 299 299 💬 |
275 | AIR001 (sodium nitrite inhalation solution) | 1件: Nitrite Nitrite | - | - | - | 1件: 86 86 💬 |
276 | Albuterol nebulizer | 1件: Salbutamol Salbutamol | 1件: Albuterol
Albuterol
💬 | 1件: ADRB2 ADRB2 💬 | 9件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 89 89 💬 |
277 | Alendronate versus alfacalcidol (1-alpha OH vitamin D) | 3件: Alendronic acid Alendronic acid, Alfacalcidol, Vitamin D | 2件: Alfacalcidol
Alfacalcidol
,
Alendronic acid
💬 | 2件: FDPS FDPS, VDR 💬 | 9件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Terpenoid backbone biosynthesis, Tuberculosis 💬 | 3件: 41 41, 46, 50 💬 |
278 | Alga Dunaliella Bardawil | - | - | - | - | 1件: 90 90 💬 |
279 | Alga Dunaliella Bardawil powder | - | - | - | - | 1件: 90 90 💬 |
280 | Alga Dunaliella Bardawill | - | - | - | - | 1件: 90 90 💬 |
281 | ALK-001 (No generic name) | - | - | - | - | 1件: 301 301 💬 |
282 | ALKS 8700 Delayed Release (DR) | 1件: Manganese citrate Manganese citrate | - | - | - | 1件: 13 13 💬 |
283 | ALKS 8700 Delayed Release (DR) Capsule | 1件: Manganese citrate Manganese citrate | - | - | - | 1件: 13 13 💬 |
284 | All subjects will receive maraviroc 300mg orally twice a day for 6 weeks | 1件: Maraviroc Maraviroc | 1件: Maraviroc
Maraviroc
💬 | 1件: CCR5 CCR5 💬 | 11件: Chemokine signaling pathway Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Endocytosis, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Toxoplasmosis, Viral carcinogenesis, Viral life cycle - HIV-1, Viral protein interaction with cytokine and cytokine receptor, Virion - Human immunodeficiency virus 💬 | 1件: 84 84 💬 |
285 | All-P-ambo-2'-O-(2-methoxyethyl)-P-thioguanylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-5-methylcytidylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)adenylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)adenylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-5-methyluridylyl-(3'-O->5'-O)-2'-deoxy-P-thioguanylyl-(3'-O->5'-O)-P-thiothymidylyl-(3'-O->5'-O)-2'-deoxy-5-methyl-P-thiocytidylyl-(3'-O->5'-O)-2'-deoxy-P-thioadenylyl-(3'-O->5'-O)-2'-deoxy-5-methyl-P-thiocytidylyl-(3'-O->5'-O)-2'-deoxy-5-methyl-P-thiocytidylyl-(3'-O->5'-O)-P-thiothymidylyl-(3'-O->5'-O)-P-thiothymidylyl-(3'-O->5'-O)-P-thiothymidylyl-(3'-O->5'-O)-2'-deoxy-5-methyl-P-thiocytidylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)adenylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-5-methyluridylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-P-thioadenylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-5-methylcytidine | - | - | - | - | 1件: 2 2 💬 |
286 | All-P-ambo-2'-O-(2-methoxyethyl)-P-thioguanylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-5-methylcytidylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)adenylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)adenylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-5-methyluridylyl-(3'-O->5'-O)-2'-deoxy-P-thioguanylyl-(3'-O->5'-O)-P-thiothymidylyl-(3'-O->5'-O)-2'-deoxy-5-methyl-P-thiocytidylyl-(3'-O->5'-O)-2'-deoxy-Pthioadenylyl-(3'-O->5'-O)-2'-deoxy-5-methyl-P-thiocytidylyl-(3'-O->5'-O)-2'-deoxy- | - | - | - | - | 1件: 2 2 💬 |
287 | ALLO-ASC-DFU | - | - | - | - | 1件: 36 36 💬 |
288 | Allogeneic adipose tissue-derived mesenchymal stem cells | - | - | - | - | 1件: 97 97 💬 |
289 | ALLOGENEIC ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS EXPANDED | - | - | - | - | 5件: 36 36, 38, 53, 96, 162 💬 |
290 | Allogeneic adipose tissue-derived MSC | - | - | - | - | 1件: 36 36 💬 |
291 | Allogeneic adipose tissue-derived stromal/stem cells | - | - | - | - | 1件: 53 53 💬 |
292 | Allogeneic Bone Marrow derived Human Mesenchymal Stem Cells (hMSCs) | - | - | - | - | 1件: 96 96 💬 |
293 | Allogeneic bone marrow-derived MSCs (1 x 10 6 MSC/kg) | - | - | - | - | 1件: 6 6 💬 |
294 | Allogeneic bone marrow-derived MSCs (10 x 10 6 MSC/kg) | - | - | - | - | 1件: 6 6 💬 |
295 | Allogeneic bone marrow-derived MSCs (3 x 10 6 MSC/kg) | - | - | - | - | 1件: 6 6 💬 |
296 | Allogeneic bone marrow-derived MSCs (6 x 10 6 MSC/kg) | - | - | - | - | 1件: 6 6 💬 |
297 | Allogeneic Cardiosphere-Derived Cells (CAP-1002) | 1件: CAP-1002 CAP-1002 | - | - | - | 1件: 113 113 💬 |
298 | Allogeneic donor derived B-lymphocytes | - | - | - | - | 1件: 60 60 💬 |
299 | Allogeneic Human Cardiosphere-Derived Stem Cells | - | - | - | - | 1件: 86 86 💬 |
300 | Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells | - | - | - | - | 1件: 13 13 💬 |
301 | ALLOGENEIC MESENCHYMAL STROMAL CELLS DERIVED FROM THE UMBILICAL CORD | 1件: Human Umbilical Cord Mesenchymal Stem Cells Human Umbilical Cord Mesenchymal Stem Cells | - | - | - | 1件: 49 49 💬 |
302 | ALLOGENEIC NEURAL RETINA-DERIVED HUMAN NEURAL RETINAL PROGENITOR CELLS EX VIVO EXPANDED | - | - | - | - | 1件: 90 90 💬 |
303 | Allogeneic skin-derived ABCB5-positive mesenchymal stem cells | - | - | - | - | 1件: 36 36 💬 |
304 | Alpha beta depletion | - | - | - | - | 2件: 60 60, 284 💬 |
305 | ALTRI FARMACI DEL SISTEMA NERVOSO | - | - | - | - | 1件: 13 13 💬 |
306 | Alvelestat oral tablet - dose 1 | 1件: Alvelestat Alvelestat | - | - | - | 1件: 231 231 💬 |
307 | Alvelestat oral tablet - dose 2 | 1件: Alvelestat Alvelestat | - | - | - | 1件: 231 231 💬 |
308 | ALX-0061 Nanobody | - | - | - | - | 1件: 46 46 💬 |
309 | Ambrisentan - high dose | 1件: Ambrisentan Ambrisentan | 1件: Ambrisentan
Ambrisentan
💬 | 1件: EDNRA EDNRA 💬 | 7件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
310 | Ambrisentan - low dose | 1件: Ambrisentan Ambrisentan | 1件: Ambrisentan
Ambrisentan
💬 | 1件: EDNRA EDNRA 💬 | 7件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
311 | Amikacin nebulization | 1件: Amikacin Amikacin | 1件: Amikacin
Amikacin
💬 | - | - | 1件: 299 299 💬 |
312 | Amikacine nebulization | 1件: Amikacin Amikacin | 1件: Amikacin
Amikacin
💬 | - | - | 1件: 299 299 💬 |
313 | Amikin, amiklin, amicacin, BB-K8, Biklin, Fabianol, Kaminax, Mikavir, Novamin, Pierami | 1件: Amikacin Amikacin | 1件: Amikacin
Amikacin
💬 | - | - | 1件: 299 299 💬 |
314 | Amikin®, amiklin, amicacin, BB-K8, Biklin®, Fabianol®, Kaminax, Mikavir, Novamin®, Pierami | 1件: Amikacin Amikacin | 1件: Amikacin
Amikacin
💬 | - | - | 1件: 299 299 💬 |
315 | Amlodipine (drug) | 1件: Amlodipine Amlodipine | 1件: Amlodipine
Amlodipine
💬 | 4件: CACNA1C CACNA1C, CACNA1D, CACNA1F, CACNA1S 💬 | 37件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy, Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy, Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 298 298 💬 |
316 | Amniotic membrane extract eye drops (AMEED) | - | - | - | - | 1件: 53 53 💬 |
317 | Amoxapine & dipyridamole | 2件: Amoxapine Amoxapine, Dipyridamole | 2件: Amoxapine
Amoxapine
,
Dipyridamole
💬 | 4件: PDE4A PDE4A, PDE5A, SLC6A2, SLC6A4 💬 | 8件: Metabolic pathways Metabolic pathways, Morphine addiction, Parathyroid hormone synthesis, secretion and action, Purine metabolism, Serotonergic synapse, Synaptic vesicle cycle, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 46 46 💬 |
318 | Amoxicillin and doxycyclin | 2件: Amoxicillin Amoxicillin, Doxycycline | 4件: Amoxicillin
Amoxicillin
,
Doxycycline
,
Amoxicillin
,
Doxycycline
💬 | - | - | 1件: 97 97 💬 |
319 | Amoxicillin, metronidazole and doxycycline | 3件: Amoxicillin Amoxicillin, Doxycycline, Metronidazole | 5件: Amoxicillin
Amoxicillin
,
Doxycycline
,
Metronidazole
,
Amoxicillin
,
Doxycycline
💬 | - | - | 1件: 97 97 💬 |
320 | Amplification by PCR and direct sequencing on the entire coding sequence and intron-exons boundaries of the candidate gene | - | - | - | - | 1件: 265 265 💬 |
321 | Amyl Nitrite | 2件: Amyl Nitrite Amyl Nitrite, Nitrite | 1件: Amyl nitrite
Amyl nitrite
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 58 58 💬 |
322 | Amyl nitrite inhalation | 2件: Amyl Nitrite Amyl Nitrite, Nitrite | 1件: Amyl nitrite
Amyl nitrite
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 58 58 💬 |
323 | Analysis of selected single nucleotide polymorphisms (SNPs) | - | - | - | - | 1件: 46 46 💬 |
324 | Anatomical Landmark-guided Suprascapular Nerve Block | - | - | - | - | 1件: 149 149 💬 |
325 | Anti-(human tumor necrosis factor) immunoglobulin G (human-mouse monoclonal cA2 heavy chain) | - | - | - | - | 1件: 271 271 💬 |
326 | Anti-(misfolded human superoxide dismutase 1) human IgG1m3 monoclonal antibody | - | - | - | - | 1件: 2 2 💬 |
327 | Anti-arrhythmic Drugs (AADs) | - | - | - | - | 1件: 84 84 💬 |
328 | Anti-blood dendritic cell antigen 2 | - | - | - | - | 1件: 49 49 💬 |
329 | Anti-CD20 B cell depletion with Truxima | - | - | - | - | 1件: 49 49 💬 |
330 | Anti-D | - | - | - | - | 1件: 63 63 💬 |
331 | Anti-inflammatory drugs | - | - | - | - | 1件: 46 46 💬 |
332 | Anti-Parkinsonian Drugs | - | - | - | - | 1件: 6 6 💬 |
333 | Anti-TNF discontinuation: Physiological saline solution | - | - | - | - | 2件: 96 96, 97 💬 |
334 | Anti-TNF Drug | - | - | - | - | 2件: 96 96, 97 💬 |
335 | Anti-Tumor Necrosing Factor (TNF) Therapy | - | - | - | - | 1件: 46 46 💬 |
336 | Anti-Tumor Necrosis Factor | - | - | - | - | 1件: 271 271 💬 |
337 | Anti-Tumor Necrosis Factor Alpha Drug (Product) | - | - | - | - | 1件: 46 46 💬 |
338 | Anti-tumor necrosis factor alpha monoclonal antibody | - | - | - | - | 1件: 107 107 💬 |
339 | Anti-von Willebrand Factor Nanobody | 1件: Von Willebrand factor human Von Willebrand factor human | - | - | - | 1件: 64 64 💬 |
340 | Anti-von Willebrand Factor Nanobody, Caplacizumab | 2件: Caplacizumab Caplacizumab, Von Willebrand factor human | 1件: Caplacizumab
Caplacizumab
💬 | 1件: VWF VWF 💬 | 8件: Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 | 1件: 64 64 💬 |
341 | Anti-von Willebrand Factor Nanobody, INN = Caplacizumab | 2件: Caplacizumab Caplacizumab, Von Willebrand factor human | 1件: Caplacizumab
Caplacizumab
💬 | 1件: VWF VWF 💬 | 8件: Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 | 1件: 64 64 💬 |
342 | Antiarrhythmic drugs | - | - | - | - | 1件: 58 58 💬 |
343 | Anticuerpo monoclonal anti-humano recombinante humanizado, receptor de IL-6R. | - | - | - | - | 1件: 46 46 💬 |
344 | Antiepileptic drug (1 to 3 only) | - | - | - | - | 1件: 158 158 💬 |
345 | Antigen-specific T cells CART/CTL and DCvac | - | - | - | - | 1件: 34 34 💬 |
346 | Antihypertensive drugs | - | - | - | - | 1件: 67 67 💬 |
347 | Antimicrobial therapy: Co-trimoxazole or Doxycycline | 1件: Doxycycline Doxycycline | 2件: Doxycycline
Doxycycline
,
Doxycycline
💬 | - | - | 1件: 85 85 💬 |
348 | Antivirale ad uso diretto | - | - | - | - | 1件: 107 107 💬 |
349 | Anxiety/depression and work and activities | - | - | - | - | 1件: 13 13 💬 |
350 | Any other approved Antiepileptic Drug | - | - | - | - | 1件: 144 144 💬 |
351 | API-AAT, AD00370, ARC-AAT, API drug Substance | - | - | - | - | 1件: 231 231 💬 |
352 | Apomorphine hydrochloride 1.8mg inhalation powder, pre-dispensed | 1件: Apomorphine Apomorphine | 1件: Apomorphine
Apomorphine
💬 | 2件: DRD1 DRD1, DRD2 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
353 | Apomorphine hydrochloride 2.8mg inhalation powder, pre-dispensed | 1件: Apomorphine Apomorphine | 1件: Apomorphine
Apomorphine
💬 | 2件: DRD1 DRD1, DRD2 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
354 | Apomorphine hydrochloride 4.0 mg inhalation powder, pre-dispensed | 1件: Apomorphine Apomorphine | 1件: Apomorphine
Apomorphine
💬 | 2件: DRD1 DRD1, DRD2 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
355 | Apomorphine hydrochloride 5.8 mg inhalation powder, pre-dispensed | 1件: Apomorphine Apomorphine | 1件: Apomorphine
Apomorphine
💬 | 2件: DRD1 DRD1, DRD2 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
356 | Apomorphine Nasal Powder | 1件: Apomorphine Apomorphine | 1件: Apomorphine
Apomorphine
💬 | 2件: DRD1 DRD1, DRD2 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
357 | ARTEGENE drug product | - | - | - | - | 1件: 65 65 💬 |
358 | ARZERRA - 1000 MG - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) - 50 ML (20 MG/ML) 1 FLACONCINO + 2 KIT DI PROLUNGA | 1件: Ofatumumab Ofatumumab | 1件: Ofatumumab
Ofatumumab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬 |
359 | Asacol (mesalamine) Delayed-release Tablets | 1件: Mesalazine Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
360 | Asacol Delayed Release Tablets | 2件: Manganese citrate Manganese citrate, Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
361 | Asacol Delayed-Release Tablets | 2件: Manganese citrate Manganese citrate, Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
362 | ASCs: Adipose derived Stem Cells | - | - | - | - | 1件: 96 96 💬 |
363 | ASK Nr. 21972 | - | - | - | - | 1件: 5 5 💬 |
364 | Atacicept: with loading dose | 1件: Atacicept Atacicept | 1件: Atacicept
Atacicept
💬 | 2件: TNFSF13 TNFSF13, TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 1件: 46 46 💬 |
365 | Atazanavir (ATV) + ritonavir (RTV), continuation of backbone 2 nucleoside reverse transcriptase inhibitor (NRTIs) | 2件: Atazanavir Atazanavir, Ritonavir | 2件: Ritonavir
Ritonavir
,
Atazanavir
💬 | - | - | 1件: 265 265 💬 |
366 | ATH434 dose level 1 | - | - | - | - | 1件: 17 17 💬 |
367 | ATH434 dose level 2 | - | - | - | - | 1件: 17 17 💬 |
368 | Atorvastatin 40 Mg Oral Tablet + N-acetylcysteine 400 mg Oral tablet | 2件: Acetylcysteine Acetylcysteine, Atorvastatin | 2件: Acetylcysteine
Acetylcysteine
,
Atorvastatin
💬 | 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 63 63 💬 |
369 | Autofluorescent detection + Injection of indocyanine green | 1件: Indocyanine green Indocyanine green | 1件: Indocyanine green
Indocyanine green
💬 | - | - | 1件: 235 235 💬 |
370 | Autologous (self) mononuclear cells derived from umbilical cord blood | - | - | - | - | 1件: 211 211 💬 |
371 | Autologous adipose derived mesenchymal cells | - | - | - | - | 1件: 13 13 💬 |
372 | Autologous Adipose Derived MSCs (ADMSCs) | - | - | - | - | 1件: 85 85 💬 |
373 | Autologous adipose derived stem cells | - | - | - | - | 1件: 46 46 💬 |
374 | Autologous ADIpose derived stromal vascular fraction | - | - | - | - | 1件: 96 96 💬 |
375 | Autologous Adipose-derived Mesenchymal Stromal Cells | 1件: Human Umbilical Cord Mesenchymal Stem Cells Human Umbilical Cord Mesenchymal Stem Cells | - | - | - | 1件: 2 2 💬 |
376 | Autologous Bone Marrow-Derived Mononuclear Stem Cells | - | - | - | - | 1件: 13 13 💬 |
377 | Autologous bone marrow-derived stem cells | - | - | - | - | 1件: 2 2 💬 |
378 | AUTOLOGOUS CD34+ CELLS TRANSDUCED WITH LENTI-D VECTOR ENCODING ABCD1 CDNA | - | - | - | - | 1件: 20 20 💬 |
379 | Autologous cell-based delivery | - | - | - | - | 1件: 211 211 💬 |
380 | Autologous ex vivo gene therapy products based on the EFS LV encoding for the human adenosine deaminase (ADA) gene (EFS-ADA LV) | 1件: Adenosine Adenosine | 1件: Adenosine
Adenosine
💬 | 4件: ADORA1 ADORA1, ADORA2A, ADORA2B, ADORA3 💬 | 12件: Alcoholism Alcoholism, Calcium signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 65 65 💬 |
381 | Autologous haematopoietic stem cells transduced with lentiviral vector Lenti-D encoding the human ABCD1 cDNA | - | - | - | - | 1件: 20 20 💬 |
382 | Autologous mature tolerogenic monocyte-derived Dendritic Cells loaded with the B29 peptide of HSP70 | - | - | - | - | 1件: 46 46 💬 |
383 | Autologous mesenchymal stem cells derived from bone marrow | - | - | - | - | 1件: 85 85 💬 |
384 | Autologous MSC-NTF cells | - | - | - | - | 1件: 2 2 💬 |
385 | Autologous stemcell transplantation with CD (cluster of differentiation) 34 selected stem cells | - | - | - | - | 1件: 51 51 💬 |
386 | Autologous VitD3 tolerogenic monocyte-derived dendritic cells loaded with a pool of myelin peptides (tolDC-VitD3) | 1件: Myelin basic protein Myelin basic protein | - | - | - | 1件: 13 13 💬 |
387 | Avalglucosidase Alfa (NeoGAA) | 1件: Avalglucosidase alfa Avalglucosidase alfa | 1件: Avalglucosidase alfa
Avalglucosidase alfa
💬 | 1件: GAA GAA 💬 | 4件: Galactose metabolism Galactose metabolism, Lysosome, Metabolic pathways, Starch and sucrose metabolism 💬 | 1件: 256 256 💬 |
388 | Avalglucosidase alfa-NGPT (GZ402666) | 1件: Avalglucosidase alfa Avalglucosidase alfa | 1件: Avalglucosidase alfa
Avalglucosidase alfa
💬 | 1件: GAA GAA 💬 | 4件: Galactose metabolism Galactose metabolism, Lysosome, Metabolic pathways, Starch and sucrose metabolism 💬 | 1件: 256 256 💬 |
389 | Avalglucosidase alfa-NGPT (GZ402666) IV | 1件: Avalglucosidase alfa Avalglucosidase alfa | 1件: Avalglucosidase alfa
Avalglucosidase alfa
💬 | 1件: GAA GAA 💬 | 4件: Galactose metabolism Galactose metabolism, Lysosome, Metabolic pathways, Starch and sucrose metabolism 💬 | 1件: 256 256 💬 |
390 | AVONEX - 30 MCG (6 MILIONI UI) POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE 4 FLACONI CON DISPOSITIVO BIOSET + 4 SIRINGHE PRERIEMPITE USO INTRAMUSCOLARE | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
391 | AVONEX 30 microgramos/0,5 ml (Interferón Beta - 1a) Solución inyectable | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
392 | Avonex 30 microgramos/0.5 ml Solución para inyección | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
393 | AXO-AAV-GM2 High Dose | - | - | - | - | 1件: 19 19 💬 |
394 | AXO-AAV-GM2 Low Dose | - | - | - | - | 1件: 19 19 💬 |
395 | AXO-AAV-GM2 Middle Dose | - | - | - | - | 1件: 19 19 💬 |
396 | AXO-AAV-GM2 Starting Dose | - | - | - | - | 1件: 19 19 💬 |
397 | Azathioprine individualised dose | 1件: Azathioprine Azathioprine | 1件: Azathioprine
Azathioprine
💬 | - | - | 1件: 96 96 💬 |
398 | Azathioprine weight-based dose | 1件: Azathioprine Azathioprine | 1件: Azathioprine
Azathioprine
💬 | - | - | 1件: 96 96 💬 |
399 | Azathioprine+enteral nutrition | 1件: Azathioprine Azathioprine | 1件: Azathioprine
Azathioprine
💬 | - | - | 1件: 96 96 💬 |
400 | AZD7325 (High-Dose) | - | - | - | - | 1件: 206 206 💬 |
401 | AZD7325 (Low-Dose) | - | - | - | - | 1件: 206 206 💬 |
402 | Azithromycin + N-acetylcystein + inhaled corticosteroid | 1件: Azithromycin Azithromycin | 2件: Azithromycin
Azithromycin
,
Azithromycin
💬 | - | - | 1件: 228 228 💬 |
403 | AZITHROMYCIN DIHYDRATE | 1件: Azithromycin Azithromycin | 2件: Azithromycin
Azithromycin
,
Azithromycin
💬 | - | - | 2件: 228 228, 299 💬 |
404 | AZLI 75 mg three times a day (TID) | - | - | - | - | 1件: 299 299 💬 |
405 | AZLI 75 mg three times daily (TID) | - | - | - | - | 1件: 299 299 💬 |
406 | AZLI 75 mg two times a day (BID)/ three times a day (TID) | - | - | - | - | 1件: 299 299 💬 |
407 | AZLI 75 mg two times a day (BID)/three times a day (TID) | - | - | - | - | 1件: 299 299 💬 |
408 | Aztreonam solución para inhalación | 1件: Aztreonam Aztreonam | 1件: Aztreonam
Aztreonam
💬 | - | - | 1件: 299 299 💬 |
409 | Aún no establecido | - | - | - | - | 1件: 53 53 💬 |
410 | B: 2 dosis | - | - | - | - | 1件: 97 97 💬 |
411 | Balanced diet | - | - | - | - | 1件: 49 49 💬 |
412 | Balsalazide Disodium | 1件: Balsalazide Balsalazide | 1件: Balsalazide
Balsalazide
💬 | - | - | 1件: 97 97 💬 |
413 | BARDOXOLONE METHYL, CDDO-Me, CDDO-Methyl Ester, NSC 713200, Chemical Name: Oleana-1,9(11)-dien-28-oic acid, 2-cyano-3,12-dioxo-, methyl ester | 2件: Bardoxolone Bardoxolone, Bardoxolone methyl | 2件: Bardoxolone
Bardoxolone
,
Bardoxolone methyl
💬 | - | - | 1件: 86 86 💬 |
414 | Bascial prescription plus or minus herbs depend on symptoms | - | - | - | - | 1件: 97 97 💬 |
415 | Baseline disease modifying therapies (DMTs) | - | - | - | - | 1件: 13 13 💬 |
416 | Bavisant dihydrochloride monohydrate | 1件: Bavisant Bavisant | 1件: Bavisant
Bavisant
💬 | 1件: HRH3 HRH3 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 6 6 💬 |
417 | BBT-401-1S, Multiple doses | - | - | - | - | 1件: 97 97 💬 |
418 | BBT-401-1S, Single dose | - | - | - | - | 1件: 97 97 💬 |
419 | BBT-877, Multiple doses | - | - | - | - | 1件: 85 85 💬 |
420 | BBT-877, Single dose | - | - | - | - | 1件: 85 85 💬 |
421 | Beclometasone dipropionate | 1件: Beclomethasone dipropionate Beclomethasone dipropionate | 1件: Beclomethasone dipropionate
Beclomethasone dipropionate
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 2件: 85 85, 97 💬 |
422 | Beclomethasone dipropionate | 1件: Beclomethasone dipropionate Beclomethasone dipropionate | 1件: Beclomethasone dipropionate
Beclomethasone dipropionate
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 2件: 97 97, 98 💬 |
423 | Beclomethasone diproprionate | - | - | - | - | 1件: 97 97 💬 |
424 | Belantamab mafodotin 1.9mg/kg or 2.5mg/kg every 4 weeks, 6 weeks or 8 weeks as determined by Part 1 recommended dosages | 1件: Belantamab mafodotin Belantamab mafodotin | 1件: Belantamab mafodotin
Belantamab mafodotin
💬 | 10件: TNFRSF17 TNFRSF17, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 | 12件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Cytokine-cytokine receptor interaction, Gap junction, Huntington disease, Intestinal immune network for IgA production, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬 | 1件: 28 28 💬 |
425 | Benzimidazole,5-methoxy-2-[[(4-methoxy- 3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1 H-benzimidazole | 1件: Benzimidazole Benzimidazole | - | - | - | 1件: 46 46 💬 |
426 | Benzimidazole,5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1 H-benzimidazole | 1件: Benzimidazole Benzimidazole | - | - | - | 1件: 46 46 💬 |
427 | Best médical treatment | - | - | - | - | 1件: 6 6 💬 |
428 | Beta carotene from Dunaliella algae | 1件: Beta carotene Beta carotene | 1件: beta Carotene
beta Carotene
💬 | - | - | 1件: 96 96 💬 |
429 | Beta-1,3/1,6-D-Glucan | - | - | - | - | 1件: 97 97 💬 |
430 | Betamethasone sodium phosphate/betamethasone acetate (Celestone® Soluspan®), 30 mg IM once a day for four days | 3件: Acetate Acetate, Betamethasone, Phosphate ion | 1件: Betamethasone
Betamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 2 2 💬 |
431 | Bezafibrate (drug) | 1件: Bezafibrate Bezafibrate | 1件: Bezafibrate
Bezafibrate
💬 | 1件: PPARA PPARA 💬 | 10件: Adipocytokine signaling pathway Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬 | 1件: 316 316 💬 |
432 | BG00002 (natalizumab) | 1件: Natalizumab Natalizumab | 1件: Natalizumab
Natalizumab
💬 | 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 💬 |
433 | BG00002-E (natalizumab high titer) | 1件: Natalizumab Natalizumab | 1件: Natalizumab
Natalizumab
💬 | 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 💬 |
434 | BG00012 (DMF) | - | - | - | - | 1件: 13 13 💬 |
435 | BG00012 (DMF) (Tecfidera®.) | - | - | - | - | 1件: 13 13 💬 |
436 | BG0002 (natalizumab) | 1件: Natalizumab Natalizumab | 1件: Natalizumab
Natalizumab
💬 | 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 💬 |
437 | BI 655064 high dose | - | - | - | - | 1件: 46 46 💬 |
438 | BI 655064 low dose | - | - | - | - | 1件: 46 46 💬 |
439 | BI 655064 medium dose | - | - | - | - | 1件: 46 46 💬 |
440 | BIA 6-512 100 mg dose | 1件: BIA BIA | - | - | - | 1件: 6 6 💬 |
441 | BIA 6-512 200 mg dose | 1件: BIA BIA | - | - | - | 1件: 6 6 💬 |
442 | BIA 6-512 25 mg dose | 1件: BIA BIA | - | - | - | 1件: 6 6 💬 |
443 | BIA 6-512 50 mg dose | 1件: BIA BIA | - | - | - | 1件: 6 6 💬 |
444 | BIA 9-1067 non-micronized | 1件: BIA BIA | - | - | - | 1件: 6 6 💬 |
445 | BIIB019 (Daclizumab High Yield Process) | 1件: Daclizumab Daclizumab | 1件: Daclizumab
Daclizumab
💬 | 1件: IL2RA IL2RA 💬 | 11件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 13 13 💬 |
446 | BIIB019 (Daclizumab) | 1件: Daclizumab Daclizumab | 1件: Daclizumab
Daclizumab
💬 | 1件: IL2RA IL2RA 💬 | 11件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 13 13 💬 |
447 | BIIL 284 BS high dose | - | - | - | - | 1件: 46 46 💬 |
448 | BIIL 284 BS low dose | - | - | - | - | 1件: 46 46 💬 |
449 | BIIL 284 BS medium dose | - | - | - | - | 1件: 46 46 💬 |
450 | BIIL 284 BS, high dose | - | - | - | - | 1件: 299 299 💬 |
451 | BIIL 284 BS, high dose, adult patients | - | - | - | - | 1件: 299 299 💬 |
452 | BIIL 284 BS, high dose, pediatric patients | - | - | - | - | 1件: 299 299 💬 |
453 | BIIL 284 BS, low dose | - | - | - | - | 1件: 299 299 💬 |
454 | BIIL 284 BS, low dose, adult patients | - | - | - | - | 1件: 299 299 💬 |
455 | BIIL 284 BS, low dose, pediatric patients | - | - | - | - | 1件: 299 299 💬 |
456 | BIIL 284 BS, medium dose, adult patients | - | - | - | - | 1件: 299 299 💬 |
457 | BIIL 284 BS, medium dose, pediatric patients | - | - | - | - | 1件: 299 299 💬 |
458 | Bilateral surgical infusion of AAV-GAD into the subthalamic nucleus | - | - | - | - | 1件: 6 6 💬 |
459 | Biologic DMARD | - | - | - | - | 2件: 46 46, 271 💬 |
460 | Biologic DMARDs | - | - | - | - | 1件: 107 107 💬 |
461 | Biological : I10E (Human normal Immunoglobulin for intravenous administration 100mg/mL) | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 1件: 14 14 💬 |
462 | Biological disease-modifying antirheumatic drugs (bDMARDs) | - | - | - | - | 1件: 46 46 💬 |
463 | Biological DMARDs | - | - | - | - | 2件: 86 86, 107 💬 |
464 | Biological Drug | - | - | - | - | 3件: 46 46, 96, 97 💬 |
465 | Biomarker identification in Parkinson disease | - | - | - | - | 1件: 6 6 💬 |
466 | BION-1301 Multiple Doses | - | - | - | - | 1件: 66 66 💬 |
467 | BION-1301 Single Dose | - | - | - | - | 1件: 66 66 💬 |
468 | BIOOPA dressing | - | - | - | - | 1件: 36 36 💬 |
469 | BIRB 796 BS, high dose | - | - | - | - | 1件: 46 46 💬 |
470 | BIRB 796 BS, low dose | - | - | - | - | 1件: 46 46 💬 |
471 | Bladder tissue of Interstitial Cystitis and normal bladder tissue | - | - | - | - | 1件: 226 226 💬 |
472 | BLI-1300 high dose | - | - | - | - | 1件: 96 96 💬 |
473 | BLI-1300 low dose | - | - | - | - | 1件: 96 96 💬 |
474 | Blood draw | - | - | - | - | 1件: 6 6 💬 |
475 | Blood draw for the laboratory assessment | - | - | - | - | 1件: 303 303 💬 |
476 | Blood Sampling and DNA collection | - | - | - | - | 1件: 6 6 💬 |
477 | BMN165 20mg/day | - | - | - | - | 1件: 240 240 💬 |
478 | BMN165 40mg/day | - | - | - | - | 1件: 240 240 💬 |
479 | BMS Drug-drug interaction cocktail (montelukast, flurbiprofen, omeprazole, midazolam, and digoxin) | 5件: Digoxin Digoxin, Flurbiprofen, Midazolam, Montelukast, Omeprazole | 5件: Digoxin
Digoxin
,
Flurbiprofen
,
Omeprazole
,
Midazolam
,
Montelukast
💬 | 25件: ATP1A1 ATP1A1, ATP1A2, ATP1A3, ATP1A4, ATP4A, ATP4B, CYSLTR1, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, PTGS1, PTGS2 💬 | 49件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Aldosterone-regulated sodium reabsorption, Alzheimer disease, Arachidonic acid metabolism, Bile secretion, C-type lectin receptor signaling pathway, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Chemical carcinogenesis - DNA adducts, Collecting duct acid secretion, Endocrine and other factor-regulated calcium reabsorption, GABAergic synapse, Gastric acid secretion, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Insulin secretion, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, Mineral absorption, Morphine addiction, NF-kappa B signaling pathway, Neuroactive ligand-receptor interaction, Nicotine addiction, Ovarian steroidogenesis, Oxidative phosphorylation, Oxytocin signaling pathway, Pancreatic secretion, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Protein digestion and absorption, Proximal tubule bicarbonate reclamation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Salivary secretion, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, Taste transduction, Thyroid hormone signaling pathway, Thyroid hormone synthesis, VEGF signaling pathway, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 46 46 💬 |
480 | Bone marrow derived mesenchymal stem cells | - | - | - | - | 2件: 6 6, 60 💬 |
481 | Bone Marrow Derived Mesenchymal Stem cells (MSCs) | - | - | - | - | 1件: 96 96 💬 |
482 | Bone marrow-derived mesenchymal stem cells | - | - | - | - | 1件: 298 298 💬 |
483 | Bone marrow-derived mesenchymal stromal cells (MSCs) | 1件: Human Umbilical Cord Mesenchymal Stem Cells Human Umbilical Cord Mesenchymal Stem Cells | - | - | - | 1件: 274 274 💬 |
484 | Bortezomib D-mannitol | 3件: Bortezomib Bortezomib, Bortezomib D-mannitol, Mannitol | 2件: Mannitol
Mannitol
,
Bortezomib
💬 | 1件: PSMB5 PSMB5 💬 | 8件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬 | 1件: 28 28 💬 |
485 | Bortezomib/dexamethasone | 2件: Bortezomib Bortezomib, Dexamethasone | 2件: Dexamethasone
Dexamethasone
,
Bortezomib
💬 | 2件: NR3C1 NR3C1, PSMB5 💬 | 9件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Neuroactive ligand-receptor interaction, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬 | 1件: 283 283 💬 |
486 | Bortezomib/Dexamethasone (BD), Followed By Autologous STC & Maintenance Bortezomib/Dexamethasone | 2件: Bortezomib Bortezomib, Dexamethasone | 2件: Dexamethasone
Dexamethasone
,
Bortezomib
💬 | 2件: NR3C1 NR3C1, PSMB5 💬 | 9件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Neuroactive ligand-receptor interaction, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬 | 1件: 28 28 💬 |
487 | BOTOX 100U in normal saline | 1件: Botulinum toxin type A Botulinum toxin type A | 1件: Botulinum toxin type A
Botulinum toxin type A
💬 | 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 1件: 226 226 💬 |
488 | BOTOX 200U in normal saline | 1件: Botulinum toxin type A Botulinum toxin type A | 1件: Botulinum toxin type A
Botulinum toxin type A
💬 | 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 1件: 226 226 💬 |
489 | Botulinum Neurotoxin | - | - | - | - | 1件: 226 226 💬 |
490 | Botulinum toxin type A (Nabota®) injection into the gastrocnemius muscle | 1件: Botulinum toxin type A Botulinum toxin type A | 1件: Botulinum toxin type A
Botulinum toxin type A
💬 | 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 1件: 70 70 💬 |
491 | BR-DIM | - | - | - | - | 1件: 49 49 💬 |
492 | BRAMICIL - 100 MG/ 2 ML SOLUZIONE INIETTABILE 10 FIALE DA 2 ML | - | - | - | - | 1件: 299 299 💬 |
493 | BRAMITOB - 300 MG/4 ML SOLUZIONE DA NEBULIZZARE 56 CONTENITORI MONODOSE 4 ML | - | - | - | - | 1件: 299 299 💬 |
494 | Bramitob 300mg/4ml Nebuliser Solution | - | - | - | - | 1件: 299 299 💬 |
495 | BRAMITOB*NEBUL 28F 300MG/4ML | - | - | - | - | 1件: 299 299 💬 |
496 | BRAMITOB*NEBUL 56F 300MG/4ML | - | - | - | - | 1件: 299 299 💬 |
497 | Bramitob® administered by PARI eFlow® rapid electronic nebulizer | - | - | - | - | 1件: 299 299 💬 |
498 | Bramitob® administered by PARI LC® PLUS nebulizer | - | - | - | - | 1件: 299 299 💬 |
499 | Brazikumab high dose | 1件: Brazikumab Brazikumab | 1件: Brazikumab
Brazikumab
💬 | 1件: IL23A IL23A 💬 | 9件: C-type lectin receptor signaling pathway C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬 | 1件: 96 96 💬 |
500 | Brazikumab Induction Dose | 1件: Brazikumab Brazikumab | 1件: Brazikumab
Brazikumab
💬 | 1件: IL23A IL23A 💬 | 9件: C-type lectin receptor signaling pathway C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬 | 2件: 96 96, 97 💬 |
501 | Brazikumab low dose | 1件: Brazikumab Brazikumab | 1件: Brazikumab
Brazikumab
💬 | 1件: IL23A IL23A 💬 | 9件: C-type lectin receptor signaling pathway C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬 | 1件: 96 96 💬 |
502 | Brazikumab Maintenance Dose | 1件: Brazikumab Brazikumab | 1件: Brazikumab
Brazikumab
💬 | 1件: IL23A IL23A 💬 | 9件: C-type lectin receptor signaling pathway C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬 | 2件: 96 96, 97 💬 |
503 | Brimonidine Tartrate Posterior Segment Drug Delivery System (Brimo PS DDS) Applicator System | 1件: Brimonidine Brimonidine | 1件: Brimonidine
Brimonidine
💬 | 3件: ADRA2A ADRA2A, ADRA2B, ADRA2C 💬 | 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬 | 1件: 90 90 💬 |
504 | Bromocriptine and other dopamine agonists | 2件: Bromocriptine Bromocriptine, Dopamine | 2件: Bromocriptine
Bromocriptine
,
Dopamine
💬 | 6件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5, PRL 💬 | 15件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Cytokine-cytokine receptor interaction, Dopaminergic synapse, Gap junction, JAK-STAT signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Parkinson disease, Prolactin signaling pathway, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
505 | Bromure d'Ipratropium | 1件: Ipratropium Ipratropium | - | - | - | 1件: 86 86 💬 |
506 | BTT1023 IV Infusion 20 mg/mL, 5 mL Drug Product | - | - | - | - | 1件: 94 94 💬 |
507 | Budesonide 0.5mg orodispersible tablet twice daily | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 💬 |
508 | Budesonide 1mg orodispersible tablet twice daily | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 💬 |
509 | Bupivacaine/epinephrine/dexamethasone | 3件: Bupivacaine Bupivacaine, Dexamethasone, Epinephrine | 3件: Epinephrine
Epinephrine
,
Dexamethasone
,
Bupivacaine
💬 | 15件: ADRA1A ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, NR3C1, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | 16件: AMPK signaling pathway AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Taste transduction, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 96 96 💬 |
510 | Bupivacaïne HCl 0,125% / Sufentanil 50 µg flacon à 50 ml | 1件: Sufentanil Sufentanil | 1件: Sufentanil
Sufentanil
💬 | 1件: OPRM1 OPRM1 💬 | 3件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction 💬 | 1件: 70 70 💬 |
511 | Busulfan test dose | 1件: Busulfan Busulfan | 1件: Busulfan
Busulfan
💬 | - | - | 1件: 65 65 💬 |
512 | By demand | - | - | - | - | 2件: 96 96, 97 💬 |
513 | C-type natriuretic peptide conjugated to a multi-arm polyethylene glycol carrier molecule through a cleavable linker | 1件: Polyethylene glycol Polyethylene glycol | 1件: Polyethylene glycol 3350
Polyethylene glycol 3350
💬 | - | - | 1件: 276 276 💬 |
514 | C-TYPE NATRIURETIC PEPTIDE CONJUGATED TO MULTI-ARM POLYETHYLENE GLYCOL CARRIER THROUGH A CLEAVABLE LINKER | 1件: Polyethylene glycol Polyethylene glycol | 1件: Polyethylene glycol 3350
Polyethylene glycol 3350
💬 | - | - | 1件: 276 276 💬 |
515 | C01CA04 - Dopamina | 1件: Dopamine Dopamine | 1件: Dopamine
Dopamine
💬 | 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
516 | Cabaletta for IV infusion once weekly during 24 weeks | 1件: Trehalose Trehalose | - | - | - | 1件: 18 18 💬 |
517 | Calcichew D3 | - | - | - | - | 1件: 274 274 💬 |
518 | Calcichew D3 Forte | - | - | - | - | 1件: 113 113 💬 |
519 | CALCIO FOLINATO DC.IT | 1件: Calcium Calcium | - | - | - | 1件: 13 13 💬 |
520 | Calcitonin nasal spray (salmon) | 1件: Salmon, unspecified Salmon, unspecified | - | - | - | 2件: 96 96, 97 💬 |
521 | Calcium and Vit D | 1件: Calcium Calcium | - | - | - | 1件: 49 49 💬 |
522 | Calcium and Vitamin D combination | 2件: Calcium Calcium, Vitamin D | - | - | - | 1件: 13 13 💬 |
523 | Calcium carbonate D | 3件: Calcium Calcium, Calcium carbonate, Carbonate ion | 2件: Calcium carbonate
Calcium carbonate
,
Calcium carbonate
💬 | - | - | 1件: 53 53 💬 |
524 | Calcium Citrate with Vitamin D2 | 3件: Calcium Calcium, Calcium citrate, Ergocalciferol | 2件: Ergocalciferol
Ergocalciferol
,
Calcium citrate
💬 | 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 84 84 💬 |
525 | Calcium D3 | 2件: Calcium Calcium, Calcium carbonate | 2件: Calcium carbonate
Calcium carbonate
,
Calcium carbonate
💬 | - | - | 1件: 274 274 💬 |
526 | CALCIUM D3 SANDOZ - 1000 MG + 880 U.I. COMPRESSE EFFERVESCENTI 30 COMPRESSE DIVISIBILI | 2件: Calcium Calcium, Calcium carbonate | 2件: Calcium carbonate
Calcium carbonate
,
Calcium carbonate
💬 | - | - | 1件: 274 274 💬 |
527 | Calcium, Dietary | 1件: Calcium Calcium | - | - | - | 1件: 298 298 💬 |
528 | CALD HR-D (High-Risk, Regimen C) | - | - | - | - | 5件: 19 19, 20, 125, 234, 326 💬 |
529 | CALD HR-D (High-Risk, Regimen D) | - | - | - | - | 5件: 19 19, 20, 125, 234, 326 💬 |
530 | Candesartan plus non-CCB agents | 1件: Candesartan Candesartan | 1件: Candesartan
Candesartan
💬 | 1件: AGTR1 AGTR1 💬 | 16件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 67 67 💬 |
531 | Cannabidiol / Dronabinol capsule 5 mg+2,5 mg | 2件: Cannabidiol Cannabidiol, Dronabinol | 2件: Dronabinol
Dronabinol
,
Cannabidiol
💬 | 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 13 13 💬 |
532 | Cannabidiol Botanical Drug Substance (CBD BDS) | 1件: Cannabidiol Cannabidiol | 1件: Cannabidiol
Cannabidiol
💬 | 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 13 13 💬 |
533 | Cannabidiol Oral Solution, is known as Epidyolex 100 mg/mL oral solution and is the approved name in the EU. Epidiolex (cannabidiol) oral solution is the approved name in the US. | 1件: Cannabidiol Cannabidiol | 1件: Cannabidiol
Cannabidiol
💬 | 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 158 158 💬 |
534 | Capillary colchicine dosage in colchicine-resistant Familial Mediterranean Fever patients. | 1件: Colchicine Colchicine | 1件: Colchicine
Colchicine
💬 | 9件: TUBB TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 | 10件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Gap junction, Huntington disease, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬 | 1件: 266 266 💬 |
535 | Caplacizumab (an anti-von Willebrand Factor Nanobody ALX-0081) | 2件: Caplacizumab Caplacizumab, Von Willebrand factor human | 1件: Caplacizumab
Caplacizumab
💬 | 1件: VWF VWF 💬 | 8件: Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 | 1件: 64 64 💬 |
536 | Caplacizumab (an anti-von Willebrand Factor Nanobody) | 2件: Caplacizumab Caplacizumab, Von Willebrand factor human | 1件: Caplacizumab
Caplacizumab
💬 | 1件: VWF VWF 💬 | 8件: Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 | 1件: 64 64 💬 |
537 | Capsule di prednisone | 1件: Prednisone Prednisone | 1件: Prednisone
Prednisone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 41 41 💬 |
538 | Carbidopa 200mg oral dose | 1件: Carbidopa Carbidopa | 1件: Carbidopa
Carbidopa
💬 | 1件: DDC DDC 💬 | 9件: Alcoholism Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 2件: 6 6, 17 💬 |
539 | Carbidopa/l-dopa | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
540 | Carbidopa/l-dopa/entacapone | 3件: Carbidopa Carbidopa, Entacapone, Levodopa | 3件: Levodopa
Levodopa
,
Carbidopa
,
Entacapone
💬 | 7件: COMT COMT, DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 17件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Steroid hormone biosynthesis, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
541 | Carbon dioxide | 2件: Activated charcoal Activated charcoal, Carbon dioxide | 1件: Carbon dioxide
Carbon dioxide
💬 | - | - | 2件: 97 97, 158 💬 |
542 | Carbonate de lithium | 1件: Carbonate ion Carbonate ion | - | - | - | 1件: 2 2 💬 |
543 | Carnosine, capsulle, 2 g/day, 8 weeks | 1件: Carnosine Carnosine | - | - | - | 1件: 13 13 💬 |
544 | CAS # in D.3.9.1 for Sodium Salt. CAS number 1639325-43-1 (Parent Acid) | - | - | - | - | 1件: 254 254 💬 |
545 | CAS Name: 1,4-Benzoxazepin-5(2H)-one, 3,4-dihydro-4-(2-pyrimidinylmethyl)-7-[4- (trifluoromethoxy)phenyl] IUPAC Name: 4-(Pyrimidin-2-ylmethyl)-7-[4- (trifluoromethoxy)phenyl]-3,4-dihydro-1,4-benzoxazepin-5(2H)-one | - | - | - | - | 1件: 58 58 💬 |
546 | CAS Name: 1,4-Benzoxazepin-5(2H)-one, 3,4-dihydro-4-(2-pyrimidinylmethyl)-7-[4-(trifluoromethoxy)phenyl] IUPAC Name: 4-(Pyrimidin-2-ylmethyl)-7-[4-(trifluoromethoxy)phenyl]-3,4-dihydro-1,4-benzoxazepin-5(2H)-one | - | - | - | - | 1件: 58 58 💬 |
547 | CAS No.: 7758-16-9 | - | - | - | - | 1件: 166 166 💬 |
548 | CAS# in D.3.9.1 for Sodium Salt. CAS number 1639325-43-1 (Parent Acid) | - | - | - | - | 1件: 254 254 💬 |
549 | Caudal Epidural Injection with DepoMedrol | - | - | - | - | 1件: 70 70 💬 |
550 | Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03) | - | - | - | - | 1件: 85 85 💬 |
551 | CAYSTON aztreonam 75 mg powder and solvent for nebuliser solution | 1件: Aztreonam Aztreonam | 1件: Aztreonam
Aztreonam
💬 | - | - | 1件: 299 299 💬 |
552 | CBD - Oral Solution, is known as Epidiolex, and is the approved name in the USA. | 1件: Cannabidiol Cannabidiol | 1件: Cannabidiol
Cannabidiol
💬 | 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 2件: 140 140, 144 💬 |
553 | CBD - Oral Solution, is known as Epidyolex, and is the approved name | 1件: Cannabidiol Cannabidiol | 1件: Cannabidiol
Cannabidiol
💬 | 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 156 156 💬 |
554 | CBD - Solution Orale, conosciuto come Epidiolex, questo è il nome approvato negli Stati Uniti | 1件: Cannabidiol Cannabidiol | 1件: Cannabidiol
Cannabidiol
💬 | 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 156 156 💬 |
555 | CBD Oral solution, is known as Epidyolex and is the approved name in the EU | 1件: Cannabidiol Cannabidiol | 1件: Cannabidiol
Cannabidiol
💬 | 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 156 156 💬 |
556 | CBD soluzione orale nota come Epidyolex e con tale nome è stato approvato in UE | 1件: Cannabidiol Cannabidiol | 1件: Cannabidiol
Cannabidiol
💬 | 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 156 156 💬 |
557 | CBD-Oral Solution, is known as Epidiolex, and is the approved name in the USA. | 1件: Cannabidiol Cannabidiol | 1件: Cannabidiol
Cannabidiol
💬 | 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 158 158 💬 |
558 | CC-220 0.3 mg Daily | - | - | - | - | 1件: 84 84 💬 |
559 | CC-220 0.6mg Daily | - | - | - | - | 1件: 84 84 💬 |
560 | CD19-directed humanised afucosylated monoclonal antibody | - | - | - | - | 1件: 11 11 💬 |
561 | CD3/CD19 depleted leukocytes | - | - | - | - | 1件: 284 284 💬 |
562 | CD3/CD19 neg allogeneic BMT | - | - | - | - | 1件: 65 65 💬 |
563 | CD3/CD19 negative allogeneic hematopoietic stem cells | - | - | - | - | 1件: 65 65 💬 |
564 | CD3/CD19 negative hematopoietic stem cells | - | - | - | - | 1件: 85 85 💬 |
565 | CD34+ enriched, T Cell Depleted donor stem cell product | - | - | - | - | 1件: 326 326 💬 |
566 | CD45RA depleted leukocytes | - | - | - | - | 1件: 284 284 💬 |
567 | CDCA Weight-Based Dose TID | 1件: Chenodeoxycholic acid Chenodeoxycholic acid | 1件: Chenodiol
Chenodiol
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 263 263 💬 |
568 | CDED+PEN+dairy products | - | - | - | - | 1件: 96 96 💬 |
569 | CEFEPIME DIHYDROCHLORIDE MONOHYDRATE | 1件: Cefepime Cefepime | 1件: Cefepime
Cefepime
💬 | - | - | 1件: 60 60 💬 |
570 | Cell-based therapy of autologous adipose derived regenerative cells transplanted intraspinally and intrathecally in ALS patients | - | - | - | - | 1件: 2 2 💬 |
571 | Cellavita HD Higher dose | - | - | - | - | 1件: 8 8 💬 |
572 | Cellavita HD Lower Dose | - | - | - | - | 1件: 8 8 💬 |
573 | Cellcept® in autoimmune bullous dermatoses | - | - | - | - | 2件: 35 35, 162 💬 |
574 | Cellule CD34+ autologhe trasdotte con IDUA LV codificante per il cDNA dell'alfa-L-iduronidasi | - | - | - | - | 1件: 19 19 💬 |
575 | Celulas hepatocitos troncales adultas alogenicas de higado expandidas | - | - | - | - | 1件: 251 251 💬 |
576 | Celulas madre mesenquimales troncales adultas alogenicas de médula ósea no expandida | - | - | - | - | 1件: 274 274 💬 |
577 | CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) | - | - | - | - | 1件: 6 6 💬 |
578 | CERE-120: AAV2-NTN | - | - | - | - | 1件: 6 6 💬 |
579 | CERE-120: Adeno-Associated Virus Delivery of Neurturin | - | - | - | - | 1件: 6 6 💬 |
580 | Cerebral Dopamine Neurotrophic Factor | 1件: Dopamine Dopamine | 1件: Dopamine
Dopamine
💬 | 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
581 | Certolizumab pegol (CDP870, tradename Cimzia)(prefilled syringes at the dose of 200mg) | 1件: Certolizumab pegol Certolizumab pegol | 1件: Certolizumab pegol
Certolizumab pegol
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
582 | Cesamet™ (nabilone) | 1件: Nabilone Nabilone | 1件: Nabilone
Nabilone
💬 | 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 13 13 💬 |
583 | CETIRIZINA DICLORIDRATO | 1件: Cetirizine Cetirizine | 1件: Cetirizine
Cetirizine
💬 | 1件: HRH1 HRH1 💬 | 3件: Calcium signaling pathway Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction 💬 | 1件: 28 28 💬 |
584 | Ch11-1F4 (NSC-711516) | - | - | - | - | 1件: 28 28 💬 |
585 | ChAdOx1 nCoV-19 | 1件: AstraZeneca COVID-19 Vaccine AstraZeneca COVID-19 Vaccine | - | - | - | 3件: 46 46, 51, 299 💬 |
586 | Change in daily dosage of Growth Hormone | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
587 | CHF10067 high dose | - | - | - | - | 1件: 85 85 💬 |
588 | CHF10067 intermediate dose | - | - | - | - | 1件: 85 85 💬 |
589 | CHF10067 starting dose | - | - | - | - | 1件: 85 85 💬 |
590 | Chinese herbal concoction twice a day for 6 months | - | - | - | - | 1件: 60 60 💬 |
591 | Chinese herbs based on syndrome differentiation | - | - | - | - | 1件: 224 224 💬 |
592 | Chloroquine diphosphate | 1件: Chloroquine Chloroquine | 1件: Chloroquine
Chloroquine
💬 | - | - | 1件: 95 95 💬 |
593 | Chloroquine diphosphate 250mg | 1件: Chloroquine Chloroquine | 1件: Chloroquine
Chloroquine
💬 | - | - | 1件: 95 95 💬 |
594 | CHLORURE DE SODIUM | - | - | - | - | 1件: 96 96 💬 |
595 | Cholecalciferol (Vitamin D3) | 1件: Cholecalciferol Cholecalciferol | 1件: Cholecalciferol
Cholecalciferol
💬 | 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 2件: 13 13, 299 💬 |
596 | CHOLECALCIFEROL CONCENTRATE (WATER-DISPERSIBLE FORM) | 2件: Cholecalciferol Cholecalciferol, Water | 2件: Water
Water
,
Cholecalciferol
💬 | 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 96 96 💬 |
597 | Cholecalciferol, Vitamin D3 | 1件: Cholecalciferol Cholecalciferol | 1件: Cholecalciferol
Cholecalciferol
💬 | 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 13 13 💬 |
598 | Chong Kun Dang Tofacitinib Tablet | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 💬 |
599 | CHX A-DTPA anti-CD66 antibody | 1件: Pentetic acid Pentetic acid | 1件: Pentetic acid
Pentetic acid
💬 | - | - | 1件: 28 28 💬 |
600 | CHX-A-DTPA-Anti-CD66 | 1件: Pentetic acid Pentetic acid | 1件: Pentetic acid
Pentetic acid
💬 | - | - | 1件: 28 28 💬 |
601 | CIANOCOBALAMINA FU DC.IT | 1件: Cyanocobalamin Cyanocobalamin | 4件: Cyanocobalamin
Cyanocobalamin
,
Cyanocobalamin Co 57
,
Cyanocobalamin Co 58
,
Cyanocobalamin Co 60
💬 | - | - | 1件: 13 13 💬 |
602 | Ciliary neurotrophic factor | 1件: Ciliary neurotrophic factor Ciliary neurotrophic factor | - | - | - | 1件: 90 90 💬 |
603 | Ciliary Neurotrophic Factor Implant NT-501 | 1件: Ciliary neurotrophic factor Ciliary neurotrophic factor | - | - | - | 1件: 90 90 💬 |
604 | Cimetidine plus Dexpramipexole | 2件: Cimetidine Cimetidine, Dexpramipexole | 2件: Cimetidine
Cimetidine
,
Dexpramipexole
💬 | 6件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5, HRH2 💬 | 12件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Gastric acid secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 2 2 💬 |
605 | CIMZIA - 200MG-SOLUZIONE INIETTABILE-USO SOTTOCUTANEO-SIRINGA PRERIEMPITA(VETRO) 1ML 6(3X2) SIRINGHE PRERIEMPITE+6(3X2) SALVIETTINE IMBEVUTE DI | 1件: Certolizumab pegol Certolizumab pegol | 1件: Certolizumab pegol
Certolizumab pegol
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
606 | CIMZIA - 200MG-SOLUZIONE INIETTABILE-USO SOTTOCUTANEO-SIRINGA PRERIEMPITA(VETRO) 1ML 6(3X2) SIRINGHE PRERIEMPITE+6(3X2) SALVIETTINE IMBEVUTE DI ALCOOL | 1件: Certolizumab pegol Certolizumab pegol | 1件: Certolizumab pegol
Certolizumab pegol
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
607 | Ciprofloxacin (BAYQ3939) dry powder for inhalation | 1件: Ciprofloxacin Ciprofloxacin | 1件: Ciprofloxacin
Ciprofloxacin
💬 | - | - | 1件: 299 299 💬 |
608 | Ciprofloxacin dispersion for inhalation | 1件: Ciprofloxacin Ciprofloxacin | 1件: Ciprofloxacin
Ciprofloxacin
💬 | - | - | 1件: 299 299 💬 |
609 | Ciprofloxacin DPI | 1件: Ciprofloxacin Ciprofloxacin | 1件: Ciprofloxacin
Ciprofloxacin
💬 | - | - | 1件: 299 299 💬 |
610 | Ciprofloxacin DPI (BAYQ3939) | 1件: Ciprofloxacin Ciprofloxacin | 1件: Ciprofloxacin
Ciprofloxacin
💬 | - | - | 1件: 299 299 💬 |
611 | CIRCADIN 2 mg comprimidos de liberación prolongada | 1件: Melatonin Melatonin | 1件: Melatonin
Melatonin
💬 | 2件: MTNR1A MTNR1A, MTNR1B 💬 | 2件: Circadian entrainment Circadian entrainment, Neuroactive ligand-receptor interaction 💬 | 1件: 90 90 💬 |
612 | Citicolina 1000 mg/die | 1件: Citicoline Citicoline | 1件: Citicoline
Citicoline
💬 | - | - | 1件: 6 6 💬 |
613 | Clarithromycin (Not used as of 4/2020) | 1件: Clarithromycin Clarithromycin | 1件: Clarithromycin
Clarithromycin
💬 | - | - | 1件: 6 6 💬 |
614 | Classic DMARDs treatment group | - | - | - | - | 1件: 46 46 💬 |
615 | Classical ketogenic diet | - | - | - | - | 1件: 137 137 💬 |
616 | Clobazam High Dose | 1件: Clobazam Clobazam | 1件: Clobazam
Clobazam
💬 | 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 1件: 144 144 💬 |
617 | Clobazam Low Dose | 1件: Clobazam Clobazam | 1件: Clobazam
Clobazam
💬 | 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 1件: 144 144 💬 |
618 | Clobazam Medium Dose | 1件: Clobazam Clobazam | 1件: Clobazam
Clobazam
💬 | 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 1件: 144 144 💬 |
619 | Cloruro de Sodio | - | - | - | - | 1件: 228 228 💬 |
620 | CNS10-NPC implantation | - | - | - | - | 1件: 90 90 💬 |
621 | CNS10-NPC-GDNF | - | - | - | - | 1件: 2 2 💬 |
622 | Co-medication: Synthetic DMARDs | - | - | - | - | 1件: 46 46 💬 |
623 | Coagulación factor VIII | 1件: Beroctocog alfa Beroctocog alfa | - | - | - | 1件: 288 288 💬 |
624 | Coenzym Q10 Nanodispersion | - | - | - | - | 1件: 5 5 💬 |
625 | Coenzyme Q-10 in Normal Control subjects | 1件: Ubidecarenone Ubidecarenone | 1件: Ubidecarenone
Ubidecarenone
💬 | - | - | 1件: 86 86 💬 |
626 | Coenzyme Q10 Nanodispersion (Nanoquinone) | 1件: Ubidecarenone Ubidecarenone | 1件: Ubidecarenone
Ubidecarenone
💬 | - | - | 1件: 6 6 💬 |
627 | Cohort 1: hATG, CsA, EPAG Day 14 to Month 6 | 1件: Antilymphocyte immunoglobulin (horse) Antilymphocyte immunoglobulin (horse) | - | - | - | 1件: 60 60 💬 |
628 | Cohort 1:Nilotinib Oral Capsules (150mg or 300mg) | 1件: Nilotinib Nilotinib | 1件: Nilotinib
Nilotinib
💬 | 4件: ABL1 ABL1, KIT, PDGFRA, PDGFRB 💬 | 33件: Acute myeloid leukemia Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬 | 1件: 6 6 💬 |
629 | Cohort 2: hATG, CsA, EPAG Day 14 to Month 3 | 1件: Antilymphocyte immunoglobulin (horse) Antilymphocyte immunoglobulin (horse) | - | - | - | 1件: 60 60 💬 |
630 | Cohort 2: Nilotinib Oral Capsules (dose to be determined from Cohort 1) | 1件: Nilotinib Nilotinib | 1件: Nilotinib
Nilotinib
💬 | 4件: ABL1 ABL1, KIT, PDGFRA, PDGFRB 💬 | 33件: Acute myeloid leukemia Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬 | 1件: 6 6 💬 |
631 | Cohort 3: hATG, CsA (dose reduced), EPAG day 1 to month 6 | 1件: Antilymphocyte immunoglobulin (horse) Antilymphocyte immunoglobulin (horse) | - | - | - | 1件: 60 60 💬 |
632 | Colecalciferol D3 (Vigantol Oil) | 1件: Cholecalciferol Cholecalciferol | 1件: Cholecalciferol
Cholecalciferol
💬 | 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 96 96 💬 |
633 | Colfinair 2 MIU Powder for Nebuliser Solution | - | - | - | - | 1件: 299 299 💬 |
634 | Colistimethat-Natrium | - | - | - | - | 1件: 299 299 💬 |
635 | Colistimethate 75 mg inhaled two times daily | 1件: Colistimethate Colistimethate | - | - | - | 1件: 299 299 💬 |
636 | Colistimethate sodium (BAN, USAN), Colistimethatum natricum, Colistin sodium methanesulfonate | 2件: Colistimethate Colistimethate, Colistin | 1件: Colistin
Colistin
💬 | - | - | 1件: 299 299 💬 |
637 | Collect of 10 ml of peripheric blood for DNA extraction | - | - | - | - | 1件: 46 46 💬 |
638 | Combination of a single dose anti-CD20 antibody and bortezomib | 1件: Bortezomib Bortezomib | 1件: Bortezomib
Bortezomib
💬 | 1件: PSMB5 PSMB5 💬 | 8件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬 | 1件: 61 61 💬 |
639 | Combination of DMARDs | - | - | - | - | 1件: 107 107 💬 |
640 | Combination of Protein A Immunoadsorption, Rituximab, Dexamethasone plus Azathioprine | 3件: Azathioprine Azathioprine, Dexamethasone, Rituximab | 3件: Azathioprine
Azathioprine
,
Dexamethasone
,
Rituximab
💬 | 2件: MS4A1 MS4A1, NR3C1 💬 | 2件: Hematopoietic cell lineage Hematopoietic cell lineage, Neuroactive ligand-receptor interaction 💬 | 1件: 35 35 💬 |
641 | Combination Product: Active treatment with dual therapy | - | - | - | - | 1件: 2 2 💬 |
642 | Combination Product: Beclomethasone dipropionate in addition to MC-EVOO | 1件: Beclomethasone dipropionate Beclomethasone dipropionate | 1件: Beclomethasone dipropionate
Beclomethasone dipropionate
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 97 97 💬 |
643 | Combination Product: Beclomethasone dipropionate in addition to refined oil | 1件: Beclomethasone dipropionate Beclomethasone dipropionate | 1件: Beclomethasone dipropionate
Beclomethasone dipropionate
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 97 97 💬 |
644 | Combination Product: EGCG 300 mg + Nintedanib | 2件: Epigallocatechin gallate Epigallocatechin gallate, Nintedanib | 1件: Nintedanib
Nintedanib
💬 | 8件: FGFR1 FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 | 34件: Adherens junction Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, Choline metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, Gap junction, Gastric cancer, Glioma, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Rheumatoid arthritis, Signaling pathways regulating pluripotency of stem cells, Thermogenesis, Transcriptional misregulation in cancer, VEGF signaling pathway 💬 | 1件: 85 85 💬 |
645 | Combination Product: EGCG 600 mg + Nintedanib | 2件: Epigallocatechin gallate Epigallocatechin gallate, Nintedanib | 1件: Nintedanib
Nintedanib
💬 | 8件: FGFR1 FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 | 34件: Adherens junction Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, Choline metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, Gap junction, Gastric cancer, Glioma, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Rheumatoid arthritis, Signaling pathways regulating pluripotency of stem cells, Thermogenesis, Transcriptional misregulation in cancer, VEGF signaling pathway 💬 | 1件: 85 85 💬 |
646 | Combination Product: L-dopa 140 mg | 1件: Levodopa Levodopa | 1件: Levodopa
Levodopa
💬 | 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
647 | Combination Product: L-dopa 35 mg | 1件: Levodopa Levodopa | 1件: Levodopa
Levodopa
💬 | 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
648 | Combination Product: L-dopa 70mg | 1件: Levodopa Levodopa | 1件: Levodopa
Levodopa
💬 | 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
649 | Combination Product: L-dopa 70mg/carbidopa 7mg | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
650 | Combination Product: ND0612 Solution for SC infusion | - | - | - | - | 1件: 6 6 💬 |
651 | Comirnaty concentrate for dispersion for injection | 1件: Tozinameran Tozinameran | 1件: Tozinameran
Tozinameran
💬 | - | - | 2件: 53 53, 299 💬 |
652 | Common Name: Sialic Acid | - | - | - | - | 1件: 30 30 💬 |
653 | Comparator: diclofenac | 1件: Diclofenac Diclofenac | 1件: Diclofenac
Diclofenac
💬 | 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 46 46 💬 |
654 | Comparator: Diclofenac sodium | 1件: Diclofenac Diclofenac | 1件: Diclofenac
Diclofenac
💬 | 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 46 46 💬 |
655 | Comparator: naproxen tablet 500 mg | 1件: Naproxen Naproxen | 1件: Naproxen
Naproxen
💬 | 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 46 46 💬 |
656 | Compressa effervescente 0,5 mg di budesonide per uso orodispersibile | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 💬 |
657 | Compressa effervescente 1 mg di budesonide per uso orodispersibile | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 💬 |
658 | Conjugated equine estrogens 0.625 mg/d + MPA 5 mg/d/10d | 1件: Conjugated estrogens Conjugated estrogens | 1件: Estrogens, conjugated
Estrogens, conjugated
💬 | - | - | 1件: 49 49 💬 |
659 | Continuation of current HAART (boosted protease inhibitor [PI] combination + 2 NRTIs) | - | - | - | - | 1件: 265 265 💬 |
660 | Continue IS (B cell depletion therapy) | - | - | - | - | 7件: 13 13, 35, 46, 49, 50, 51, 107 💬 |
661 | Continuous Release Dopamine Agonists | 1件: Dopamine Dopamine | 1件: Dopamine
Dopamine
💬 | 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
662 | Control intervention (no dexamethasone) | 1件: Dexamethasone Dexamethasone | 1件: Dexamethasone
Dexamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 46 46 💬 |
663 | Convection enhanced delivery/AAV2-GDNF | - | - | - | - | 1件: 6 6 💬 |
664 | Conventional DMARD combination | - | - | - | - | 1件: 46 46 💬 |
665 | Conventional DMARDs | - | - | - | - | 1件: 46 46 💬 |
666 | Conventional drug therapy(expectorant,bronchodilator) | - | - | - | - | 1件: 86 86 💬 |
667 | Conventional Glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone) | 7件: Acetate Acetate, Cortisone, Cortisone acetate, Dexamethasone, Hydrocortisone, Prednisolone, Prednisone | 6件: Hydrocortisone
Hydrocortisone
,
Dexamethasone
,
Prednisolone
,
Prednisone
,
Cortisone acetate
,
Cortisone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 81 81 💬 |
668 | Conventional synthetic antirheumatic drugs | - | - | - | - | 1件: 46 46 💬 |
669 | Conventional Synthetic DMARD | - | - | - | - | 1件: 46 46 💬 |
670 | Conventional treatment (glucocoticoid, immunosupressive drugs and/or mesalazine) | 1件: Mesalazine Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 2件: 96 96, 97 💬 |
671 | COPAXONE - 40 MG/ML SOLUZIONE INIETTABILE IN SIRINGA PRERIEMPITA 12 SIRINGHE PRERIEMPITE DA 1 ML CON AGO | 1件: Glatiramer Glatiramer | - | - | - | 1件: 13 13 💬 |
672 | COPAXONE 20 mg/ml solución inyectable en jeringa precargada | 1件: Glatiramer Glatiramer | - | - | - | 1件: 13 13 💬 |
673 | Copaxone 20 mg/ml solución para inyección en jeringa precargada | 1件: Glatiramer Glatiramer | - | - | - | 1件: 13 13 💬 |
674 | Corticosteroid and non-biological agents. | - | - | - | - | 1件: 46 46 💬 |
675 | Corticosteroid or NSAID | - | - | - | - | 1件: 46 46 💬 |
676 | Corynebacterium diphtheriae | 1件: Corynebacterium diphtheriae Corynebacterium diphtheriae | - | - | - | 1件: 11 11 💬 |
677 | COVID-19 mRNA Vaccine (nucleoside modified) | - | - | - | - | 3件: 13 13, 46, 51 💬 |
678 | COVID-19 mRNA vaccine (nucleoside-modified) | - | - | - | - | 4件: 13 13, 46, 51, 299 💬 |
679 | COVID-19 vaccine AstraZeneca (ChAdOx1 nCoV-19) | 1件: AstraZeneca COVID-19 Vaccine AstraZeneca COVID-19 Vaccine | - | - | - | 3件: 46 46, 51, 299 💬 |
680 | COVID-19 Vaccine Moderna dispersion for injection | 1件: Moderna COVID-19 Vaccine Moderna COVID-19 Vaccine | 1件: Elasomeran
Elasomeran
💬 | - | - | 1件: 299 299 💬 |
681 | CP-690-550-10 (DMID D1600180) | - | - | - | - | 1件: 107 107 💬 |
682 | CPL500036 - high dose | - | - | - | - | 1件: 6 6 💬 |
683 | CPL500036 - low dose | - | - | - | - | 1件: 6 6 💬 |
684 | Crema de rapamicina al 1% y excipientes | - | - | - | - | 1件: 157 157 💬 |
685 | Creon N | - | - | - | - | 1件: 299 299 💬 |
686 | CREON N 25000 | - | - | - | - | 1件: 299 299 💬 |
687 | Creon® (DR/GR) | - | - | - | - | 1件: 299 299 💬 |
688 | Crinecerfont is a novel non-peptide selective corticotropin releasing factor 1 (CRF1 ) receptor antagonist. | 1件: Corticotropin Corticotropin | 1件: Corticotropin
Corticotropin
💬 | 1件: MC2R MC2R 💬 | 5件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 81 81 💬 |
689 | Crohn's Disease | - | - | - | - | 1件: 96 96 💬 |
690 | Crohn's disease exclusion diet (CDED) | - | - | - | - | 1件: 96 96 💬 |
691 | Crohns Disease Exclusion Diet + PEN | - | - | - | - | 1件: 96 96 💬 |
692 | Cromoglicato disodico | - | - | - | - | 1件: 85 85 💬 |
693 | Cromolyn sodio (cromoglicato disodico, DSCG) | 1件: Cromoglicic acid Cromoglicic acid | 1件: Cromoglicic acid
Cromoglicic acid
💬 | - | - | 1件: 85 85 💬 |
694 | Cromolyn sodium [Disodium Cromoglycate] | 1件: Cromoglicic acid Cromoglicic acid | 1件: Cromoglicic acid
Cromoglicic acid
💬 | - | - | 1件: 85 85 💬 |
695 | CS20AT04 (allogenic bone marrow derived mesenchymal stem cell) | - | - | - | - | 1件: 49 49 💬 |
696 | CSM allogéniques issues de cordons ombilicaux ( MTI-PP) | - | - | - | - | 1件: 49 49 💬 |
697 | Cu-64 DOTATATE | 1件: Dotatate Dotatate | - | - | - | 1件: 84 84 💬 |
698 | Cufence (trientine dihydrochloride) | 1件: Triethylenetetramine Triethylenetetramine | - | - | - | 1件: 171 171 💬 |
699 | CVT-301 (Dose Level 1) | - | - | - | - | 1件: 6 6 💬 |
700 | CVT-301 (Dose Level 2) | - | - | - | - | 1件: 6 6 💬 |
701 | CVT-301 High Dose | - | - | - | - | 1件: 6 6 💬 |
702 | CVT-301 Low Dose | - | - | - | - | 1件: 6 6 💬 |
703 | Cyclo ((diaminoethyl-carbamate)HyPro-Phg-(D) Trp-Ly di-aspartate | - | - | - | - | 1件: 75 75 💬 |
704 | Cyclo ((diaminoethyl-carbamate)HyPro-Phg-(D)Trp-Ly di-aspartate | - | - | - | - | 1件: 75 75 💬 |
705 | Cyclo((diaminoethyl-carbamate)HyPro-Phg-(D)Trp-Lys-Tyr(Bzl)-Phe) di-aspartate | - | - | - | - | 1件: 75 75 💬 |
706 | Cyclo(diaminoethyl-carbamate)HyPro-Phg-(D)Trp-Lys-Tyr(Bzl)-Phe) | - | - | - | - | 1件: 75 75 💬 |
707 | CYCLO[L-ALANYL-L-SERYL-L-ISOLEUCYL-L-PROLYL-L-PROLYL-L-GLUTAMINYL-L-LYSYL-L-TYROSYL-D-PROLYL-L-PROLYL-(2S)-2-AMINODECANOYL-L-ALPHA-GLUTAMYL-L-THREONYL] | - | - | - | - | 1件: 299 299 💬 |
708 | Cyclophosphamide (drug) | 1件: Cyclophosphamide Cyclophosphamide | 2件: Cyclophosphamide
Cyclophosphamide
,
Cyclophosphamide
💬 | - | - | 1件: 13 13 💬 |
709 | Cyclophosphamide Dose Level 1 | 1件: Cyclophosphamide Cyclophosphamide | 2件: Cyclophosphamide
Cyclophosphamide
,
Cyclophosphamide
💬 | - | - | 2件: 65 65, 284 💬 |
710 | Cyclophosphamide Dose Level 2 | 1件: Cyclophosphamide Cyclophosphamide | 2件: Cyclophosphamide
Cyclophosphamide
,
Cyclophosphamide
💬 | - | - | 2件: 65 65, 284 💬 |
711 | Cyclophosphamide Dose Level 3 | 1件: Cyclophosphamide Cyclophosphamide | 2件: Cyclophosphamide
Cyclophosphamide
,
Cyclophosphamide
💬 | - | - | 2件: 65 65, 284 💬 |
712 | Cyclophosphamide Dose Level 4 | 1件: Cyclophosphamide Cyclophosphamide | 2件: Cyclophosphamide
Cyclophosphamide
,
Cyclophosphamide
💬 | - | - | 2件: 65 65, 284 💬 |
713 | Cyclophosphamide, bortezomib, and Dexamethasone (CyBorD) regimen | 3件: Bortezomib Bortezomib, Cyclophosphamide, Dexamethasone | 4件: Cyclophosphamide
Cyclophosphamide
,
Dexamethasone
,
Bortezomib
,
Cyclophosphamide
💬 | 2件: NR3C1 NR3C1, PSMB5 💬 | 9件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Neuroactive ligand-receptor interaction, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬 | 1件: 28 28 💬 |
714 | Cyclophosphamide, Bortezomib, dexamethasone | 3件: Bortezomib Bortezomib, Cyclophosphamide, Dexamethasone | 4件: Cyclophosphamide
Cyclophosphamide
,
Dexamethasone
,
Bortezomib
,
Cyclophosphamide
💬 | 2件: NR3C1 NR3C1, PSMB5 💬 | 9件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Neuroactive ligand-receptor interaction, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬 | 1件: 28 28 💬 |
715 | Cyclophosphamide, Bortezomib, dexamethasone plus Daratumumab | 4件: Bortezomib Bortezomib, Cyclophosphamide, Daratumumab, Dexamethasone | 5件: Cyclophosphamide
Cyclophosphamide
,
Dexamethasone
,
Bortezomib
,
Cyclophosphamide
,
Daratumumab
💬 | 3件: CD38 CD38, NR3C1, PSMB5 💬 | 16件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Calcium signaling pathway, Hematopoietic cell lineage, Huntington disease, Metabolic pathways, Neuroactive ligand-receptor interaction, Nicotinate and nicotinamide metabolism, Oxytocin signaling pathway, Pancreatic secretion, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Salivary secretion, Spinocerebellar ataxia 💬 | 1件: 28 28 💬 |
716 | Cyclosporin, low dose steroid | 1件: Cyclosporine Cyclosporine | 1件: Cyclosporine
Cyclosporine
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 222 222 💬 |
717 | Cyclosporine 5 mg/kg bid days 0-14 | 1件: Cyclosporine Cyclosporine | 1件: Cyclosporine
Cyclosporine
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 2件: 38 38, 39 💬 |
718 | Cyclosporine A dry powder inhalation (Drug) | 1件: Cyclosporine Cyclosporine | 1件: Cyclosporine
Cyclosporine
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 228 228 💬 |
719 | CYSTADROPS 0.55% eye drops, solution | 1件: Cysteamine Cysteamine | 1件: Cysteamine
Cysteamine
💬 | - | - | 1件: 19 19 💬 |
720 | Cysteamine Bitartrate Delayed-release Capsules | 1件: Cysteamine Cysteamine | 1件: Cysteamine
Cysteamine
💬 | - | - | 1件: 19 19 💬 |
721 | Cysteamine Bitartrate Delayed-release Capsules (RP103) | 1件: Cysteamine Cysteamine | 1件: Cysteamine
Cysteamine
💬 | - | - | 1件: 19 19 💬 |
722 | Cápsulas de Laquinimod 0.6 mg | 1件: Laquinimod Laquinimod | - | - | - | 1件: 13 13 💬 |
723 | Células madre mesenquimales de tejido adiposo autólogo | - | - | - | - | 1件: 2 2 💬 |
724 | Células madre mesenquimales haploidénticas derivadas de médula ósea | - | - | - | - | 1件: 36 36 💬 |
725 | Células Mesenquimales de tejido adiposo | - | - | - | - | 1件: 2 2 💬 |
726 | Células mesenquimales troncales adultas alogénicas de médula ósea no expandidas | - | - | - | - | 1件: 274 274 💬 |
727 | Células mesenquimales troncales adultas alogénicas de médula ósea no expandidas(ref cruzada PEI nº 12-088) | - | - | - | - | 1件: 274 274 💬 |
728 | Células mesenquimales troncales adultas autólogas de medula ósea expandidas | - | - | - | - | 1件: 117 117 💬 |
729 | Células mesenquimales troncales adultas autólogas de médula ósea expandidas | - | - | - | - | 1件: 117 117 💬 |
730 | Células troncales hematopoyéticas autólogas adultas extraidas de médula ósea | - | - | - | - | 1件: 2 2 💬 |
731 | D-glucitol, 1-deoxy-1-(methylamino)-, 2-(3,5-dichlorophenyl)-6-benzoxazolecarboxylate (1:1) | 1件: Sorbitol Sorbitol | 1件: Sorbitol solution
Sorbitol solution
💬 | - | - | 1件: 28 28 💬 |
732 | D-glucitol, 1-deoxy-1-(methylamino)-,2-(3,5-dichlorophenyl)-6-benzoxazolecarboxylate (1:1) | 1件: Sorbitol Sorbitol | 1件: Sorbitol solution
Sorbitol solution
💬 | - | - | 1件: 28 28 💬 |
733 | D-serine (~2g/day) | 2件: D-Serine D-Serine, Serine | 1件: Serine
Serine
💬 | - | - | 1件: 6 6 💬 |
734 | D.3.6.2 - dose massima specificare: giornaliera | - | - | - | - | 1件: 86 86 💬 |
735 | D6-25-hydroxyvitamin D3 | 1件: Calcifediol Calcifediol | 1件: Calcifediol
Calcifediol
💬 | 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 299 299 💬 |
736 | Daclizumab HYP (DAC HYP | 1件: Daclizumab Daclizumab | 1件: Daclizumab
Daclizumab
💬 | 1件: IL2RA IL2RA 💬 | 11件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 13 13 💬 |
737 | Daclizumab HYP (DAC HYP) | 1件: Daclizumab Daclizumab | 1件: Daclizumab
Daclizumab
💬 | 1件: IL2RA IL2RA 💬 | 11件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 13 13 💬 |
738 | Dacortín 2,5mg | - | - | - | - | 1件: 222 222 💬 |
739 | Dacortín 30mg | - | - | - | - | 1件: 222 222 💬 |
740 | Dacortín 5mg | - | - | - | - | 1件: 222 222 💬 |
741 | DAND (14-Deoxyandrographolide) | - | - | - | - | 1件: 97 97 💬 |
742 | Dapirolizumab pegol (DZP) | 1件: Dapirolizumab pegol Dapirolizumab pegol | - | - | - | 1件: 49 49 💬 |
743 | Davunetide (AL-108, NAP) | 1件: Davunetide Davunetide | 1件: Davunetide
Davunetide
💬 | - | - | 3件: 5 5, 7, 127 💬 |
744 | DDAND (14-deoxy-11,12-didehydroandrographolide) | - | - | - | - | 1件: 97 97 💬 |
745 | DDAVP (Desmopressin) | 1件: Desmopressin Desmopressin | 1件: Desmopressin
Desmopressin
💬 | 2件: AVPR2 AVPR2, F8 💬 | 4件: Complement and coagulation cascades Complement and coagulation cascades, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 288 288 💬 |
746 | Deferiprone 600 mg delayed release tablet | 1件: Deferiprone Deferiprone | 1件: Deferiprone
Deferiprone
💬 | - | - | 1件: 6 6 💬 |
747 | Deferiprone DR | 1件: Deferiprone Deferiprone | 1件: Deferiprone
Deferiprone
💬 | - | - | 2件: 2 2, 6 💬 |
748 | Dehydroepiandrosterone (DHEA) | 1件: Prasterone Prasterone | 1件: Prasterone
Prasterone
💬 | 3件: AR AR, ESR1, ESR2 💬 | 12件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Oocyte meiosis, Pathways in cancer, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬 | 1件: 49 49 💬 |
749 | Dehydroepiandrosterone [DHEA] | 1件: Prasterone Prasterone | 1件: Prasterone
Prasterone
💬 | 3件: AR AR, ESR1, ESR2 💬 | 12件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Oocyte meiosis, Pathways in cancer, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬 | 1件: 96 96 💬 |
750 | Depletion in CD45RA graft donor | - | - | - | - | 1件: 65 65 💬 |
751 | Desmopressine nasal spray 10 mg/ml, flacon 60 doses | 1件: Desmopressin Desmopressin | 1件: Desmopressin
Desmopressin
💬 | 2件: AVPR2 AVPR2, F8 💬 | 4件: Complement and coagulation cascades Complement and coagulation cascades, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 225 225 💬 |
752 | Determination of drug effects through amantadine cessation | 1件: Amantadine Amantadine | 1件: Amantadine
Amantadine
💬 | 5件: GRIN1 GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬 | 20件: Alcoholism Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
753 | Dexamethasone (50mg 1dd6, 3 consecutive days/month) | 1件: Dexamethasone Dexamethasone | 1件: Dexamethasone
Dexamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 35 35 💬 |
754 | Dexamethasone 21-dihydrogen phosphate | 3件: Dexamethasone Dexamethasone, Hydrogen, Phosphate ion | 1件: Dexamethasone
Dexamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 65 65 💬 |
755 | Dexamethasone oral tablet 8mg (Dexamethasone Krka tablets(8mg), Warsaw, Poland). | 1件: Dexamethasone Dexamethasone | 1件: Dexamethasone
Dexamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 235 235 💬 |
756 | Dexpramipexole (dose 1) | 1件: Dexpramipexole Dexpramipexole | 1件: Dexpramipexole
Dexpramipexole
💬 | 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 2 2 💬 |
757 | Dexpramipexole (dose 2) | 1件: Dexpramipexole Dexpramipexole | 1件: Dexpramipexole
Dexpramipexole
💬 | 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 2 2 💬 |
758 | Dexpramipexole Dichydrochloride | 1件: Dexpramipexole Dexpramipexole | 1件: Dexpramipexole
Dexpramipexole
💬 | 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 2 2 💬 |
759 | Dexpramipexole Dihydrochloride | 1件: Dexpramipexole Dexpramipexole | 1件: Dexpramipexole
Dexpramipexole
💬 | 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 2 2 💬 |
760 | Dexrazoxane (DRZ) plus Mitoxantrone (MX) | 2件: Dexrazoxane Dexrazoxane, Mitoxantrone | 2件: Dexrazoxane
Dexrazoxane
,
Mitoxantrone
💬 | 2件: TOP2A TOP2A, TOP2B 💬 | 1件: Platinum drug resistance Platinum drug resistance 💬 | 1件: 13 13 💬 |
761 | Dextran Sodium Sulfur Salt 5, Mw 5 kDa. a type of Low Molecular Weight Dextran Sulfate (LMW-DS) | 2件: Dextran Dextran, Sulfate ion | 1件: Dextran 1
Dextran 1
💬 | - | - | 1件: 2 2 💬 |
762 | Dextromethorphan/quinidine 20mg/10mg (DM/Q 20mg/10mg) | 2件: Dextromethorphan Dextromethorphan, Quinidine | 2件: Dextromethorphan
Dextromethorphan
,
Quinidine
💬 | 11件: GRIN1 GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A, SIGMAR1 💬 | 22件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, Taste transduction, cAMP signaling pathway 💬 | 1件: 8 8 💬 |
763 | Diagnosis of Fabry disease | - | - | - | - | 1件: 19 19 💬 |
764 | Dietanolamina de treprostinilo | 1件: Treprostinil Treprostinil | 1件: Treprostinil
Treprostinil
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 💬 |
765 | Diethyl-[6-(4-hydroxycarbamoyl- phenyl carbamoyloxymethyl)-naphthalen-2-yl methyl]-ammonium chloride | 2件: Ammonium chloride Ammonium chloride, Chloride ion | 1件: Ammonium chloride
Ammonium chloride
💬 | - | - | 1件: 107 107 💬 |
766 | Diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphtalen-2-ylmethyl]-ammonium chloride mon | 2件: Ammonium chloride Ammonium chloride, Chloride ion | 1件: Ammonium chloride
Ammonium chloride
💬 | - | - | 1件: 96 96 💬 |
767 | Dietician designed diet | - | - | - | - | 1件: 96 96 💬 |
768 | Different diets | - | - | - | - | 1件: 6 6 💬 |
769 | Diflunisal (dolobid) | 1件: Diflunisal Diflunisal | 1件: Diflunisal
Diflunisal
💬 | 1件: PTGS2 PTGS2 💬 | 22件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 28 28 💬 |
770 | Dimebon + Dextromethorphan | 2件: Dextromethorphan Dextromethorphan, Latrepirdine | 2件: Dextromethorphan
Dextromethorphan
,
Latrepirdine
💬 | 7件: ACHE ACHE, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, SIGMAR1 💬 | 22件: Alcoholism Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Cholinergic synapse, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Glycerophospholipid metabolism, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, cAMP signaling pathway 💬 | 1件: 8 8 💬 |
771 | Dimebon Dihydrochloride | 1件: Latrepirdine Latrepirdine | 1件: Latrepirdine
Latrepirdine
💬 | 6件: ACHE ACHE, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬 | 22件: Alcoholism Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Cholinergic synapse, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Glycerophospholipid metabolism, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, cAMP signaling pathway 💬 | 1件: 8 8 💬 |
772 | Dimethyl Fumarate (DMF) | 1件: Dimethyl fumarate Dimethyl fumarate | 1件: Dimethyl fumarate
Dimethyl fumarate
💬 | 1件: KEAP1 KEAP1 💬 | 6件: Chemical carcinogenesis - reactive oxygen species Chemical carcinogenesis - reactive oxygen species, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Parkinson disease, Pathways in cancer, Ubiquitin mediated proteolysis 💬 | 3件: 13 13, 51, 86 💬 |
773 | Dimethyl fumarate [DMF] | 1件: Dimethyl fumarate Dimethyl fumarate | 1件: Dimethyl fumarate
Dimethyl fumarate
💬 | 1件: KEAP1 KEAP1 💬 | 6件: Chemical carcinogenesis - reactive oxygen species Chemical carcinogenesis - reactive oxygen species, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Parkinson disease, Pathways in cancer, Ubiquitin mediated proteolysis 💬 | 1件: 13 13 💬 |
774 | Dimethyl sulfoxide (DMSO) | 1件: Dimethyl sulfoxide Dimethyl sulfoxide | 1件: Dimethyl sulfoxide
Dimethyl sulfoxide
💬 | - | - | 1件: 226 226 💬 |
775 | Diprofos Depot | - | - | - | - | 1件: 46 46 💬 |
776 | Diroximel Fumarate (DRF) | 1件: Diroximel fumarate Diroximel fumarate | 1件: Diroximel fumarate
Diroximel fumarate
💬 | - | - | 1件: 13 13 💬 |
777 | Discontinuation of disease modifying therapy | - | - | - | - | 1件: 13 13 💬 |
778 | Disease modified antirheumatic drugs or biological agents | - | - | - | - | 1件: 46 46 💬 |
779 | Disease modifying treatment (DMT) | - | - | - | - | 1件: 13 13 💬 |
780 | Disease-modifying anti-rheumatic drugs | - | - | - | - | 1件: 46 46 💬 |
781 | Disease-modifying antirheumatic drug | - | - | - | - | 1件: 46 46 💬 |
782 | Disease-modifying antirheumatic drugs (DMARDs) | - | - | - | - | 1件: 46 46 💬 |
783 | Disodium cromoglycate (DSCG) | 1件: Cromoglicic acid Cromoglicic acid | 1件: Cromoglicic acid
Cromoglicic acid
💬 | - | - | 1件: 85 85 💬 |
784 | Diuretics (plus antiarrhythmic drugs, i.e. amiodarone, in case of complex ventricular arrhithmias) | 1件: Amiodarone Amiodarone | 1件: Amiodarone
Amiodarone
💬 | 16件: ADRA1A ADRA1A, ADRA1B, ADRA1D, ADRB1, KCND3, KCNJ11, KCNJ12, KCNJ3, KCNJ5, KCNJ8, KCNQ1, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | 32件: AMPK signaling pathway AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Circadian entrainment, Dilated cardiomyopathy, Dopaminergic synapse, Estrogen signaling pathway, Gap junction, Gastric acid secretion, Glutamatergic synapse, GnRH secretion, Insulin secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Oxytocin signaling pathway, Pancreatic secretion, Protein digestion and absorption, Regulation of lipolysis in adipocytes, Renin secretion, Retrograde endocannabinoid signaling, Salivary secretion, Serotonergic synapse, Spinocerebellar ataxia, Taste transduction, Type II diabetes mellitus, Vascular smooth muscle contraction, Vibrio cholerae infection, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 28 28 💬 |
785 | Diuretics (plus antiarrhythmic drugs, i.e. amiodarone, in case of complex ventricular arrhythmias) plus EGCG | 2件: Amiodarone Amiodarone, Epigallocatechin gallate | 1件: Amiodarone
Amiodarone
💬 | 16件: ADRA1A ADRA1A, ADRA1B, ADRA1D, ADRB1, KCND3, KCNJ11, KCNJ12, KCNJ3, KCNJ5, KCNJ8, KCNQ1, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | 32件: AMPK signaling pathway AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Circadian entrainment, Dilated cardiomyopathy, Dopaminergic synapse, Estrogen signaling pathway, Gap junction, Gastric acid secretion, Glutamatergic synapse, GnRH secretion, Insulin secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Oxytocin signaling pathway, Pancreatic secretion, Protein digestion and absorption, Regulation of lipolysis in adipocytes, Renin secretion, Retrograde endocannabinoid signaling, Salivary secretion, Serotonergic synapse, Spinocerebellar ataxia, Taste transduction, Type II diabetes mellitus, Vascular smooth muscle contraction, Vibrio cholerae infection, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 28 28 💬 |
786 | Dl-3-n-butylphthalide (NBP) | 1件: Butylphthalide Butylphthalide | - | - | - | 1件: 22 22 💬 |
787 | DMARDs (disease-modifying antirheumatic drugs) | - | - | - | - | 1件: 46 46 💬 |
788 | DNL151, DN0001575, DN1575 | - | - | - | - | 1件: 6 6 💬 |
789 | DNL310 Drug Substance | - | - | - | - | 1件: 19 19 💬 |
790 | DNS-7801 (high dose) | - | - | - | - | 1件: 6 6 💬 |
791 | DNS-7801 (low-dose) | - | - | - | - | 1件: 6 6 💬 |
792 | Docosahexaenoic Acid (DHA) | 1件: Doconexent Doconexent | - | - | - | 3件: 6 6, 94, 299 💬 |
793 | Docosahexaenoic Acid (DHA) Dietary Supplement | 1件: Doconexent Doconexent | - | - | - | 1件: 301 301 💬 |
794 | Docosahexaenoic acid administration: 50 mg/kg/day during 12 months | 1件: Doconexent Doconexent | - | - | - | 1件: 299 299 💬 |
795 | Dolutegravir/Lamivudine 50 MG-300 MG Oral Tablet [DOVATO] | 2件: Dolutegravir Dolutegravir, Lamivudine | 2件: Lamivudine
Lamivudine
,
Dolutegravir
💬 | - | - | 1件: 265 265 💬 |
796 | Domperidone (drug) | 1件: Domperidone Domperidone | 2件: Domperidone
Domperidone
,
Domperidone maleate
💬 | 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
797 | Donepezil HCI (drug) | 1件: Donepezil Donepezil | 1件: Donepezil
Donepezil
💬 | 1件: ACHE ACHE 💬 | 2件: Cholinergic synapse Cholinergic synapse, Glycerophospholipid metabolism 💬 | 1件: 13 13 💬 |
798 | Donor Lymphocyte Infusion (DLI) | - | - | - | - | 1件: 60 60 💬 |
799 | DopaFuse Delivery System | - | - | - | - | 1件: 6 6 💬 |
800 | Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate 100 MG-300 MG-300 MG Oral Tablet [DELSTRIGO] | 4件: Doravirine Doravirine, Lamivudine, Tenofovir, Tenofovir disoproxil | 3件: Lamivudine
Lamivudine
,
Tenofovir
,
Doravirine
💬 | - | - | 1件: 265 265 💬 |
801 | Dose-Establishing Study 1 Niacin 250mg | 1件: Niacin Niacin | 1件: Niacin
Niacin
💬 | - | - | 1件: 78 78 💬 |
802 | Dose-Establishing Study 1 Niacin 500mg | 1件: Niacin Niacin | 1件: Niacin
Niacin
💬 | - | - | 1件: 78 78 💬 |
803 | Dose-Establishing Study 2 Niacin 500mg | 1件: Niacin Niacin | 1件: Niacin
Niacin
💬 | - | - | 1件: 78 78 💬 |
804 | Dosing Interruption of Natalizumab | 1件: Natalizumab Natalizumab | 1件: Natalizumab
Natalizumab
💬 | 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 💬 |
805 | Double Dose | - | - | - | - | 2件: 38 38, 162 💬 |
806 | Doxycycline 100-200mg capsules daily for 6 months | 1件: Doxycycline Doxycycline | 2件: Doxycycline
Doxycycline
,
Doxycycline
💬 | - | - | 1件: 167 167 💬 |
807 | Doxycycline Injection [Doxy] | 1件: Doxycycline Doxycycline | 2件: Doxycycline
Doxycycline
,
Doxycycline
💬 | - | - | 1件: 34 34 💬 |
808 | Dr. Reddy’s Rituximab (DRL_RI) 100mg | 1件: Rituximab Rituximab | 1件: Rituximab
Rituximab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 46 46 💬 |
809 | Dr. Reddy’s Rituximab (DRL_RI) 500mg | 1件: Rituximab Rituximab | 1件: Rituximab
Rituximab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 46 46 💬 |
810 | Dried blood spot (DBS) sampling | - | - | - | - | 1件: 19 19 💬 |
811 | Dronabinol 25 mg/ml, oral drops | 1件: Dronabinol Dronabinol | 1件: Dronabinol
Dronabinol
💬 | 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 13 13 💬 |
812 | Droxidopa 100 MG [Northera] | 1件: Droxidopa Droxidopa | 1件: Droxidopa
Droxidopa
💬 | 9件: ADRA1A ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3 💬 | 14件: AMPK signaling pathway AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 6 6 💬 |
813 | DTR Melatonin (NIH CC PDS) | 1件: Melatonin Melatonin | 1件: Melatonin
Melatonin
💬 | 2件: MTNR1A MTNR1A, MTNR1B 💬 | 2件: Circadian entrainment Circadian entrainment, Neuroactive ligand-receptor interaction 💬 | 1件: 202 202 💬 |
814 | E-Device | - | - | - | - | 3件: 46 46, 96, 271 💬 |
815 | E. coli Nissle | - | - | - | - | 1件: 97 97 💬 |
816 | E. coli Nissle 1917 (Mutaflor®) | - | - | - | - | 1件: 97 97 💬 |
817 | Ecombinanat DNA-derived human growth h | - | - | - | - | 1件: 78 78 💬 |
818 | EDG-5506 Dose 1 | - | - | - | - | 1件: 113 113 💬 |
819 | EDG-5506 Dose 2 | - | - | - | - | 1件: 113 113 💬 |
820 | EDG-5506 Dose 3 | - | - | - | - | 1件: 113 113 💬 |
821 | EDG-5506 Dose 4 | - | - | - | - | 1件: 113 113 💬 |
822 | EDG-5506 Dose 5 | - | - | - | - | 1件: 113 113 💬 |
823 | EDP-305 Dose 1 | - | - | - | - | 1件: 93 93 💬 |
824 | EDP-305 Dose 2 | - | - | - | - | 1件: 93 93 💬 |
825 | EDS-EP dose range of ~14-22 mg DSP/infusion | - | - | - | - | 1件: 65 65 💬 |
826 | EDS-EP dose range of ~5-10 mg DSP/infusion | - | - | - | - | 1件: 65 65 💬 |
827 | EEN (Nestle Modulen®) | - | - | - | - | 1件: 96 96 💬 |
828 | Eflornithine plus Nifurtimox combination therapy | 2件: Eflornithine Eflornithine, Nifurtimox | 2件: Nifurtimox
Nifurtimox
,
Eflornithine
💬 | 1件: ODC1 ODC1 💬 | 3件: Arginine and proline metabolism Arginine and proline metabolism, Glutathione metabolism, Metabolic pathways 💬 | 1件: 65 65 💬 |
829 | EGCG as putative neuroprotective agent | 1件: Epigallocatechin gallate Epigallocatechin gallate | - | - | - | 1件: 17 17 💬 |
830 | EH301 (Nicotinamide Riboside/Pterostilbene) | 2件: Nicotinamide Nicotinamide, Nicotinamide riboside | 1件: Niacinamide
Niacinamide
💬 | - | - | 1件: 2 2 💬 |
831 | Elamipretide (high dose) | 1件: Elamipretide Elamipretide | 1件: Elamipretide
Elamipretide
💬 | - | - | 1件: 21 21 💬 |
832 | Elamipretide (intermediate dose) | 1件: Elamipretide Elamipretide | 1件: Elamipretide
Elamipretide
💬 | - | - | 1件: 21 21 💬 |
833 | Elamipretide (low dose) | 1件: Elamipretide Elamipretide | 1件: Elamipretide
Elamipretide
💬 | - | - | 1件: 21 21 💬 |
834 | Else nutrition formula | - | - | - | - | 1件: 98 98 💬 |
835 | Eltrombopag plus diacerein | 2件: Diacerein Diacerein, Eltrombopag | 1件: Diacerein
Diacerein
💬 | - | - | 1件: 63 63 💬 |
836 | EMFLAZA® (DEFLAZACORT) | 1件: Deflazacort Deflazacort | 1件: Deflazacort
Deflazacort
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 113 113 💬 |
837 | Emtricitabine (FTC)/Tenofovir Disoproxil (TDF) | 3件: Emtricitabine Emtricitabine, Tenofovir, Tenofovir disoproxil | 2件: Emtricitabine
Emtricitabine
,
Tenofovir
💬 | - | - | 1件: 93 93 💬 |
838 | ENBREL - 50 MG SOLUZIONE INIETTABILE IN SIRINGA (VETRO DA 1 ML) PRERIEMPITA - USO SOTTOCUTANEO 12 SIRINGHE PRERIEMPITE + 24 TAMPONI IMBEVUTI DI ALCOL | 1件: Etanercept Etanercept | 1件: Etanercept
Etanercept
💬 | 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
839 | ENBREL 25 mg/ml polvo y disolvente para solución inyectable para uso pediátrico | 1件: Etanercept Etanercept | 1件: Etanercept
Etanercept
💬 | 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 107 107 💬 |
840 | ENBREL 50 mg solución inyectable en jeringas precargadas | 1件: Etanercept Etanercept | 1件: Etanercept
Etanercept
💬 | 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 107 107 💬 |
841 | End-of-life nursing education consortium-pediatric palliative care as web based-training plus usual care | - | - | - | - | 2件: 113 113, 299 💬 |
842 | Engineerd Protein Inhibitor of human Neutrophil Elastase | - | - | - | - | 1件: 299 299 💬 |
843 | Engineered humanized monoclonal anti-human CD19 antibody. Lot Numbers: 1-FIN-1588 (9.6mg/ml) | - | - | - | - | 1件: 46 46 💬 |
844 | Engineered Protein Inhibitor of human Neutrophil Elastase | - | - | - | - | 1件: 299 299 💬 |
845 | ENOS transfected EPCs will be delivered via a PA line | - | - | - | - | 1件: 86 86 💬 |
846 | Enpatoran high dose | - | - | - | - | 1件: 49 49 💬 |
847 | Enpatoran low dose | - | - | - | - | 1件: 49 49 💬 |
848 | Enpatoran medium dose | - | - | - | - | 1件: 49 49 💬 |
849 | Entacapone 400mg oral dose | 1件: Entacapone Entacapone | 1件: Entacapone
Entacapone
💬 | 1件: COMT COMT 💬 | 4件: Dopaminergic synapse Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism 💬 | 2件: 6 6, 17 💬 |
850 | Enteral nutrition | - | - | - | - | 1件: 96 96 💬 |
851 | Enteral nutrition. | - | - | - | - | 1件: 96 96 💬 |
852 | Eosinophilic Esophagitis (EoE) Food introduction-3rd dose | - | - | - | - | 1件: 98 98 💬 |
853 | EPA and DHA | - | - | - | - | 1件: 113 113 💬 |
854 | EPA and DHA supplementation | - | - | - | - | 2件: 48 48, 49 💬 |
855 | EPAX 6000 EE 1000mg (0.6 gr DHA+EPA) | - | - | - | - | 1件: 46 46 💬 |
856 | EPI-hNE4 DX-890 | - | - | - | - | 1件: 299 299 💬 |
857 | Epidyolex and is the approved name in the EU | 1件: Cannabidiol Cannabidiol | 1件: Cannabidiol
Cannabidiol
💬 | 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 156 156 💬 |
858 | Ergocalciferol (vitamin D2) | 1件: Ergocalciferol Ergocalciferol | 1件: Ergocalciferol
Ergocalciferol
💬 | 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 299 299 💬 |
859 | ERY-DEX | - | - | - | - | 1件: 96 96 💬 |
860 | Etanercept (Full-Dose) | 1件: Etanercept Etanercept | 1件: Etanercept
Etanercept
💬 | 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 271 271 💬 |
861 | Etanercept (Half-Dose) | 1件: Etanercept Etanercept | 1件: Etanercept
Etanercept
💬 | 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 271 271 💬 |
862 | Etanercept 50 mg sc day 0 and day 3 | 1件: Etanercept Etanercept | 1件: Etanercept
Etanercept
💬 | 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 2件: 38 38, 39 💬 |
863 | Etanercept Optimal dosing | 1件: Etanercept Etanercept | 1件: Etanercept
Etanercept
💬 | 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 2件: 46 46, 107 💬 |
864 | Etanercept, methotrexate and depomedrone | 2件: Etanercept Etanercept, Methotrexate | 2件: Methotrexate
Methotrexate
,
Etanercept
💬 | 4件: DHFR DHFR, DHFR2, LTA, TNF 💬 | 71件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, Biosynthesis of cofactors, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Folate biosynthesis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, Metabolic pathways, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, One carbon pool by folate, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
865 | Etanercept, other Biologics, Disease-modifying antirheumatic drugs (DMARDs), etc | 1件: Etanercept Etanercept | 1件: Etanercept
Etanercept
💬 | 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
866 | ETD001 multiple once daily doses | - | - | - | - | 1件: 299 299 💬 |
867 | ETD001 multiple twice daily doses | - | - | - | - | 1件: 299 299 💬 |
868 | ETD001 single dose | - | - | - | - | 1件: 299 299 💬 |
869 | Ethylmethylcarbamic acid 3-[(1S)-1-(dimethylamino)ethyl]phenyl ester (**See other 2 names below) | - | - | - | - | 1件: 6 6 💬 |
870 | Etiprednol dicloacetate | 1件: Etiprednol dicloacetate Etiprednol dicloacetate | 1件: Etiprednol dicloacetate
Etiprednol dicloacetate
💬 | - | - | 1件: 96 96 💬 |
871 | EU Orphan Designation Number EU/3/02/120 | - | - | - | - | 1件: 299 299 💬 |
872 | EUR-1008 (APT-1008) High Dose | - | - | - | - | 1件: 298 298 💬 |
873 | EUR-1008 (APT-1008) Low Dose | - | - | - | - | 1件: 298 298 💬 |
874 | EUS procedure with drug injection | - | - | - | - | 1件: 298 298 💬 |
875 | Everolimus 2mg dispersible tablet | 1件: Everolimus Everolimus | 1件: Everolimus
Everolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 158 158 💬 |
876 | Exclusive Enteral Nutrition | - | - | - | - | 1件: 96 96 💬 |
877 | Exclusive Enteral Nutrition Therapy | - | - | - | - | 1件: 96 96 💬 |
878 | Expanded allogenic adipose-derived adult stem cells | - | - | - | - | 1件: 96 96 💬 |
879 | Expanded autologous adipose-derived adult stem cells (eASCs) | - | - | - | - | 1件: 96 96 💬 |
880 | Expanded human first trimester fetal liver-derived mesenchymal stem cells | - | - | - | - | 1件: 274 274 💬 |
881 | Experimental (Non Immunosuppressive Symptomatic Treatment (NIST) and Rituximab) | 1件: Rituximab Rituximab | 1件: Rituximab
Rituximab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 222 222 💬 |
882 | Experimental: Arm A: DRL_RI | - | - | - | - | 1件: 46 46 💬 |
883 | Exposure to one or more disease-modifying drug(s)(DMDs) used to treat MS | - | - | - | - | 1件: 13 13 💬 |
884 | Extavia (interferon beta-1b), Novartis Pharma AG | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
885 | Extended release dipyridamole 200mg/aspirin 25mg | 2件: Acetylsalicylic acid Acetylsalicylic acid, Dipyridamole | 2件: Aspirin
Aspirin
,
Dipyridamole
💬 | 4件: PDE4A PDE4A, PDE5A, PTGS1, PTGS2 💬 | 28件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, Morphine addiction, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Purine metabolism, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 49 49 💬 |
886 | Extra blood draw samples | - | - | - | - | 1件: 300 300 💬 |
887 | Ezetimibe+Simvastatin Drug Combination | 2件: Ezetimibe Ezetimibe, Simvastatin | 2件: Simvastatin
Simvastatin
,
Ezetimibe
💬 | 2件: HMGCR HMGCR, NPC1L1 💬 | 5件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Fat digestion and absorption, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 49 49 💬 |
888 | F-A-F-A (FIASP-NovoRapid-FIASP-NovoRapid) | - | - | - | - | 1件: 299 299 💬 |
889 | Fampridine-SR b.i.d. (Twice Daily) | 1件: Dalfampridine Dalfampridine | 1件: Dalfampridine
Dalfampridine
💬 | 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 1件: 13 13 💬 |
890 | FAMPYRA - 10 MG - COMPRESSA A RILASCIO PROLUNGATO - USO ORALE - FLACONE (HDPE) 56 COMPRESSE (4 FLACONI DA 14) | 1件: Dalfampridine Dalfampridine | 1件: Dalfampridine
Dalfampridine
💬 | 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 1件: 13 13 💬 |
891 | Fat diet | - | - | - | - | 1件: 78 78 💬 |
892 | Fendrix suspension for injection Hepatitis B (rDNA) vaccine (adjuvanted, adsorbed). | 1件: Hepatitis B Vaccine (Recombinant) Hepatitis B Vaccine (Recombinant) | - | - | - | 1件: 46 46 💬 |
893 | Fenfluramine HCl, DL-Fenfluramine, (±)-Fenfluramine | 1件: Fenfluramine Fenfluramine | 1件: Fenfluramine
Fenfluramine
💬 | 5件: HTR1D HTR1D, HTR2A, HTR2C, SIGMAR1, SLC6A4 💬 | 10件: Amyotrophic lateral sclerosis Amyotrophic lateral sclerosis, Calcium signaling pathway, Gap junction, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction, Pathways of neurodegeneration - multiple diseases, Serotonergic synapse, Synaptic vesicle cycle, Taste transduction, cAMP signaling pathway 💬 | 1件: 144 144 💬 |
894 | Fenofibrate IDD-P (Insoluble Drug Delivery-Micro Particle) | 1件: Fenofibrate Fenofibrate | 1件: Fenofibrate
Fenofibrate
💬 | 1件: PPARA PPARA 💬 | 10件: Adipocytokine signaling pathway Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬 | 1件: 93 93 💬 |
895 | Fentanyl (High Dose) | 1件: Fentanyl Fentanyl | 1件: Fentanyl
Fentanyl
💬 | 1件: OPRM1 OPRM1 💬 | 3件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction 💬 | 1件: 215 215 💬 |
896 | Fentanyl (Low Dose) | 1件: Fentanyl Fentanyl | 1件: Fentanyl
Fentanyl
💬 | 1件: OPRM1 OPRM1 💬 | 3件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction 💬 | 1件: 215 215 💬 |
897 | Fentanyl (Low Dose) + Dexmedetomidine | 2件: Dexmedetomidine Dexmedetomidine, Fentanyl | 2件: Fentanyl
Fentanyl
,
Dexmedetomidine
💬 | 4件: ADRA2A ADRA2A, ADRA2B, ADRA2C, OPRM1 💬 | 4件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬 | 1件: 215 215 💬 |
898 | Ferrprox (Deferiprone) | 1件: Deferiprone Deferiprone | 1件: Deferiprone
Deferiprone
💬 | - | - | 1件: 6 6 💬 |
899 | Fetal porcine cells, Neurocell-PD | - | - | - | - | 1件: 6 6 💬 |
900 | Filgotinib 200mg/day | 1件: Filgotinib Filgotinib | 1件: Filgotinib
Filgotinib
💬 | 1件: JAK1 JAK1 💬 | 27件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 💬 |
901 | Fipamezole hydrochloride 30 mg oral disintegrating tablets | 1件: Fipamezole Fipamezole | - | - | - | 2件: 6 6, 17 💬 |
902 | Fipamezole hydrochloride 60 mg oral disintegrating tablets | 1件: Fipamezole Fipamezole | - | - | - | 2件: 6 6, 17 💬 |
903 | Fipamezole hydrochloride 90 mg oral disintegrating tablets | 1件: Fipamezole Fipamezole | - | - | - | 2件: 6 6, 17 💬 |
904 | Firategrast (USAN approved name) | 1件: Firategrast Firategrast | 1件: Firategrast
Firategrast
💬 | 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 💬 |
905 | First line DMT | - | - | - | - | 1件: 13 13 💬 |
906 | Fixed dose combination Ciprofloxacin/Celecoxib | 2件: Celecoxib Celecoxib, Ciprofloxacin | 2件: Ciprofloxacin
Ciprofloxacin
,
Celecoxib
💬 | 1件: PTGS2 PTGS2 💬 | 22件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 2 2 💬 |
907 | FK506 level 2-3 ng/ml | - | - | - | - | 1件: 86 86 💬 |
908 | FK506 level 3-5 ng/ml | - | - | - | - | 1件: 86 86 💬 |
909 | FK506 level < 2 ng/ml | - | - | - | - | 1件: 86 86 💬 |
910 | Flebogamma 5% DIF | - | - | - | - | 1件: 65 65 💬 |
911 | FLOLAN injection with currently marketed diluent | 1件: Epoprostenol Epoprostenol | 1件: Epoprostenol
Epoprostenol
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 💬 |
912 | FLOLAN injection with reformulated diluent | 1件: Epoprostenol Epoprostenol | 1件: Epoprostenol
Epoprostenol
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 💬 |
913 | FLOLAN TM and Glycine Diluent | 2件: Epoprostenol Epoprostenol, Glycine | 2件: Glycine
Glycine
,
Epoprostenol
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 💬 |
914 | FLOLAN™ and Glycine Diluent | 2件: Epoprostenol Epoprostenol, Glycine | 2件: Glycine
Glycine
,
Epoprostenol
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 💬 |
915 | FLUDARABINA ACCORD - 25 MG/ML CONCENTRATO PER SOLUZIONE INIETTABILE O PER INFUSIONE 5 FLACONCINI IN VETRO DA 2 ML | 1件: Fludarabine Fludarabine | 1件: Fludarabine
Fludarabine
💬 | 1件: RRM1 RRM1 💬 | 6件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Nucleotide metabolism, Purine metabolism, Pyrimidine metabolism 💬 | 1件: 19 19 💬 |
916 | FLUDARABINA TEVA - 25 MG/ML CONCENTRATO PER SOLUZIONE INIETTABILE O PER INFUSIONE 1 FLACONCINO DI VETRO DA 2 ML | 1件: Fludarabine Fludarabine | 1件: Fludarabine
Fludarabine
💬 | 1件: RRM1 RRM1 💬 | 6件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Nucleotide metabolism, Purine metabolism, Pyrimidine metabolism 💬 | 1件: 65 65 💬 |
917 | FLX-787-ODT (orally disintegrating tablet) | - | - | - | - | 1件: 10 10 💬 |
918 | FLX-787-ODT (orally disintigrating tablet) | - | - | - | - | 1件: 2 2 💬 |
919 | FMP30 Donor Stool | - | - | - | - | 1件: 13 13 💬 |
920 | Folic acid (non-investigational product) | 1件: Folic acid Folic acid | 1件: Folic acid
Folic acid
💬 | - | - | 1件: 46 46 💬 |
921 | Formoterol fumarate dihydrate | 1件: Formoterol Formoterol | 1件: Formoterol
Formoterol
💬 | 1件: ADRB2 ADRB2 💬 | 9件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 85 85 💬 |
922 | Formulation D | - | - | - | - | 1件: 13 13 💬 |
923 | Forxiga (dapagliflozin) | 1件: Dapagliflozin Dapagliflozin | 1件: Dapagliflozin
Dapagliflozin
💬 | 1件: SLC5A2 SLC5A2 💬 | - | 2件: 86 86, 88 💬 |
924 | Fosfamatinib Disodium | - | - | - | - | 1件: 46 46 💬 |
925 | Fosfato sodico de dexametasona | 1件: Dexamethasone Dexamethasone | 1件: Dexamethasone
Dexamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 96 96 💬 |
926 | FOSFOMYCIN DISODIUM | 1件: Fosfomycin Fosfomycin | 1件: Fosfomycin
Fosfomycin
💬 | - | - | 1件: 97 97 💬 |
927 | FOSMETPANTOTENATE DRUG SUBSTANCE | - | - | - | - | 1件: 120 120 💬 |
928 | Fostamatinib Disodium | 1件: Fostamatinib Fostamatinib | 1件: Fostamatinib
Fostamatinib
💬 | 1件: SYK SYK 💬 | 17件: B cell receptor signaling pathway B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Coronavirus disease - COVID-19, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Herpes simplex virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, NF-kappa B signaling pathway, Natural killer cell mediated cytotoxicity, Neutrophil extracellular trap formation, Osteoclast differentiation, PI3K-Akt signaling pathway, Phospholipase D signaling pathway, Platelet activation, Tuberculosis, Viral carcinogenesis 💬 | 3件: 46 46, 61, 66 💬 |
929 | Fostamatinib Disodium (R935788) | 1件: Fostamatinib Fostamatinib | 1件: Fostamatinib
Fostamatinib
💬 | 1件: SYK SYK 💬 | 17件: B cell receptor signaling pathway B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Coronavirus disease - COVID-19, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Herpes simplex virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, NF-kappa B signaling pathway, Natural killer cell mediated cytotoxicity, Neutrophil extracellular trap formation, Osteoclast differentiation, PI3K-Akt signaling pathway, Phospholipase D signaling pathway, Platelet activation, Tuberculosis, Viral carcinogenesis 💬 | 2件: 46 46, 49 💬 |
930 | Fostamatinib Disodium tablet 100 mg | 1件: Fostamatinib Fostamatinib | 1件: Fostamatinib
Fostamatinib
💬 | 1件: SYK SYK 💬 | 17件: B cell receptor signaling pathway B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Coronavirus disease - COVID-19, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Herpes simplex virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, NF-kappa B signaling pathway, Natural killer cell mediated cytotoxicity, Neutrophil extracellular trap formation, Osteoclast differentiation, PI3K-Akt signaling pathway, Phospholipase D signaling pathway, Platelet activation, Tuberculosis, Viral carcinogenesis 💬 | 1件: 66 66 💬 |
931 | Fostamatinib Disodium tablet 150 mg | 1件: Fostamatinib Fostamatinib | 1件: Fostamatinib
Fostamatinib
💬 | 1件: SYK SYK 💬 | 17件: B cell receptor signaling pathway B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Coronavirus disease - COVID-19, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Herpes simplex virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, NF-kappa B signaling pathway, Natural killer cell mediated cytotoxicity, Neutrophil extracellular trap formation, Osteoclast differentiation, PI3K-Akt signaling pathway, Phospholipase D signaling pathway, Platelet activation, Tuberculosis, Viral carcinogenesis 💬 | 1件: 66 66 💬 |
932 | Freeze-dried black raspberry powder | 1件: Raspberry Raspberry | 1件: Raspberry
Raspberry
💬 | - | - | 1件: 97 97 💬 |
933 | Freeze-Dried Sulfonated Human Normal Immunoglobulin (GGS) | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 3件: 14 14, 43, 45 💬 |
934 | From August 2020 'no additional treatment' | - | - | - | - | 1件: 51 51 💬 |
935 | Fully human monoclonal antibody directed against CXCL10 | - | - | - | - | 1件: 93 93 💬 |
936 | Fully humanized anti-human IL-6 receptor (IL-6R) neutralizing monoclonal antibody | - | - | - | - | 1件: 13 13 💬 |
937 | Fultium-D3 800IU capsules | - | - | - | - | 1件: 274 274 💬 |
938 | GA Depot | - | - | - | - | 1件: 13 13 💬 |
939 | GA Depot 25mg once monthly | - | - | - | - | 1件: 13 13 💬 |
940 | GA Depot 40 mg | - | - | - | - | 1件: 13 13 💬 |
941 | GA Depot 40mg once monthly | - | - | - | - | 1件: 13 13 💬 |
942 | GA Depot 80 mg | - | - | - | - | 1件: 13 13 💬 |
943 | Ga-68-DOTA-NOC | - | - | - | - | 1件: 84 84 💬 |
944 | Gabapentin (neurontin® capsule 300mg) treatment | 1件: Gabapentin Gabapentin | 1件: Gabapentin
Gabapentin
💬 | 5件: CACNA2D1 CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4, SLC6A1 💬 | 9件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Arrhythmogenic right ventricular cardiomyopathy, Cardiac muscle contraction, Dilated cardiomyopathy, GABAergic synapse, Hypertrophic cardiomyopathy, MAPK signaling pathway, Oxytocin signaling pathway, Synaptic vesicle cycle 💬 | 1件: 70 70 💬 |
945 | Gadobenate Dimeglumine | 1件: Gadobenic acid Gadobenic acid | 1件: Gadobenic acid
Gadobenic acid
💬 | - | - | 1件: 13 13 💬 |
946 | GADOVIST 1 mmol/ml solución inyectable en jeringa precargada/ cartucho precargado | - | - | - | - | 1件: 13 13 💬 |
947 | Gallium nitrate | 2件: Gallium nitrate Gallium nitrate, Nitrate | 2件: Gallium nitrate
Gallium nitrate
,
Nitric acid
💬 | - | - | 1件: 299 299 💬 |
948 | Gallium-68 DOTATATE | 1件: Dotatate Dotatate | - | - | - | 1件: 84 84 💬 |
949 | Gallium-68-DOTA-N-Octreotide | 1件: Octreotide Octreotide | 1件: Octreotide
Octreotide
💬 | 1件: SSTR2 SSTR2 💬 | 4件: Gastric acid secretion Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 84 84 💬 |
950 | Gallium68-Dota-Noc | - | - | - | - | 1件: 85 85 💬 |
951 | Gamma-secretase/Notch signalling pathway inhibitor RO4929097 | - | - | - | - | 1件: 74 74 💬 |
952 | Gammagard S/D (Solvent/Detergent) | - | - | - | - | 1件: 65 65 💬 |
953 | Genetic analysis by SANGER and WHOLE EXOME NEXT GENERATION SEQUENCING | - | - | - | - | 1件: 84 84 💬 |
954 | Genetic diagnosis | - | - | - | - | 1件: 335 335 💬 |
955 | Genicular nerve block | - | - | - | - | 1件: 107 107 💬 |
956 | Genome-wide DNA methylation | - | - | - | - | 1件: 96 96 💬 |
957 | Genotonorm Kabipen 5.3 mg polvo y disolvente para sol. inyectable (Marca internacional Genotropin) | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
958 | Genotonorm Kabipen 5.3 mg polvo y disolvente para solución inyectable (Marca internacional Genotropin) | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
959 | GENOTROPIN (Somatropin) is a growth hormone treatment. It is an exact copy of the natural growth hormone that our bodies make. The main difference is that GENOTROPIN is man-made. | 1件: Somatotropin Somatotropin | - | - | - | 1件: 193 193 💬 |
960 | Genotype Detection | - | - | - | - | 1件: 49 49 💬 |
961 | GILENYA - 0.5 MG - CAPSULE RIGIDE - USO ORALE - BLISTER DIVISIBILE PER DOSE UNITARIA(PVC/PVDC/ALU) SCATOLA DA 7X1 CAPSULE | 1件: Fingolimod Fingolimod | 1件: Fingolimod
Fingolimod
💬 | 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 💬 |
962 | GILENYA - 0.5 MG - CAPSULE RIGIDE - USO ORALE - BLISTER(PVC/PVDC/ALU) SCATOLA DA 28 CAPSULE | 1件: Fingolimod Fingolimod | 1件: Fingolimod
Fingolimod
💬 | 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 💬 |
963 | GILENYA 0,5 mg cápsulas duras | 1件: Fingolimod Fingolimod | 1件: Fingolimod
Fingolimod
💬 | 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 14 14 💬 |
964 | Giving DHA-rich supplement | - | - | - | - | 1件: 299 299 💬 |
965 | Glatiramer Acetate (DB) | 2件: Acetate Acetate, Glatiramer | - | - | - | 1件: 13 13 💬 |
966 | Glatiramer Acetate, N-Acetylcysteine | 3件: Acetate Acetate, Acetylcysteine, Glatiramer | 1件: Acetylcysteine
Acetylcysteine
💬 | - | - | 1件: 13 13 💬 |
967 | Glial cell line-derived neurotrophic factor | - | - | - | - | 1件: 6 6 💬 |
968 | Glial Cell Line-Derived Neurotrophic Factor (GDNF) | - | - | - | - | 1件: 6 6 💬 |
969 | Glicerol-1,3-didecanoato-2-octadeca-(6Z,9Z,12Z)-trienoato | - | - | - | - | 1件: 13 13 💬 |
970 | Global DNA methylation will be quantified in the DNA samples by colorimetry | - | - | - | - | 1件: 63 63 💬 |
971 | GLPG1837 dose 1 | - | - | - | - | 1件: 299 299 💬 |
972 | GLPG1837 dose 2 | - | - | - | - | 1件: 299 299 💬 |
973 | GLPG1837 dose 3 | - | - | - | - | 1件: 299 299 💬 |
974 | GLPG2222 150 mg q.d. | - | - | - | - | 1件: 299 299 💬 |
975 | GLPG2222 300 mg q.d. | - | - | - | - | 1件: 299 299 💬 |
976 | GLPG2451 dose regimen A | - | - | - | - | 1件: 299 299 💬 |
977 | GLPG2451 dose regimen B | - | - | - | - | 1件: 299 299 💬 |
978 | GLPG2737 single dose | - | - | - | - | 1件: 299 299 💬 |
979 | GLPG3067 single dose | - | - | - | - | 1件: 299 299 💬 |
980 | Glucocorticoids (permitted,not necessary) | - | - | - | - | 1件: 46 46 💬 |
981 | Glucocorticoids - Reduced Dose | - | - | - | - | 2件: 43 43, 44 💬 |
982 | Glucocorticoids - Standard Dose | - | - | - | - | 2件: 43 43, 44 💬 |
983 | Glucocorticoids [Reduced Dose] | - | - | - | - | 2件: 43 43, 44 💬 |
984 | Glucocorticoids [Standard Dose] | - | - | - | - | 2件: 43 43, 44 💬 |
985 | GLUT1 DS | - | - | - | - | 1件: 248 248 💬 |
986 | Gluten-free diet | - | - | - | - | 1件: 94 94 💬 |
987 | Glycerol-1,3-didecanoate-2-octadeca-(6Z,9Z,12Z)-trienoate | 1件: Glycerin Glycerin | 1件: Glycerin
Glycerin
💬 | - | - | 1件: 13 13 💬 |
988 | GlycosBio Nutritional Supplement | - | - | - | - | 1件: 299 299 💬 |
989 | Gold Nanocrystals | 1件: Gold Gold | - | - | - | 3件: 2 2, 6, 13 💬 |
990 | Golimumab Dose 1 | 1件: Golimumab Golimumab | 1件: Golimumab
Golimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 97 97 💬 |
991 | Golimumab Dose 2 | 1件: Golimumab Golimumab | 1件: Golimumab
Golimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 97 97 💬 |
992 | Graft intracerebral of foetal neurons | - | - | - | - | 1件: 8 8 💬 |
993 | Group 1- Control Diet | - | - | - | - | 1件: 97 97 💬 |
994 | Group 2- UCD Diet | - | - | - | - | 1件: 97 97 💬 |
995 | Growth hormone (Nutropin) | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
996 | Growth hormone replacement therapy in growth hormone deficient patients only. | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
997 | GS030-DP | - | - | - | - | 1件: 90 90 💬 |
998 | GSK1605786 GSK direct-fill: formulation C | - | - | - | - | 1件: 96 96 💬 |
999 | GSK1605786 GSK modified-process: formulation D | - | - | - | - | 1件: 96 96 💬 |
1000 | GSK2018682 CD3 non-micronised Tablet | - | - | - | - | 1件: 13 13 💬 |
1001 | GSK2018682 CD3 non-micronised Tablet in fed state | - | - | - | - | 1件: 13 13 💬 |
1002 | GSK2586184 800mg single and repeat dose | - | - | - | - | 1件: 49 49 💬 |
1003 | GSK2586184 new formulation | - | - | - | - | 1件: 49 49 💬 |
1004 | GSK2831781 - Double Blind Phase | - | - | - | - | 1件: 97 97 💬 |
1005 | GSK2982772A, where A denotes the free base | - | - | - | - | 2件: 46 46, 97 💬 |
1006 | GSK3008348 Nebuliser solution | - | - | - | - | 1件: 85 85 💬 |
1007 | GSK3196165 Dose 1 | - | - | - | - | 1件: 46 46 💬 |
1008 | GSK3196165 Dose 2 | - | - | - | - | 1件: 46 46 💬 |
1009 | GSK3196165 Dose 3 | - | - | - | - | 1件: 46 46 💬 |
1010 | GTX-102 high dose fast Period 1 and Period 2 | 1件: GTX-102 GTX-102 | - | - | - | 1件: 65 65 💬 |
1011 | GTX-102 low dose fast Period 1 and Period 2 | 1件: GTX-102 GTX-102 | - | - | - | 1件: 65 65 💬 |
1012 | GTX-102 medium dose fast Period 1 and Period 2 | 1件: GTX-102 GTX-102 | - | - | - | 1件: 65 65 💬 |
1013 | GTX-102 medium dose slow Period 1 and Period 2 | 1件: GTX-102 GTX-102 | - | - | - | 1件: 65 65 💬 |
1014 | Guselkumab Dose 1 | 1件: Guselkumab Guselkumab | 1件: Guselkumab
Guselkumab
💬 | 1件: IL23A IL23A 💬 | 9件: C-type lectin receptor signaling pathway C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬 | 3件: 51 51, 96, 97 💬 |
1015 | Guselkumab Dose 2 | 1件: Guselkumab Guselkumab | 1件: Guselkumab
Guselkumab
💬 | 1件: IL23A IL23A 💬 | 9件: C-type lectin receptor signaling pathway C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬 | 3件: 51 51, 96, 97 💬 |
1016 | Guselkumab Dose 3 | 1件: Guselkumab Guselkumab | 1件: Guselkumab
Guselkumab
💬 | 1件: IL23A IL23A 💬 | 9件: C-type lectin receptor signaling pathway C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬 | 2件: 96 96, 97 💬 |
1017 | Guselkumab Dose 4 | 1件: Guselkumab Guselkumab | 1件: Guselkumab
Guselkumab
💬 | 1件: IL23A IL23A 💬 | 9件: C-type lectin receptor signaling pathway C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬 | 1件: 96 96 💬 |
1018 | Guselkumab Dose 5 | 1件: Guselkumab Guselkumab | 1件: Guselkumab
Guselkumab
💬 | 1件: IL23A IL23A 💬 | 9件: C-type lectin receptor signaling pathway C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬 | 1件: 96 96 💬 |
1019 | GWP42003-P 10 mg/kg/day Dose | - | - | - | - | 1件: 140 140 💬 |
1020 | GWP42003-P 20 mg/kg/day Dose | - | - | - | - | 2件: 140 140, 144 💬 |
1021 | GWP42003-P 5 mg/kg/day Dose | - | - | - | - | 1件: 140 140 💬 |
1022 | GYPP-06 (GKT137831 free base), C10071301-D | - | - | - | - | 1件: 93 93 💬 |
1023 | H-116PI-DE.pdf | - | - | - | - | 1件: 18 18 💬 |
1024 | H02AB02 Desametasone | - | - | - | - | 1件: 28 28 💬 |
1025 | Haplo BM with T cell depletion | - | - | - | - | 1件: 65 65 💬 |
1026 | HBM9161 Dose A | - | - | - | - | 1件: 63 63 💬 |
1027 | HBM9161 Dose B | - | - | - | - | 1件: 63 63 💬 |
1028 | Heparán N sulfatasa humana recombinante | - | - | - | - | 1件: 19 19 💬 |
1029 | Heparán N sulfatasa humana recombinante (rhHNS) | - | - | - | - | 1件: 19 19 💬 |
1030 | Heterologous Human Adult Liver-derived Progenitor Cells | - | - | - | - | 1件: 251 251 💬 |
1031 | Heterologous Human Adult Liver-derived Progenitor Cells (HHALPC) | - | - | - | - | 1件: 251 251 💬 |
1032 | HIBERIX - POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE PER USO INTRAMUSCOLARE 1 FLACONCINO DI POLVERE + 1 SIRINGA PRERIEMPITA DI SOLVENTE DA 0.5 ML | 1件: Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen | - | - | - | 3件: 61 61, 62, 66 💬 |
1033 | Hidrocloruro de efedrina | 1件: Ephedrine Ephedrine | 1件: Ephedrine
Ephedrine
💬 | 9件: ADRA1A ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3 💬 | 14件: AMPK signaling pathway AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 11 11 💬 |
1034 | Hidrocloruro de fingolimod | 1件: Fingolimod Fingolimod | 1件: Fingolimod
Fingolimod
💬 | 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 2件: 13 13, 14 💬 |
1035 | HIDS DONOR | - | - | - | - | 1件: 19 19 💬 |
1036 | High Dietary Sodium | - | - | - | - | 1件: 49 49 💬 |
1037 | High dose | - | - | - | - | 1件: 97 97 💬 |
1038 | High dose AFFITOPE® PD03A + Adjuvant | - | - | - | - | 1件: 6 6 💬 |
1039 | High dose ANAVEX2-73 | - | - | - | - | 1件: 6 6 💬 |
1040 | High Dose Aspirin (1300 mg/day) | 1件: Acetylsalicylic acid Acetylsalicylic acid | 1件: Aspirin
Aspirin
💬 | 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 13 13 💬 |
1041 | High dose BIBF 1120 twice daily | - | - | - | - | 1件: 85 85 💬 |
1042 | High Dose Budesonide | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 97 97 💬 |
1043 | High dose budesonide suspension | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 💬 |
1044 | High dose budesonide tablet | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 💬 |
1045 | High dose Dexamethasone pulses | 1件: Dexamethasone Dexamethasone | 1件: Dexamethasone
Dexamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 63 63 💬 |
1046 | High dose lactulose | 1件: Lactulose Lactulose | 1件: Lactulose
Lactulose
💬 | - | - | 1件: 291 291 💬 |
1047 | High dose levodopa | 1件: Levodopa Levodopa | 1件: Levodopa
Levodopa
💬 | 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1048 | High Dose LX2006 | - | - | - | - | 1件: 18 18 💬 |
1049 | High Dose Mesenchymal Stem Cells (MSCs) | - | - | - | - | 1件: 49 49 💬 |
1050 | High Dose MT-1303 | - | - | - | - | 1件: 97 97 💬 |
1051 | High Dose MYOBLOC | 1件: Botulinum toxin type B Botulinum toxin type B | 1件: Rimabotulinumtoxin B
Rimabotulinumtoxin B
💬 | 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 1件: 13 13 💬 |
1052 | High dose of BIIL 284 BS tablets | - | - | - | - | 1件: 46 46 💬 |
1053 | High dose of budesonide | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 299 299 💬 |
1054 | High dose ORTD-1 | - | - | - | - | 1件: 46 46 💬 |
1055 | High dose TSO | - | - | - | - | 1件: 96 96 💬 |
1056 | High dose vehicle control | - | - | - | - | 1件: 46 46 💬 |
1057 | High Dose-VIS649 | - | - | - | - | 1件: 66 66 💬 |
1058 | High doses of Thiamine y Biotin | 2件: Biotin Biotin, Thiamine | 2件: Biotin
Biotin
,
Thiamine
💬 | - | - | 1件: 8 8 💬 |
1059 | High protein high fiber diet | - | - | - | - | 2件: 93 93, 95 💬 |
1060 | High Protein. T-Diet plus Range | - | - | - | - | 1件: 6 6 💬 |
1061 | High serine diet | 1件: Serine Serine | 1件: Serine
Serine
💬 | - | - | 1件: 96 96 💬 |
1062 | High-caloric fatty diet | - | - | - | - | 1件: 2 2 💬 |
1063 | High-dose Cyclophosphamide | 1件: Cyclophosphamide Cyclophosphamide | 2件: Cyclophosphamide
Cyclophosphamide
,
Cyclophosphamide
💬 | - | - | 1件: 96 96 💬 |
1064 | High-dose intravenous immunoglobulin (IVIG) | - | - | - | - | 1件: 18 18 💬 |
1065 | High-dose intravenous immunoglobulin (Venoglobulin-IH) | - | - | - | - | 1件: 51 51 💬 |
1066 | High-dose REGN4461 | - | - | - | - | 1件: 265 265 💬 |
1067 | High-dose vitamin D (2000 IU per day) | 1件: Vitamin D Vitamin D | - | - | - | 1件: 274 274 💬 |
1068 | High-Dose Vitamin D3 | 1件: Cholecalciferol Cholecalciferol | 1件: Cholecalciferol
Cholecalciferol
💬 | 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 299 299 💬 |
1069 | High/Low Sodium Diet | - | - | - | - | 1件: 13 13 💬 |
1070 | Hiomega-3 supplement of Naturalis® company - | - | - | - | - | 1件: 49 49 💬 |
1071 | Histone Deacetylase Inhibitor | - | - | - | - | 1件: 127 127 💬 |
1072 | HLL2 (trivial name or chemical description) | - | - | - | - | 1件: 49 49 💬 |
1073 | HM71224 Multiple ascending dose | - | - | - | - | 1件: 46 46 💬 |
1074 | HM71224 single ascending dose | - | - | - | - | 1件: 46 46 💬 |
1075 | HMPL-004 1800 mg/day | - | - | - | - | 1件: 97 97 💬 |
1076 | HMPL-004 2400 mg/day | - | - | - | - | 1件: 97 97 💬 |
1077 | HMPL-004 high dose | - | - | - | - | 1件: 97 97 💬 |
1078 | HMPL-004 low dose | - | - | - | - | 1件: 97 97 💬 |
1079 | Hologene 5 DS | - | - | - | - | 1件: 36 36 💬 |
1080 | Hourly dosing of the nychtemeral secretion of melatonin | 1件: Melatonin Melatonin | 1件: Melatonin
Melatonin
💬 | 2件: MTNR1A MTNR1A, MTNR1B 💬 | 2件: Circadian entrainment Circadian entrainment, Neuroactive ligand-receptor interaction 💬 | 1件: 202 202 💬 |
1081 | HRPC DP | - | - | - | - | 1件: 90 90 💬 |
1082 | HUC-MSC + DMARDs | - | - | - | - | 1件: 46 46 💬 |
1083 | Human allogeneic adipose tissue-derived mesenchymal stem cells expanded | - | - | - | - | 1件: 36 36 💬 |
1084 | Human dermal fibroblasts cultured on a bioresorbable polyglactin mesh | - | - | - | - | 1件: 36 36 💬 |
1085 | Human Embryonic Stem Cell Derived Retinal Pigment Epithelium (RPE) | - | - | - | - | 1件: 90 90 💬 |
1086 | Human fetal-derived Neural Stem Cells (hNSCs) | - | - | - | - | 1件: 13 13 💬 |
1087 | Human fibroblast-derived dermal substitute, Dermagraft | - | - | - | - | 1件: 36 36 💬 |
1088 | Human monoclonal antibody directed against CD20 on B-cells | - | - | - | - | 1件: 46 46 💬 |
1089 | Human monoclonal antibody directed against complement 5 protein | - | - | - | - | 1件: 62 62 💬 |
1090 | Human neural stem cell | - | - | - | - | 1件: 6 6 💬 |
1091 | Human Neural Stem Cells | - | - | - | - | 2件: 2 2, 13 💬 |
1092 | Human normal 10% immunoglobulin for intravenous administration | - | - | - | - | 1件: 14 14 💬 |
1093 | Human normal 10% immunoglobulin for intravenous administrationn | - | - | - | - | 1件: 14 14 💬 |
1094 | Human normal immunoglobulin | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 9件: 11 11, 13, 14, 43, 45, 50, 51, 63, 65 💬 |
1095 | HUMAN NORMAL IMMUNOGLOBULIN (IV) | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 4件: 11 11, 14, 63, 65 💬 |
1096 | Human normal immunoglobulin (IVIg) | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 3件: 14 14, 50, 65 💬 |
1097 | Human normal immunoglobulin (SCIg) | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 1件: 14 14 💬 |
1098 | Human Normal Immunoglobulin (Subcutaneous - Intramuscular Immunoglobulin) | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 1件: 65 65 💬 |
1099 | Human normal immunoglobulin (subcutaneous) | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 1件: 65 65 💬 |
1100 | HUMAN NORMAL IMMUNOGLOBULIN FOR | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 1件: 65 65 💬 |
1101 | Human normal immunoglobulin for intravenous (IV) administration | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 1件: 51 51 💬 |
1102 | Human normal immunoglobulin for intravenous administration | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 3件: 14 14, 51, 65 💬 |
1103 | HUMAN NORMAL IMMUNOGLOBULIN FOR INTRAVENOUS USE | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 2件: 63 63, 65 💬 |
1104 | Human normal immunoglobulin for intravenous use (IVIG) | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 1件: 65 65 💬 |
1105 | HUMAN NORMAL IMMUNOGLOBULIN FOR INTRVENOUS USE | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 1件: 63 63 💬 |
1106 | Human normal immunoglobulin for subcutaneous administration | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 2件: 51 51, 65 💬 |
1107 | Human Normal Immunoglobulin for Subcutaneous Administration (IGSC) | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 1件: 65 65 💬 |
1108 | Human normal immunoglobulin G (IgG > 98% purity) | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 3件: 14 14, 63, 65 💬 |
1109 | Human normal immunoglobulin G (IgG) | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 1件: 11 11 💬 |
1110 | Human normal immunoglogulin (IVIg) | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 1件: 50 50 💬 |
1111 | Human Placenta-Derived Cells PDA001 Intravenous Infusion | - | - | - | - | 1件: 96 96 💬 |
1112 | Human Placental Derived Stem Cell | - | - | - | - | 4件: 19 19, 20, 60, 284 💬 |
1113 | Human Recombinant Tissue Non-Specific Alkaline Phosphatase Fusion Protein | 1件: Alkaline Phosphatase Alkaline Phosphatase | - | - | - | 1件: 172 172 💬 |
1114 | Human Retinal Progenitor Cells Drug Product | - | - | - | - | 1件: 90 90 💬 |
1115 | Human Umbilical Cord Blood-derived Mesenchymal Stem Cells | - | - | - | - | 1件: 36 36 💬 |
1116 | Human umbilical cord derived MSC transplantation for SLE | - | - | - | - | 1件: 49 49 💬 |
1117 | Human umbilical cord-derived MSCs | - | - | - | - | 1件: 271 271 💬 |
1118 | Humanised IgG1 monoclonal antibody against blood dendritic cell antigen 2 | - | - | - | - | 1件: 49 49 💬 |
1119 | HUMIRA - 40 MG SOLUZIONE INIETTABILE USO SOTTOCUTANEO 1 SIRINGA PRERIEMPITA 0.8 ML + 1 TAMPONE IMBEVUTO DI ALCOL IN UN BLISTER | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 2件: 56 56, 97 💬 |
1120 | HUMIRA - 40 MG SOLUZIONE INIETTABILE USO SOTTOCUTANEO 2 SIRINGHE PRERIEMPITE 0.8 ML + 2 TAMPONI IMBEVUTI DI ALCOL IN 1 BLISTER | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1121 | HUMIRA 40 mg solución inyectable en jeringa precargada | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 2件: 46 46, 96 💬 |
1122 | Hydroxychloroquine + low-dose prednisone | 2件: Hydroxychloroquine Hydroxychloroquine, Prednisone | 2件: Prednisone
Prednisone
,
Hydroxychloroquine
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 84 84 💬 |
1123 | Hydroxychloroquine 400mg/d | 1件: Hydroxychloroquine Hydroxychloroquine | 1件: Hydroxychloroquine
Hydroxychloroquine
💬 | - | - | 1件: 53 53 💬 |
1124 | Hydroxychloroquine higher dose | 1件: Hydroxychloroquine Hydroxychloroquine | 1件: Hydroxychloroquine
Hydroxychloroquine
💬 | - | - | 1件: 90 90 💬 |
1125 | Hydroxychloroquine lower dose | 1件: Hydroxychloroquine Hydroxychloroquine | 1件: Hydroxychloroquine
Hydroxychloroquine
💬 | - | - | 1件: 90 90 💬 |
1126 | IBD98-M Delayed-release Capsules | 1件: Manganese citrate Manganese citrate | - | - | - | 1件: 97 97 💬 |
1127 | Iberogast N | - | - | - | - | 1件: 97 97 💬 |
1128 | IDPM: Inhaled Dry Powder Mannitol | 1件: Mannitol Mannitol | 1件: Mannitol
Mannitol
💬 | - | - | 1件: 299 299 💬 |
1129 | IDROCORTISONE ACETATO DYNACREN - 1 % CREMA 1 TUBO DA 30 G | - | - | - | - | 1件: 272 272 💬 |
1130 | IDROCORTISONE ACETATO DYNACREN 1% CREMA | - | - | - | - | 1件: 272 272 💬 |
1131 | IFB-088 50mg/day | - | - | - | - | 1件: 2 2 💬 |
1132 | IFN-a 2b Kinoid Drug Substance | - | - | - | - | 1件: 49 49 💬 |
1133 | IFN-Kinoid Drug Substance | - | - | - | - | 2件: 49 49, 50 💬 |
1134 | IgG Next Generation | - | - | - | - | 2件: 63 63, 65 💬 |
1135 | IgG Next Generation (BT595) | - | - | - | - | 1件: 65 65 💬 |
1136 | IgPro20 (high dose) | - | - | - | - | 1件: 14 14 💬 |
1137 | IgPro20 (low dose) | - | - | - | - | 1件: 14 14 💬 |
1138 | IGSC 20% daily push versus 2 times per week pump | - | - | - | - | 1件: 65 65 💬 |
1139 | IGSC 20% daily push versus every 2 weeks pump | - | - | - | - | 1件: 65 65 💬 |
1140 | IGSC 20% daily push versus once a week pump | - | - | - | - | 1件: 65 65 💬 |
1141 | IL-6R nanobody | - | - | - | - | 1件: 49 49 💬 |
1142 | Iloprost low dose | 1件: Iloprost Iloprost | 1件: Iloprost
Iloprost
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 51 51 💬 |
1143 | ILOPROST SALE DI TROMETAMOLO | 1件: Iloprost Iloprost | 1件: Iloprost
Iloprost
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 51 51 💬 |
1144 | Iloprost therapy up to 2 ng/kg x min | 1件: Iloprost Iloprost | 1件: Iloprost
Iloprost
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 51 51 💬 |
1145 | Imiglucérase (drug) pharmacokinetics | - | - | - | - | 1件: 19 19 💬 |
1146 | Immunoglobulin G (Ig NextGen 16%) | - | - | - | - | 1件: 65 65 💬 |
1147 | Immunoglobulin G1, anti (protein Nogo A) (human Mus musculus monoclonal heavy | - | - | - | - | 1件: 2 2 💬 |
1148 | Immunoglobulin G1, anti (protein Nogo A) (human Mus musculus monoclonal heavy chain), disulfide with human Mus musculus monoclonal light chain, dimer | - | - | - | - | 1件: 2 2 💬 |
1149 | Immunoglobulin G1, anti-(human type I interferon receptor) (human monoclonal MEDI-546 heavy chain), disulfide with human monoclonal MEDI-546-chain, dimer | - | - | - | - | 1件: 49 49 💬 |
1150 | Immunoglobulina normale umana | - | - | - | - | 1件: 51 51 💬 |
1151 | Immunoglobulina Normale Umana per somministrazione endovenosa | - | - | - | - | 1件: 51 51 💬 |
1152 | Immunoglobulina Normale Umana per somministrazione sottocutanea | - | - | - | - | 1件: 51 51 💬 |
1153 | IMMUNOGLOBULINA UMANA NORMALE | - | - | - | - | 2件: 51 51, 65 💬 |
1154 | IMMUNOGLOBULINA UMANA NORMALE per somministrazione endovenosa | - | - | - | - | 1件: 14 14 💬 |
1155 | Immunoglobulins, normal human | - | - | - | - | 1件: 65 65 💬 |
1156 | Immunoglobulins, normal human, for extravascular adm. | - | - | - | - | 1件: 14 14 💬 |
1157 | Immunoglobulins, normal human, for intravascular adm. | - | - | - | - | 2件: 14 14, 15 💬 |
1158 | Immunological diagnosis tests | - | - | - | - | 1件: 65 65 💬 |
1159 | Immunoscintigraphy with radiolabeled Cimzia®. | 1件: Certolizumab pegol Certolizumab pegol | 1件: Certolizumab pegol
Certolizumab pegol
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1160 | IMO-8400 Dose Group 1 | - | - | - | - | 1件: 50 50 💬 |
1161 | IMO-8400 Dose Group 2 | - | - | - | - | 1件: 50 50 💬 |
1162 | IMod.Fc, H-Fcv3-N4 | - | - | - | - | 1件: 84 84 💬 |
1163 | IMP will be labeled as ''PF-04236921 106mg/vial, Clonal SC lyophilized form''. | - | - | - | - | 1件: 96 96 💬 |
1164 | Impact-Nutridrink | - | - | - | - | 1件: 299 299 💬 |
1165 | Imsidolimab high dose | 1件: Imsidolimab Imsidolimab | 1件: Imsidolimab
Imsidolimab
💬 | 1件: IL1RL2 IL1RL2 💬 | 1件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction 💬 | 1件: 37 37 💬 |
1166 | Imsidolimab low dose | 1件: Imsidolimab Imsidolimab | 1件: Imsidolimab
Imsidolimab
💬 | 1件: IL1RL2 IL1RL2 💬 | 1件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction 💬 | 1件: 37 37 💬 |
1167 | IMU-838 (30 mg/day) | - | - | - | - | 1件: 13 13 💬 |
1168 | IMU-838 (45 mg/day) | - | - | - | - | 1件: 13 13 💬 |
1169 | In double-blind phase: treatment with tofacitinib | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 107 107 💬 |
1170 | INALOSSIN - 800 PPM MOL/MOL GAS MEDICINALE COMPRESSO BOMBOLA IN ALLUMINIO CON VALVOLA VI DA 20 LITRI | - | - | - | - | 1件: 294 294 💬 |
1171 | INCB000928 fumarate dihydrate | - | - | - | - | 1件: 272 272 💬 |
1172 | INCRELEX 10 mg/ml, solución inyectable | 1件: Mecasermin Mecasermin | 1件: Mecasermin
Mecasermin
💬 | 2件: GHR GHR, IGF1R 💬 | 33件: AMPK signaling pathway AMPK signaling pathway, Adherens junction, Autophagy - animal, Breast cancer, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endocytosis, Focal adhesion, FoxO signaling pathway, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, JAK-STAT signaling pathway, Long-term depression, Longevity regulating pathway, Longevity regulating pathway - multiple species, MAPK signaling pathway, Melanoma, Neuroactive ligand-receptor interaction, Oocyte meiosis, Ovarian steroidogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Progesterone-mediated oocyte maturation, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Signaling pathways regulating pluripotency of stem cells, Transcriptional misregulation in cancer, mTOR signaling pathway 💬 | 1件: 78 78 💬 |
1173 | Indium-DTPA | 2件: Indium Indium, Pentetic acid | 1件: Pentetic acid
Pentetic acid
💬 | - | - | 1件: 299 299 💬 |
1174 | Individualized dose of rituximab | 1件: Rituximab Rituximab | 1件: Rituximab
Rituximab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 49 49 💬 |
1175 | Infliximab (INF) + MTX, DB | 1件: Infliximab Infliximab | 1件: Infliximab
Infliximab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1176 | Infliximab Increased Dose | 1件: Infliximab Infliximab | 1件: Infliximab
Infliximab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1177 | Infliximab therapeutic drug monitoring | 1件: Infliximab Infliximab | 1件: Infliximab
Infliximab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 2件: 96 96, 97 💬 |
1178 | Inhaled Dry Powder Mannitol | 1件: Mannitol Mannitol | 1件: Mannitol
Mannitol
💬 | - | - | 1件: 299 299 💬 |
1179 | Inhaled dry powder treprostinil (LIQ861) | 1件: Treprostinil Treprostinil | 1件: Treprostinil
Treprostinil
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 💬 |
1180 | Inhaled Nitric Oxide | 1件: Nitric Oxide Nitric Oxide | 1件: Nitric oxide
Nitric oxide
💬 | - | - | 2件: 85 85, 86 💬 |
1181 | Inhaled nitric oxide & INOpulse delivery | 1件: Nitric Oxide Nitric Oxide | 1件: Nitric oxide
Nitric oxide
💬 | - | - | 1件: 86 86 💬 |
1182 | Inhaled Nitric Oxide (iNO) use | 1件: Nitric Oxide Nitric Oxide | 1件: Nitric oxide
Nitric oxide
💬 | - | - | 1件: 294 294 💬 |
1183 | Inhaled Nitric Oxide - 30 mcg/kg IBW/hr | 1件: Nitric Oxide Nitric Oxide | 1件: Nitric oxide
Nitric oxide
💬 | - | - | 1件: 85 85 💬 |
1184 | Inhaled Nitric Oxide 5,10,15 mcg/Kg IBW/hr | 1件: Nitric Oxide Nitric Oxide | 1件: Nitric oxide
Nitric oxide
💬 | - | - | 1件: 85 85 💬 |
1185 | Inhaled nitric oxide 75 mcg/kg IBW/hr | 1件: Nitric Oxide Nitric Oxide | 1件: Nitric oxide
Nitric oxide
💬 | - | - | 2件: 85 85, 86 💬 |
1186 | Inhaled NO with pulsed delivery | - | - | - | - | 1件: 86 86 💬 |
1187 | Injectable MS DMT | - | - | - | - | 1件: 13 13 💬 |
1188 | Injection of autologous bone marrow derived mesenchymal stem cells | - | - | - | - | 1件: 13 13 💬 |
1189 | Injection of normal saline | - | - | - | - | 1件: 6 6 💬 |
1190 | Injection of Umbilical cord derived MSCs | - | - | - | - | 1件: 6 6 💬 |
1191 | INN Not available | - | - | - | - | 2件: 19 19, 46 💬 |
1192 | INN not available yet | - | - | - | - | 1件: 222 222 💬 |
1193 | INN Not yet proposed | - | - | - | - | 1件: 193 193 💬 |
1194 | Insulin detemir | 1件: Insulin detemir Insulin detemir | 1件: Insulin detemir
Insulin detemir
💬 | 1件: INSR INSR 💬 | 22件: AMPK signaling pathway AMPK signaling pathway, Adherens junction, Aldosterone-regulated sodium reabsorption, Alzheimer disease, Diabetic cardiomyopathy, FoxO signaling pathway, HIF-1 signaling pathway, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, MAPK signaling pathway, Non-alcoholic fatty liver disease, Ovarian steroidogenesis, PI3K-Akt signaling pathway, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway, Regulation of lipolysis in adipocytes, Type II diabetes mellitus, cGMP-PKG signaling pathway, mTOR signaling pathway 💬 | 1件: 299 299 💬 |
1195 | Insulin detemir [rDNA origin] injection | 1件: Insulin detemir Insulin detemir | 1件: Insulin detemir
Insulin detemir
💬 | 1件: INSR INSR 💬 | 22件: AMPK signaling pathway AMPK signaling pathway, Adherens junction, Aldosterone-regulated sodium reabsorption, Alzheimer disease, Diabetic cardiomyopathy, FoxO signaling pathway, HIF-1 signaling pathway, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, MAPK signaling pathway, Non-alcoholic fatty liver disease, Ovarian steroidogenesis, PI3K-Akt signaling pathway, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway, Regulation of lipolysis in adipocytes, Type II diabetes mellitus, cGMP-PKG signaling pathway, mTOR signaling pathway 💬 | 1件: 299 299 💬 |
1196 | Interferon beta 1a, oral doxycycline | 3件: Doxycycline Doxycycline, Human interferon beta, Interferon beta-1a | 3件: Doxycycline
Doxycycline
,
Interferon beta-1a
,
Doxycycline
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
1197 | Interferon beta-1a (new process, manufactured without FBS) | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
1198 | Interferon beta-1b, FRP within 15 days after randomization | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
1199 | Interferons, glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, cladribine, fingolimod, ponesimod, rituximab, ocrelizumab, ofatumumab, natalizumab | 12件: Acetate Acetate, Alemtuzumab, Cladribine, Dimethyl fumarate, Fingolimod, Glatiramer, Natalizumab, Ocrelizumab, Ofatumumab, Ponesimod, Rituximab, Teriflunomide | 10件: Cladribine
Cladribine
,
Alemtuzumab
,
Rituximab
,
Dimethyl fumarate
,
Ocrelizumab
,
Natalizumab
,
Ofatumumab
,
Fingolimod
,
Teriflunomide
,
Ponesimod
💬 | 7件: CD52 CD52, DHODH, ITGA4, KEAP1, MS4A1, RRM1, S1PR1 💬 | 30件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Biosynthesis of cofactors, Cell adhesion molecules, Chemical carcinogenesis - reactive oxygen species, Dilated cardiomyopathy, Drug metabolism - other enzymes, ECM-receptor interaction, Fluid shear stress and atherosclerosis, Focal adhesion, FoxO signaling pathway, Glutathione metabolism, Hematopoietic cell lineage, Hepatocellular carcinoma, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, Metabolic pathways, Neuroactive ligand-receptor interaction, Nucleotide metabolism, PI3K-Akt signaling pathway, Parkinson disease, Pathways in cancer, Purine metabolism, Pyrimidine metabolism, Regulation of actin cytoskeleton, Sphingolipid signaling pathway, Ubiquitin mediated proteolysis, Yersinia infection 💬 | 1件: 13 13 💬 |
1200 | Interferón beta 1a | - | - | - | - | 1件: 13 13 💬 |
1201 | Interferón beta 1a pegilado | - | - | - | - | 1件: 13 13 💬 |
1202 | Interferón Beta-1a pegilado | - | - | - | - | 1件: 13 13 💬 |
1203 | Interleukin-2 (aldesleukin). | 2件: Aldesleukin Aldesleukin, Human interleukin-2 | 1件: Aldesleukin
Aldesleukin
💬 | 3件: IL2RA IL2RA, IL2RB, IL2RG 💬 | 14件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Inflammatory bowel disease, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Primary immunodeficiency, Th1 and Th2 cell differentiation, Th17 cell differentiation, Transcriptional misregulation in cancer, Viral protein interaction with cytokine and cytokine receptor 💬 | 2件: 96 96, 97 💬 |
1204 | Intermediate dose BIBF 1120 twice daily | - | - | - | - | 1件: 85 85 💬 |
1205 | Intervention for incipient patients at low risk of disease progression | - | - | - | - | 1件: 66 66 💬 |
1206 | Intervention for patients at high risk of disease progression | - | - | - | - | 1件: 66 66 💬 |
1207 | Intraarticular dexamethasone | 1件: Dexamethasone Dexamethasone | 1件: Dexamethasone
Dexamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 46 46 💬 |
1208 | Intrathecal administration of autologous MSC-NP | - | - | - | - | 1件: 13 13 💬 |
1209 | Intrathecal MSC-NP injection | - | - | - | - | 1件: 13 13 💬 |
1210 | Intravenous Dexamethasone 1 mg | 1件: Dexamethasone Dexamethasone | 1件: Dexamethasone
Dexamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 46 46 💬 |
1211 | Intravenous Infusion of Diclofenac Sodium | 1件: Diclofenac Diclofenac | 1件: Diclofenac
Diclofenac
💬 | 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 78 78 💬 |
1212 | InVita D3 | - | - | - | - | 1件: 96 96 💬 |
1213 | Ioflupane 123I (DATSCAN®) | 1件: Ioflupane I-123 Ioflupane I-123 | - | - | - | 1件: 6 6 💬 |
1214 | IONIS-DMPKRx | - | - | - | - | 1件: 113 113 💬 |
1215 | Ipratropium bromide (drug) | 1件: Ipratropium Ipratropium | - | - | - | 1件: 6 6 💬 |
1216 | Ips-nsc cells | - | - | - | - | 1件: 6 6 💬 |
1217 | Irbesartan 150-300mg capsules daily for 6 months | 1件: Irbesartan Irbesartan | 1件: Irbesartan
Irbesartan
💬 | 1件: AGTR1 AGTR1 💬 | 16件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 167 167 💬 |
1218 | Irbesartan tablets (Approved in the USA. Reference listed drug Avapro) NDC # 43547-0374-03 | 1件: Irbesartan Irbesartan | 1件: Irbesartan
Irbesartan
💬 | 1件: AGTR1 AGTR1 💬 | 16件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 2件: 66 66, 222 💬 |
1219 | Irbesartan tablets (NDA 020 757) | 1件: Irbesartan Irbesartan | 1件: Irbesartan
Irbesartan
💬 | 1件: AGTR1 AGTR1 💬 | 16件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 66 66 💬 |
1220 | Irbesartan tablets (NDC# 31722-729-30 approved in the United states) | 1件: Irbesartan Irbesartan | 1件: Irbesartan
Irbesartan
💬 | 1件: AGTR1 AGTR1 💬 | 16件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 222 222 💬 |
1221 | Irbesartan tablets (NDC# 43547-0374-03 and NDC 43547-374-09, approved in the USA) Generic tablets distributed by Solco Healthcare US, LLC | 1件: Irbesartan Irbesartan | 1件: Irbesartan
Irbesartan
💬 | 1件: AGTR1 AGTR1 💬 | 16件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 222 222 💬 |
1222 | Iron Dextran | 2件: Dextran Dextran, Iron Dextran | 2件: Dextran 1
Dextran 1
,
Iron dextran
💬 | - | - | 1件: 62 62 💬 |
1223 | Iron supplement 300-600 mg/day | 1件: Iron Iron | - | - | - | 2件: 96 96, 97 💬 |
1224 | Iron(III)- hydroxide dextran complex | 3件: Dextran Dextran, Hydroxide ion, Iron | 1件: Dextran 1
Dextran 1
💬 | - | - | 2件: 96 96, 97 💬 |
1225 | Isocaloric Diet | - | - | - | - | 2件: 2 2, 83 💬 |
1226 | ISOSORBIDE DINITRATE | 2件: Isosorbide Isosorbide, Isosorbide dinitrate | 2件: Isosorbide
Isosorbide
,
Isosorbide dinitrate
💬 | - | - | 1件: 113 113 💬 |
1227 | Isosorbide Dinitrate 20 mg | 2件: Isosorbide Isosorbide, Isosorbide dinitrate | 2件: Isosorbide
Isosorbide
,
Isosorbide dinitrate
💬 | - | - | 1件: 113 113 💬 |
1228 | Isosorbide Dinitrate 40 mg | 2件: Isosorbide Isosorbide, Isosorbide dinitrate | 2件: Isosorbide
Isosorbide
,
Isosorbide dinitrate
💬 | - | - | 1件: 113 113 💬 |
1229 | Isosorbide Dinitrate 60 mg | 2件: Isosorbide Isosorbide, Isosorbide dinitrate | 2件: Isosorbide
Isosorbide
,
Isosorbide dinitrate
💬 | - | - | 1件: 113 113 💬 |
1230 | Isosorbide Dinitrate 80 mg | 2件: Isosorbide Isosorbide, Isosorbide dinitrate | 2件: Isosorbide
Isosorbide
,
Isosorbide dinitrate
💬 | - | - | 1件: 113 113 💬 |
1231 | ITIS diet | - | - | - | - | 1件: 46 46 💬 |
1232 | Itraconazole 400 mg/day and terbinafine 500 mg/day administered orally. | 2件: Itraconazole Itraconazole, Terbinafine | 2件: Itraconazole
Itraconazole
,
Terbinafine
💬 | - | - | 1件: 96 96 💬 |
1233 | IUPAC name: 1-(2-Isopropoxyethyl)-2-thioxo-1,2,3,5-tetrahydro-pyrrolo[3,2-d] pyrimidin-4-one | - | - | - | - | 1件: 17 17 💬 |
1234 | IUPAC name: 2-[4-[(2-amino-5-methyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl)methylam ino]benzoyl]amino | - | - | - | - | 1件: 337 337 💬 |
1235 | Ixazomib (NINLARO®) capsules | 1件: Ixazomib Ixazomib | 1件: Ixazomib
Ixazomib
💬 | 1件: PSMB5 PSMB5 💬 | 8件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬 | 1件: 13 13 💬 |
1236 | Jaktinib Dihydrochloride Monohydrate 50mg BID and Mimic tablets of jakitinib hydrochloride 75mg BID and Acetylcysteine Effervescent Tablets | 1件: Acetylcysteine Acetylcysteine | 1件: Acetylcysteine
Acetylcysteine
💬 | - | - | 1件: 85 85 💬 |
1237 | Jaktinib Dihydrochloride Monohydrate 75mg BID and Mimic tablets of jakitinib hydrochloride 50mg BID and Acetylcysteine Effervescent Tablets | 1件: Acetylcysteine Acetylcysteine | 1件: Acetylcysteine
Acetylcysteine
💬 | - | - | 1件: 85 85 💬 |
1238 | Jianpixiaozhong particles and Wuse Dietotherapy | - | - | - | - | 1件: 222 222 💬 |
1239 | JNJ-54781532 150 mg once daily | - | - | - | - | 1件: 97 97 💬 |
1240 | JNJ-54781532 25 mg once daily | - | - | - | - | 1件: 97 97 💬 |
1241 | JNJ-54781532 75 mg once daily | - | - | - | - | 1件: 97 97 💬 |
1242 | JNJ-54781532 75 mg twice daily | - | - | - | - | 1件: 97 97 💬 |
1243 | Juvit D3 | - | - | - | - | 1件: 6 6 💬 |
1244 | K(D)PT | - | - | - | - | 1件: 97 97 💬 |
1245 | KB407 (Nebulization) | - | - | - | - | 1件: 299 299 💬 |
1246 | Ketocal 4:1 liquid Nutricia (intervention) | - | - | - | - | 1件: 256 256 💬 |
1247 | Ketogenic diet | - | - | - | - | 2件: 49 49, 145 💬 |
1248 | Ketone ester drink | - | - | - | - | 1件: 6 6 💬 |
1249 | Ketone Ester Elite endurance Nutrition Drink | - | - | - | - | 1件: 6 6 💬 |
1250 | Keyhole limpet hemocyanin (KLH) neo-antigen | 1件: Keyhole limpet hemocyanin Keyhole limpet hemocyanin | - | - | - | 1件: 13 13 💬 |
1251 | Kiovig® (Human normal Immunoglobulin for intravenous administration 100mg/mL) | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 1件: 14 14 💬 |
1252 | KPS-0373, High dose | - | - | - | - | 1件: 18 18 💬 |
1253 | KPS-0373, Low dose | - | - | - | - | 1件: 18 18 💬 |
1254 | KREON de Liberación Inmediata | - | - | - | - | 1件: 299 299 💬 |
1255 | KREON N 25000 | - | - | - | - | 1件: 299 299 💬 |
1256 | Kuvan® (sapropterin dihydrochloride) | 1件: Sapropterin Sapropterin | 1件: Sapropterin
Sapropterin
💬 | - | - | 1件: 240 240 💬 |
1257 | KW-6356 High Dose | 1件: KW-6356 KW-6356 | - | - | - | 1件: 6 6 💬 |
1258 | KW-6356 Low Dose | 1件: KW-6356 KW-6356 | - | - | - | 1件: 6 6 💬 |
1259 | KW-6356 Middle Dose | 1件: KW-6356 KW-6356 | - | - | - | 1件: 6 6 💬 |
1260 | KW-6356 X Dose | 1件: KW-6356 KW-6356 | - | - | - | 1件: 6 6 💬 |
1261 | KW-6356 Y Dose | 1件: KW-6356 KW-6356 | - | - | - | 1件: 6 6 💬 |
1262 | Kyo-Dophilus | - | - | - | - | 1件: 97 97 💬 |
1263 | L-3-(3,4-Dihydroxyphenyl)alanine | 1件: Alanine Alanine | 1件: Alanine
Alanine
💬 | - | - | 1件: 6 6 💬 |
1264 | L-DOPA | 1件: Levodopa Levodopa | 1件: Levodopa
Levodopa
💬 | 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1265 | L-Dopa/ MODOPAR | 1件: Levodopa Levodopa | 1件: Levodopa
Levodopa
💬 | 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1266 | L-DOPA/DDCI | 1件: Levodopa Levodopa | 1件: Levodopa
Levodopa
💬 | 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1267 | L-DOPS | 1件: Droxidopa Droxidopa | 1件: Droxidopa
Droxidopa
💬 | 9件: ADRA1A ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3 💬 | 14件: AMPK signaling pathway AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 6 6 💬 |
1268 | L-Lysine N acetylcysteinate | 1件: Lysine Lysine | 1件: Lysine
Lysine
💬 | - | - | 1件: 299 299 💬 |
1269 | L-Lysine N-acetylcysteinate | 1件: Lysine Lysine | 1件: Lysine
Lysine
💬 | - | - | 1件: 299 299 💬 |
1270 | L-Lysine- N-acetylcysteinate | 1件: Lysine Lysine | 1件: Lysine
Lysine
💬 | - | - | 1件: 299 299 💬 |
1271 | L-Lysine-N-acetyl-L-cysteinate | 1件: Lysine Lysine | 1件: Lysine
Lysine
💬 | - | - | 1件: 299 299 💬 |
1272 | L-Lysine-N-acetylcysteinate | 1件: Lysine Lysine | 1件: Lysine
Lysine
💬 | - | - | 1件: 299 299 💬 |
1273 | L-Lysyl-D-Prolyl-L-Threonine Acetate | 2件: Acetate Acetate, Threonine | 1件: Threonine
Threonine
💬 | - | - | 1件: 97 97 💬 |
1274 | L-Lysyl-D-Prolyl-LThreonine acetate, lyophilisate | 1件: Acetate Acetate | - | - | - | 1件: 97 97 💬 |
1275 | L-Threo DOPS | 1件: Droxidopa Droxidopa | 1件: Droxidopa
Droxidopa
💬 | 9件: ADRA1A ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3 💬 | 14件: AMPK signaling pathway AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 17 17 💬 |
1276 | L01XE31 - Nintedanib | 1件: Nintedanib Nintedanib | 1件: Nintedanib
Nintedanib
💬 | 8件: FGFR1 FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 | 34件: Adherens junction Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, Choline metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, Gap junction, Gastric cancer, Glioma, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Rheumatoid arthritis, Signaling pathways regulating pluripotency of stem cells, Thermogenesis, Transcriptional misregulation in cancer, VEGF signaling pathway 💬 | 1件: 85 85 💬 |
1277 | L04AA04 - IMMUNOGLOBULINA ANTITIMOCITARIA (DI CONIGLIO) IMMUNOGLOBULINA DI CONIGLIO ANTITIMOCITI UMANI THYMOGLOBULINE | 1件: Antithymocyte immunoglobulin (rabbit) Antithymocyte immunoglobulin (rabbit) | - | - | - | 1件: 13 13 💬 |
1278 | Lactizole nebulization | - | - | - | - | 1件: 299 299 💬 |
1279 | Lactobacillus casei DG | 1件: Lactobacillus casei Lactobacillus casei | 1件: Lactobacillus casei
Lactobacillus casei
💬 | - | - | 1件: 97 97 💬 |
1280 | Lactobacillus casei DG (Enterolactis duo®) | 1件: Lactobacillus casei Lactobacillus casei | 1件: Lactobacillus casei
Lactobacillus casei
💬 | - | - | 1件: 6 6 💬 |
1281 | Lamotrigin ”Nordic Prime 100 mg | - | - | - | - | 1件: 114 114 💬 |
1282 | Lamotrigin ”Nordic Prime 25 mg | - | - | - | - | 1件: 114 114 💬 |
1283 | Lamotrigin ”Nordic Prime 50 mg | - | - | - | - | 1件: 114 114 💬 |
1284 | Lamotrigine dispers | 1件: Lamotrigine Lamotrigine | 1件: Lamotrigine
Lamotrigine
💬 | 5件: SCN1A SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | 3件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬 | 1件: 34 34 💬 |
1285 | Large dose of prednisolone plus intra-lesional of Triamcinolone Acetonide followed the systemic combination of mycophenolate mofetil (MMF), dapsone and low dose prednisolone in treatment of MMP | 5件: Dapsone Dapsone, Mycophenolate mofetil, Mycophenolic acid, Prednisolone, Triamcinolone | 5件: Triamcinolone
Triamcinolone
,
Prednisolone
,
Dapsone
,
Mycophenolate mofetil
,
Mycophenolic acid
💬 | 3件: IMPDH1 IMPDH1, IMPDH2, NR3C1 💬 | 5件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Neuroactive ligand-receptor interaction, Nucleotide metabolism, Purine metabolism 💬 | 1件: 162 162 💬 |
1286 | Large Neutral Amino Acid Therapy | - | - | - | - | 1件: 240 240 💬 |
1287 | LCIG (Duodopa) | - | - | - | - | 1件: 6 6 💬 |
1288 | Leflunomide (permitted, not necessary) | 1件: Leflunomide Leflunomide | 1件: Leflunomide
Leflunomide
💬 | 1件: DHODH DHODH 💬 | 3件: Biosynthesis of cofactors Biosynthesis of cofactors, Metabolic pathways, Pyrimidine metabolism 💬 | 1件: 46 46 💬 |
1289 | Leflunomide 20 mg+prednisone 0.5mg/kg/d | 2件: Leflunomide Leflunomide, Prednisone | 2件: Prednisone
Prednisone
,
Leflunomide
💬 | 2件: DHODH DHODH, NR3C1 💬 | 4件: Biosynthesis of cofactors Biosynthesis of cofactors, Metabolic pathways, Neuroactive ligand-receptor interaction, Pyrimidine metabolism 💬 | 1件: 66 66 💬 |
1290 | Leflunomide 20mg/d | 1件: Leflunomide Leflunomide | 1件: Leflunomide
Leflunomide
💬 | 1件: DHODH DHODH 💬 | 3件: Biosynthesis of cofactors Biosynthesis of cofactors, Metabolic pathways, Pyrimidine metabolism 💬 | 1件: 53 53 💬 |
1291 | Lenadogene nolparvovec | 1件: Lenadogene nolparvovec Lenadogene nolparvovec | - | - | - | 1件: 302 302 💬 |
1292 | Lenalidomide and dexamethasone | 2件: Dexamethasone Dexamethasone, Lenalidomide | 2件: Dexamethasone
Dexamethasone
,
Lenalidomide
💬 | 2件: NR3C1 NR3C1, TNF 💬 | 68件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Neuroactive ligand-receptor interaction, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 16 16 💬 |
1293 | Lenalidomide+Dexamethasone | 2件: Dexamethasone Dexamethasone, Lenalidomide | 2件: Dexamethasone
Dexamethasone
,
Lenalidomide
💬 | 2件: NR3C1 NR3C1, TNF 💬 | 68件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Neuroactive ligand-receptor interaction, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 16 16 💬 |
1294 | Lenalidomide, Dexamethasone | 2件: Dexamethasone Dexamethasone, Lenalidomide | 2件: Dexamethasone
Dexamethasone
,
Lenalidomide
💬 | 2件: NR3C1 NR3C1, TNF 💬 | 68件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Neuroactive ligand-receptor interaction, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 16 16 💬 |
1295 | Lenalidomide, Dexamethasone and Cyclophosphamide | 3件: Cyclophosphamide Cyclophosphamide, Dexamethasone, Lenalidomide | 4件: Cyclophosphamide
Cyclophosphamide
,
Dexamethasone
,
Lenalidomide
,
Cyclophosphamide
💬 | 2件: NR3C1 NR3C1, TNF 💬 | 68件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Neuroactive ligand-receptor interaction, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 28 28 💬 |
1296 | Lenti-D | - | - | - | - | 1件: 20 20 💬 |
1297 | Lenti-D Drug Product | - | - | - | - | 1件: 20 20 💬 |
1298 | Lentivirus-mediated delivery of ARSA to the CNS. | - | - | - | - | 1件: 19 19 💬 |
1299 | Leuplin DPS 11.25mg | - | - | - | - | 1件: 76 76 💬 |
1300 | Leuprolide Acetate 3 Month Depot | 2件: Acetate Acetate, Leuprolide | - | - | - | 1件: 76 76 💬 |
1301 | Leuprolide acetate depot | 2件: Acetate Acetate, Leuprolide | - | - | - | 1件: 76 76 💬 |
1302 | Leuprorelin Acetate Depot 3M | 2件: Acetate Acetate, Leuprolide | - | - | - | 1件: 76 76 💬 |
1303 | LEVOCETIRIZINA DICLORIDRATO | 1件: Levocetirizine Levocetirizine | 1件: Levocetirizine
Levocetirizine
💬 | 1件: HRH1 HRH1 💬 | 3件: Calcium signaling pathway Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction 💬 | 1件: 61 61 💬 |
1304 | LEVODOPA (DC.IT) (FU) | 1件: Levodopa Levodopa | 1件: Levodopa
Levodopa
💬 | 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1305 | Levodopa (delivered intravenously) | 1件: Levodopa Levodopa | 1件: Levodopa
Levodopa
💬 | 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1306 | Levodopa (drug), intraduodenal administration | 1件: Levodopa Levodopa | 1件: Levodopa
Levodopa
💬 | 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1307 | Levodopa (L-dopa) | 1件: Levodopa Levodopa | 1件: Levodopa
Levodopa
💬 | 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1308 | Levodopa (L-DOPA) + Standard care | 1件: Levodopa Levodopa | 1件: Levodopa
Levodopa
💬 | 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1309 | Levodopa and decarboxylase inhibitor | 1件: Levodopa Levodopa | 1件: Levodopa
Levodopa
💬 | 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1310 | Levodopa and Domperidone | 2件: Domperidone Domperidone, Levodopa | 3件: Levodopa
Levodopa
,
Domperidone
,
Domperidone maleate
💬 | 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1311 | LEVODOPA DC.IT FU | 1件: Levodopa Levodopa | 1件: Levodopa
Levodopa
💬 | 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1312 | Levodopa dispersible | 1件: Levodopa Levodopa | 1件: Levodopa
Levodopa
💬 | 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1313 | Levodopa, decarboxylase inhibitor and COMT inhibitor | 1件: Levodopa Levodopa | 1件: Levodopa
Levodopa
💬 | 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1314 | Levodopa/DDCI | 1件: Levodopa Levodopa | 1件: Levodopa
Levodopa
💬 | 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1315 | Levodopa/dopa decarboxylase inhibitor | 1件: Levodopa Levodopa | 1件: Levodopa
Levodopa
💬 | 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1316 | Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 1 | 1件: Aminolevulinic acid Aminolevulinic acid | 1件: Aminolevulinic acid
Aminolevulinic acid
💬 | - | - | 1件: 34 34 💬 |
1317 | Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 2 | 1件: Aminolevulinic acid Aminolevulinic acid | 1件: Aminolevulinic acid
Aminolevulinic acid
💬 | - | - | 1件: 34 34 💬 |
1318 | Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 3 | 1件: Aminolevulinic acid Aminolevulinic acid | 1件: Aminolevulinic acid
Aminolevulinic acid
💬 | - | - | 1件: 34 34 💬 |
1319 | LION-101 dose level 1 | - | - | - | - | 1件: 113 113 💬 |
1320 | LION-101 dose level 2 | - | - | - | - | 1件: 113 113 💬 |
1321 | Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer. | 1件: Amikacin Amikacin | 1件: Amikacin
Amikacin
💬 | - | - | 1件: 299 299 💬 |
1322 | Liposomal Doxorubicin | 1件: Doxorubicin Doxorubicin | 1件: Doxorubicin
Doxorubicin
💬 | 2件: TOP2A TOP2A, TOP2B 💬 | 1件: Platinum drug resistance Platinum drug resistance 💬 | 1件: 331 331 💬 |
1323 | LiRIS low dose and LiRIS high dose | - | - | - | - | 1件: 226 226 💬 |
1324 | Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field | - | - | - | - | 1件: 13 13 💬 |
1325 | Lithium Gluconate (drug) Glyceryl Triacetate GTA (drug) | 1件: Triacetin Triacetin | 1件: Triacetin
Triacetin
💬 | - | - | 1件: 307 307 💬 |
1326 | Live Necator americanus larvae | - | - | - | - | 1件: 13 13 💬 |
1327 | LO2A eye drops | - | - | - | - | 1件: 53 53 💬 |
1328 | Local Trade Name, 2mg | - | - | - | - | 1件: 6 6 💬 |
1329 | Local Trade Name, 4mg | - | - | - | - | 1件: 6 6 💬 |
1330 | Local Trade Name, 8mg | - | - | - | - | 1件: 6 6 💬 |
1331 | Lodotra (delayed release prednisolone) | 1件: Prednisolone Prednisolone | 1件: Prednisolone
Prednisolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 41 41 💬 |
1332 | Loestrin (norethindrone acetate and ethinyl estradiol) | 4件: Acetate Acetate, Estradiol, Ethinylestradiol, Norethisterone | 3件: Estradiol
Estradiol
,
Norethindrone
,
Ethinyl estradiol
💬 | 3件: ESR1 ESR1, ESR2, PGR 💬 | 12件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Oocyte meiosis, Pathways in cancer, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬 | 1件: 299 299 💬 |
1333 | Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 µg ethinyl estradiol) | 4件: Acetate Acetate, Estradiol, Ethinylestradiol, Norethisterone | 3件: Estradiol
Estradiol
,
Norethindrone
,
Ethinyl estradiol
💬 | 3件: ESR1 ESR1, ESR2, PGR 💬 | 12件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Oocyte meiosis, Pathways in cancer, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬 | 2件: 46 46, 49 💬 |
1334 | Lonapegsomatropin drug product | 1件: Lonapegsomatropin Lonapegsomatropin | 1件: Lonapegsomatropin
Lonapegsomatropin
💬 | 1件: GHR GHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 1件: 78 78 💬 |
1335 | Long-chain n-3 PUFA | - | - | - | - | 1件: 46 46 💬 |
1336 | Lopinavir/ritonavir + nevirapine | 3件: Lopinavir Lopinavir, Nevirapine, Ritonavir | 3件: Ritonavir
Ritonavir
,
Nevirapine
,
Lopinavir
💬 | - | - | 1件: 265 265 💬 |
1337 | LORTAAN*28CPR RIV DIV 50MG | - | - | - | - | 1件: 167 167 💬 |
1338 | Losartan and nebivolol | 2件: Losartan Losartan, Nebivolol | 2件: Nebivolol
Nebivolol
,
Losartan
💬 | 2件: ADRB1 ADRB1, AGTR1 💬 | 22件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Renin-angiotensin system, Salivary secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 167 167 💬 |
1339 | Low antigen content diet | - | - | - | - | 1件: 66 66 💬 |
1340 | Low carbohydrate ketogenic diet | - | - | - | - | 1件: 256 256 💬 |
1341 | Low copper diet | 1件: Copper Copper | - | - | - | 1件: 171 171 💬 |
1342 | Low Dietary Sodium | - | - | - | - | 1件: 49 49 💬 |
1343 | Low dose | - | - | - | - | 1件: 97 97 💬 |
1344 | Low dose AFFITOPE® PD03A + Adjuvant | - | - | - | - | 1件: 6 6 💬 |
1345 | Low dose arm receiving neutral oil and 400 IU/g of Vitamin D every second day | 1件: Vitamin D Vitamin D | - | - | - | 1件: 13 13 💬 |
1346 | Low Dose Aspirin (162 mg/day) | 1件: Acetylsalicylic acid Acetylsalicylic acid | 1件: Aspirin
Aspirin
💬 | 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 13 13 💬 |
1347 | Low dose BIBF 1120 twice daily | - | - | - | - | 1件: 85 85 💬 |
1348 | Low dose BIBF1120 once daily | - | - | - | - | 1件: 85 85 💬 |
1349 | Low Dose Budesonide | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 97 97 💬 |
1350 | Low dose budesonide tablet | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 💬 |
1351 | Low dose cannabis | 1件: Medical Cannabis Medical Cannabis | - | - | - | 1件: 13 13 💬 |
1352 | Low dose levodopa | 1件: Levodopa Levodopa | 1件: Levodopa
Levodopa
💬 | 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1353 | Low dose LX2006 | - | - | - | - | 1件: 18 18 💬 |
1354 | Low Dose Mesenchymal Stem Cells (MSCs) | - | - | - | - | 1件: 49 49 💬 |
1355 | Low Dose MT-1303 | - | - | - | - | 1件: 97 97 💬 |
1356 | Low Dose MYOBLOC | 1件: Botulinum toxin type B Botulinum toxin type B | 1件: Rimabotulinumtoxin B
Rimabotulinumtoxin B
💬 | 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 1件: 13 13 💬 |
1357 | Low dose naltrexone | 1件: Naltrexone Naltrexone | 1件: Naltrexone
Naltrexone
💬 | 3件: OPRD1 OPRD1, OPRK1, OPRM1 💬 | 5件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | 2件: 96 96, 97 💬 |
1358 | Low dose of BIIL 284 BS tablets | - | - | - | - | 1件: 46 46 💬 |
1359 | Low dose ORTD-1 | - | - | - | - | 1件: 46 46 💬 |
1360 | Low dose prednisolone | 1件: Prednisolone Prednisolone | 1件: Prednisolone
Prednisolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 84 84 💬 |
1361 | Low dose TSO | - | - | - | - | 1件: 96 96 💬 |
1362 | Low dose vehicle control | - | - | - | - | 1件: 46 46 💬 |
1363 | Low Dose-VIS649 | - | - | - | - | 1件: 66 66 💬 |
1364 | Low Residue Diet Intervention | - | - | - | - | 1件: 21 21 💬 |
1365 | Low serine diet | 1件: Serine Serine | 1件: Serine
Serine
💬 | - | - | 1件: 96 96 💬 |
1366 | Low-dose Aldesleukin (Proleukin®) | 1件: Aldesleukin Aldesleukin | 1件: Aldesleukin
Aldesleukin
💬 | 3件: IL2RA IL2RA, IL2RB, IL2RG 💬 | 14件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Inflammatory bowel disease, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Primary immunodeficiency, Th1 and Th2 cell differentiation, Th17 cell differentiation, Transcriptional misregulation in cancer, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 49 49 💬 |
1367 | Low-dose IL-2 | 1件: Human interleukin-2 Human interleukin-2 | - | - | - | 1件: 56 56 💬 |
1368 | Low-dose interleukin-2 | 1件: Human interleukin-2 Human interleukin-2 | - | - | - | 1件: 53 53 💬 |
1369 | Low-dose naltrexone | 1件: Naltrexone Naltrexone | 1件: Naltrexone
Naltrexone
💬 | 3件: OPRD1 OPRD1, OPRK1, OPRM1 💬 | 5件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 226 226 💬 |
1370 | Low-Dose REGN4461 | - | - | - | - | 1件: 265 265 💬 |
1371 | LUM/IVA fixed-dose combination | - | - | - | - | 1件: 299 299 💬 |
1372 | Lumacaftor, Ivacaftor Drug Combination | 2件: Ivacaftor Ivacaftor, Lumacaftor | 2件: Ivacaftor
Ivacaftor
,
Lumacaftor
💬 | 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
1373 | Lumbar Interbody Fusion with NeoFuse | 2件: Iron polymaltose Iron polymaltose, Lactobacillus casei | 1件: Lactobacillus casei
Lactobacillus casei
💬 | - | - | 1件: 70 70 💬 |
1374 | Luphere depot 3.75mg(Leuprolide acetate 3.75mg) | 2件: Acetate Acetate, Leuprolide | - | - | - | 1件: 76 76 💬 |
1375 | Lutein (10 or 30 mg/day) capsules | 1件: Lutein Lutein | - | - | - | 1件: 90 90 💬 |
1376 | LX3305 Dihydrate | - | - | - | - | 1件: 46 46 💬 |
1377 | LX3305 high dose | - | - | - | - | 1件: 46 46 💬 |
1378 | LX3305 low dose | - | - | - | - | 1件: 46 46 💬 |
1379 | LX3305 mid dose | - | - | - | - | 1件: 46 46 💬 |
1380 | LY03003( the name of rotigotine) | 1件: Rotigotine Rotigotine | 1件: Rotigotine
Rotigotine
💬 | 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1381 | Lysine-D-Proline-Threonine | 4件: D-Proline D-Proline, Lysine, Proline, Threonine | 3件: Proline
Proline
,
Threonine
,
Lysine
💬 | - | - | 1件: 97 97 💬 |
1382 | M2951 (Other Name: Evobrutinib) | 1件: Evobrutinib Evobrutinib | 1件: Evobrutinib
Evobrutinib
💬 | 1件: BTK BTK 💬 | 7件: B cell receptor signaling pathway B cell receptor signaling pathway, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Platelet activation, Primary immunodeficiency 💬 | 1件: 49 49 💬 |
1383 | M5049 high dose | - | - | - | - | 2件: 49 49, 50 💬 |
1384 | M5049 low dose | - | - | - | - | 1件: 49 49 💬 |
1385 | M5049 medium dose | - | - | - | - | 1件: 49 49 💬 |
1386 | MABCAMPATH 10 mg/ml concentrado para solución para perfusión | 1件: Alemtuzumab Alemtuzumab | 1件: Alemtuzumab
Alemtuzumab
💬 | 1件: CD52 CD52 💬 | - | 1件: 13 13 💬 |
1387 | MABTHERA 500 mg concentrado para solución para perfusión | 1件: Rituximab Rituximab | 1件: Rituximab
Rituximab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 46 46 💬 |
1388 | MabThera®, 100 mg Concentrado para solución para perfusión | 1件: Rituximab Rituximab | 1件: Rituximab
Rituximab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 46 46 💬 |
1389 | Macitentan 10 mg tablet, once daily. | 1件: Macitentan Macitentan | 1件: Macitentan
Macitentan
💬 | 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
1390 | MAG-DHA | - | - | - | - | 1件: 299 299 💬 |
1391 | Marketed plasma-derived VWF/FVIII concentrate | - | - | - | - | 1件: 288 288 💬 |
1392 | MBX-8025 50 mg (Dose Escalation Period 1) | - | - | - | - | 1件: 79 79 💬 |
1393 | MBX-8025 50 mg or 100 mg (Dose Escalation Period 2) | - | - | - | - | 1件: 79 79 💬 |
1394 | MBX-8025 50 mg, 100 mg or 200 mg (Dose Escalation Period 3) | - | - | - | - | 1件: 79 79 💬 |
1395 | MBX-8025, DSIC | - | - | - | - | 1件: 93 93 💬 |
1396 | MEDI7183 high dose | - | - | - | - | 1件: 97 97 💬 |
1397 | MEDI7183 low dose | - | - | - | - | 1件: 97 97 💬 |
1398 | MEDI7183 medium dose | - | - | - | - | 1件: 97 97 💬 |
1399 | Mediterranean diet supplemented with medium-chain triglyceride oil | - | - | - | - | 1件: 6 6 💬 |
1400 | Medium dose prednisolone | 1件: Prednisolone Prednisolone | 1件: Prednisolone
Prednisolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 84 84 💬 |
1401 | Medium dose TSO | - | - | - | - | 1件: 96 96 💬 |
1402 | Medium Dose-VIS649 | - | - | - | - | 1件: 66 66 💬 |
1403 | MEDROL*10CPR DIV 4MG | 1件: Methylprednisolone Methylprednisolone | 1件: Methylprednisolone
Methylprednisolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 222 222 💬 |
1404 | Melarsoprol 1.8 mg/kg/d, 10d + eflornithine 400 mg/kg/d, 7d | 2件: Eflornithine Eflornithine, Melarsoprol | 2件: Melarsoprol
Melarsoprol
,
Eflornithine
💬 | 1件: ODC1 ODC1 💬 | 3件: Arginine and proline metabolism Arginine and proline metabolism, Glutathione metabolism, Metabolic pathways 💬 | 1件: 65 65 💬 |
1405 | Melarsoprol 1.8 mg/kg/d, 10d + nifurtimox 15/20 mg/kg/d, 10d | 2件: Melarsoprol Melarsoprol, Nifurtimox | 2件: Melarsoprol
Melarsoprol
,
Nifurtimox
💬 | - | - | 1件: 65 65 💬 |
1406 | Melevodopa and decarboxylase inhibitor | 1件: Melevodopa Melevodopa | 1件: Melevodopa
Melevodopa
💬 | - | - | 1件: 6 6 💬 |
1407 | MELISSAE FOLII DRY AQUEOUS EXTRACT | - | - | - | - | 1件: 97 97 💬 |
1408 | Melphalan, thalidomide and dexamethasone | 3件: Dexamethasone Dexamethasone, Melphalan, Thalidomide | 3件: Dexamethasone
Dexamethasone
,
Melphalan
,
Thalidomide
💬 | 2件: NR3C1 NR3C1, TNF 💬 | 68件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Neuroactive ligand-receptor interaction, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 28 28 💬 |
1409 | Memantine (drug) | 1件: Memantine Memantine | 1件: Memantine
Memantine
💬 | 5件: GRIN1 GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬 | 20件: Alcoholism Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1410 | Menadiol Diphosphate | 1件: Menadiol diphosphate Menadiol diphosphate | 1件: Menadiol sodium sulfate
Menadiol sodium sulfate
💬 | - | - | 1件: 299 299 💬 |
1411 | Menadiol sodium diphosphate | 1件: Kappadione Kappadione | 1件: Menadiol sodium diphosphate
Menadiol sodium diphosphate
💬 | - | - | 1件: 299 299 💬 |
1412 | MENINGOCOCCAL GROUP A OLIGOSACCHARIDES CONJUGATED TO CORYNEBACTERIUM DIPHTHERIAE C7 (beta197) M8 (CRM197) PROTEIN | 2件: Corynebacterium diphtheriae Corynebacterium diphtheriae, Corynebacterium diphtheriae CRM197 protein | - | - | - | 1件: 11 11 💬 |
1413 | MENINGOCOCCAL GROUP A OLIGOSACCHARIDES CONJUGATED TO CORYNEBACTERIUM DIPHTHERIAE C7 (ß197) M8 (CRM197) PROTEIN | 2件: Corynebacterium diphtheriae Corynebacterium diphtheriae, Corynebacterium diphtheriae CRM197 protein | - | - | - | 1件: 11 11 💬 |
1414 | MENINGOCOCCAL GROUP W OLIGOSACCHARIDES CONJUGATED TO CORYNEBACTERIUM DIPHTHERIAE C7 (beta197) M8 (CRM197) PROTEIN | 2件: Corynebacterium diphtheriae Corynebacterium diphtheriae, Corynebacterium diphtheriae CRM197 protein | - | - | - | 1件: 11 11 💬 |
1415 | MENINGOCOCCAL GROUP W OLIGOSACCHARIDES CONJUGATED TO CORYNEBACTERIUM DIPHTHERIAE C7 (ß197) M8 (CRM197) PROTEIN | 2件: Corynebacterium diphtheriae Corynebacterium diphtheriae, Corynebacterium diphtheriae CRM197 protein | - | - | - | 1件: 11 11 💬 |
1416 | MENINGOCOCCAL GROUP Y OLIGOSACCHARIDES CONJUGATED TO CORYNEBACTERIUM DIPHTHERIAE C7 (Â197) M8 (CRM197) PROTEIN | 2件: Corynebacterium diphtheriae Corynebacterium diphtheriae, Corynebacterium diphtheriae CRM197 protein | - | - | - | 1件: 11 11 💬 |
1417 | Meningococcal polysaccharide diphtheria conjugate vaccine (quadrivalent) | - | - | - | - | 1件: 13 13 💬 |
1418 | Mercaptopurine (Puri-Nethol) | 1件: Mercaptopurine Mercaptopurine | 2件: Mercaptopurine
Mercaptopurine
,
Mercaptopurine
💬 | 1件: HPRT1 HPRT1 💬 | 4件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬 | 1件: 97 97 💬 |
1419 | Mesalamine Delayed Release Tablets 400mg | 2件: Manganese citrate Manganese citrate, Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
1420 | Mesalamine Once-Daily | 1件: Mesalazine Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
1421 | Mesalamine Twice-Daily | 1件: Mesalazine Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
1422 | Mesalazine 250Mg Tablet and nitazoxanide 500Mg Oral Tablet | 2件: Mesalazine Mesalazine, Nitazoxanide | 2件: Mesalamine
Mesalamine
,
Nitazoxanide
💬 | - | - | 1件: 97 97 💬 |
1423 | Mesencephalic Neuronal Precursor Cells | - | - | - | - | 1件: 6 6 💬 |
1424 | Mesenchymal stem cells derived from bone marrow (BM-MSCs) | - | - | - | - | 1件: 36 36 💬 |
1425 | Metformin 500 Mg Oral Tablet, up to 4 tablets a day | 1件: Metformin Metformin | 1件: Metformin
Metformin
💬 | 2件: PRKAA1 PRKAA1, PRKAA2 💬 | 20件: AMPK signaling pathway AMPK signaling pathway, Adipocytokine signaling pathway, Alcoholic liver disease, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Hypertrophic cardiomyopathy, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease, Oxytocin signaling pathway, PI3K-Akt signaling pathway, Thermogenesis, Tight junction, mTOR signaling pathway 💬 | 1件: 13 13 💬 |
1426 | Methotrexate (stable dose) | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
1427 | Methotrexate (tapering dose) | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
1428 | METHOTREXATE - 20 MG/0.8 ML SOLUZIONE INIETTABILE 4 SIRINGHE PRERIEMPITE MONOUSO DA 1.25 ML | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 96 96 💬 |
1429 | Methotrexate - DAVA | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
1430 | Methotrexate - Delay | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
1431 | Methotrexate as methotrexate disodium | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
1432 | METHOTREXATE DISODIUM | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 5件: 46 46, 96, 97, 107, 271 💬 |
1433 | Methotrexate(MTX) administration is at the discretion of the rheumatologist and no tradename is fixed by the protocol | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
1434 | Methotrexate(MTX) administration is at the discretion of the rheumatologist and no tradename is fixed by the protocol. | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
1435 | Methotrexate(necessary) | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
1436 | Methyl 1-[N6-(3-iodobenzyl)-adenin-9-yl]-beta-Dribofuronamide | 1件: Adenine Adenine | 1件: Adenine
Adenine
💬 | - | - | 1件: 46 46 💬 |
1437 | Methyl 1-[N6-(3-iodobenzyl)-adenin-9-yl]-ß-Dribofuronamide | 1件: Adenine Adenine | 1件: Adenine
Adenine
💬 | - | - | 1件: 46 46 💬 |
1438 | Methyl 4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo | - | - | - | - | 1件: 86 86 💬 |
1439 | Methyl 4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo [3,4-b]pyridine-3-yl]-5-pyrimidinyl(methyl)carb | - | - | - | - | 2件: 86 86, 88 💬 |
1440 | Methyl [4,6-diamino-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl]meth | - | - | - | - | 2件: 86 86, 88 💬 |
1441 | Methylenetetrahydrofolate reductase (MTHFR) deficiency | - | - | - | - | 1件: 337 337 💬 |
1442 | Methylprednisolon-21-hydrogensuccinat, Natriumsalz | 1件: Methylprednisolone Methylprednisolone | 1件: Methylprednisolone
Methylprednisolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 13 13 💬 |
1443 | Methylprednisolone (drug) | 1件: Methylprednisolone Methylprednisolone | 1件: Methylprednisolone
Methylprednisolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 13 13 💬 |
1444 | Methylprednisolone 1250 mg/24h x3 days | 1件: Methylprednisolone Methylprednisolone | 1件: Methylprednisolone
Methylprednisolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 13 13 💬 |
1445 | Methylprednisolone bolus IV 15 mg/kg/d for 3 days. | 1件: Methylprednisolone Methylprednisolone | 1件: Methylprednisolone
Methylprednisolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 84 84 💬 |
1446 | METHYLPREDNISOLONE MYLAN Générique | 1件: Methylprednisolone Methylprednisolone | 1件: Methylprednisolone
Methylprednisolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 66 66 💬 |
1447 | Methylprednisoloni natrii succinas | - | - | - | - | 1件: 50 50 💬 |
1448 | Metoprolol succinate + doxazosin | 2件: Doxazosin Doxazosin, Metoprolol | 2件: Metoprolol
Metoprolol
,
Doxazosin
💬 | 4件: ADRA1A ADRA1A, ADRA1B, ADRA1D, ADRB1 💬 | 13件: AMPK signaling pathway AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 57 57 💬 |
1449 | Mid dose ANAVEX2-73 | - | - | - | - | 1件: 6 6 💬 |
1450 | Mild dose cannabis | 1件: Medical Cannabis Medical Cannabis | - | - | - | 1件: 13 13 💬 |
1451 | Minibody against CD8 conjugated to desferrioxamine labeled with zirconium Zr 89 | 1件: Deferoxamine Deferoxamine | 1件: Deferoxamine
Deferoxamine
💬 | - | - | 2件: 51 51, 53 💬 |
1452 | Mirdametinib (PD-0325901) oral capsule or dispersible tablet | 1件: Mirdametinib Mirdametinib | 1件: Mirdametinib
Mirdametinib
💬 | 2件: MAP2K1 MAP2K1, MAP2K2 💬 | 89件: Acute myeloid leukemia Acute myeloid leukemia, Alcoholism, Alzheimer disease, Apelin signaling pathway, Apoptosis, Autophagy - animal, B cell receptor signaling pathway, Bladder cancer, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, Colorectal cancer, Cushing syndrome, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Focal adhesion, FoxO signaling pathway, Gap junction, Gastric cancer, Glioma, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Influenza A, Insulin signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Long-term depression, Long-term potentiation, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-small cell lung cancer, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Serotonergic synapse, Signaling pathways regulating pluripotency of stem cells, Sphingolipid signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Thyroid cancer, Thyroid hormone signaling pathway, Toll-like receptor signaling pathway, VEGF signaling pathway, Vascular smooth muscle contraction, Yersinia infection, cAMP signaling pathway, cGMP-PKG signaling pathway, mTOR signaling pathway 💬 | 1件: 34 34 💬 |
1453 | MK0812 / Duration of Treatment: 12 Weeks | - | - | - | - | 1件: 46 46 💬 |
1454 | MMF and Dexamethasone | 1件: Dexamethasone Dexamethasone | 1件: Dexamethasone
Dexamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 222 222 💬 |
1455 | MMX Mesalamine/Mesalazine (High Dose) | 1件: Mesalazine Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
1456 | MMX Mesalamine/Mesalazine (Low Dose) | 1件: Mesalazine Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
1457 | MN-08 24 mg/day | - | - | - | - | 1件: 86 86 💬 |
1458 | MN-08 60 mg/day | - | - | - | - | 1件: 86 86 💬 |
1459 | Moderate doses of Thiamine y Biotin | 2件: Biotin Biotin, Thiamine | 2件: Biotin
Biotin
,
Thiamine
💬 | - | - | 1件: 8 8 💬 |
1460 | Modified Atkins diet | - | - | - | - | 3件: 145 145, 157, 187 💬 |
1461 | Modified Gegen Qinlian Decoction | - | - | - | - | 1件: 97 97 💬 |
1462 | Modified recombinant human C-type natriuretic peptide | - | - | - | - | 1件: 276 276 💬 |
1463 | MODULEN IBD (R) (specific Enteral Nutrition) | - | - | - | - | 1件: 96 96 💬 |
1464 | Molgramostim 300 mcg nebuliser solution | 1件: Molgramostim Molgramostim | 1件: Molgramostim
Molgramostim
💬 | 1件: CSF2RA CSF2RA 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬 | 1件: 229 229 💬 |
1465 | Molgramostim 300 µg nebulizer solution | 1件: Molgramostim Molgramostim | 1件: Molgramostim
Molgramostim
💬 | 1件: CSF2RA CSF2RA 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬 | 1件: 229 229 💬 |
1466 | Molgramostim Nebuliser solution 300 mcg | 1件: Molgramostim Molgramostim | 1件: Molgramostim
Molgramostim
💬 | 1件: CSF2RA CSF2RA 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬 | 1件: 229 229 💬 |
1467 | Molgramostim nebulizer solution | 1件: Molgramostim Molgramostim | 1件: Molgramostim
Molgramostim
💬 | 1件: CSF2RA CSF2RA 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬 | 1件: 299 299 💬 |
1468 | Moli 1901 (2622U90, duramycin) | 1件: Lancovutide Lancovutide | - | - | - | 1件: 299 299 💬 |
1469 | Moli1901 (2622U90, duramycin) | 1件: Lancovutide Lancovutide | - | - | - | 1件: 299 299 💬 |
1470 | Mono Nuclear Cell (MNC) transplantation | - | - | - | - | 1件: 57 57 💬 |
1471 | Monovalent [B.1.351] CoV2 preS dTM-AS03 | - | - | - | - | 7件: 13 13, 35, 46, 49, 50, 51, 107 💬 |
1472 | Montelukast, Flurbiprofen, Midazolam, Digoxin, Pravastatin and BMS-986142 | 6件: BMS-986142 BMS-986142, Digoxin, Flurbiprofen, Midazolam, Montelukast, Pravastatin | 5件: Digoxin
Digoxin
,
Flurbiprofen
,
Midazolam
,
Montelukast
,
Pravastatin
💬 | 24件: ATP1A1 ATP1A1, ATP1A2, ATP1A3, ATP1A4, CYSLTR1, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, HMGCR, PTGS1, PTGS2 💬 | 49件: AMPK signaling pathway AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Aldosterone-regulated sodium reabsorption, Alzheimer disease, Arachidonic acid metabolism, Bile secretion, C-type lectin receptor signaling pathway, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Chemical carcinogenesis - DNA adducts, Endocrine and other factor-regulated calcium reabsorption, GABAergic synapse, Gastric acid secretion, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Insulin secretion, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, Mineral absorption, Morphine addiction, NF-kappa B signaling pathway, Neuroactive ligand-receptor interaction, Nicotine addiction, Ovarian steroidogenesis, Oxytocin signaling pathway, Pancreatic secretion, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Protein digestion and absorption, Proximal tubule bicarbonate reclamation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Salivary secretion, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, Taste transduction, Terpenoid backbone biosynthesis, Thyroid hormone signaling pathway, Thyroid hormone synthesis, VEGF signaling pathway, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 46 46 💬 |
1473 | MP-435(dose1) + Methotrexate | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
1474 | MRNA che codifica l’enzima umano deramificante del glicogeno formulato in una nanopaticella lipidica | - | - | - | - | 1件: 257 257 💬 |
1475 | MRNA encoding the human glycogen debranching enzyme | - | - | - | - | 1件: 257 257 💬 |
1476 | MRNA encoding the human glycogen debranching enzyme formulated in a lipid nanoparticle delivery | - | - | - | - | 1件: 257 257 💬 |
1477 | MRX Drug Substance (formerly Maralixibat , SHP625 or LUM001) | 1件: Maralixibat Maralixibat | 1件: Maralixibat
Maralixibat
💬 | 2件: SLC10A1 SLC10A1, SLC10A2 💬 | 2件: Bile secretion Bile secretion, Hepatitis B 💬 | 1件: 338 338 💬 |
1478 | MRX Drug Substance (formerly Maralixibat, SHP625 or LUM001) | 1件: Maralixibat Maralixibat | 1件: Maralixibat
Maralixibat
💬 | 2件: SLC10A1 SLC10A1, SLC10A2 💬 | 2件: Bile secretion Bile secretion, Hepatitis B 💬 | 1件: 338 338 💬 |
1479 | MSC-NTF cells transplantation (IM) | - | - | - | - | 1件: 2 2 💬 |
1480 | MSC-NTF cells transplantation (IT) | - | - | - | - | 1件: 2 2 💬 |
1481 | MSK-DA01 | - | - | - | - | 1件: 6 6 💬 |
1482 | MT-1303 High dose | - | - | - | - | 1件: 49 49 💬 |
1483 | MT-1303 Low dose | - | - | - | - | 1件: 49 49 💬 |
1484 | MT-7117 High Dose | - | - | - | - | 1件: 254 254 💬 |
1485 | MT-7117 Low Dose | - | - | - | - | 1件: 254 254 💬 |
1486 | Multimodal Bundle Drugs | - | - | - | - | 1件: 226 226 💬 |
1487 | Multiple (4 autologous subcutaneous T cell vaccinations with T cell lines reactive to nine myelin peptides) | 1件: Myelin basic protein Myelin basic protein | - | - | - | 1件: 13 13 💬 |
1488 | Multiple Dose | - | - | - | - | 1件: 2 2 💬 |
1489 | Multiple dose- Group B | - | - | - | - | 1件: 97 97 💬 |
1490 | Multiple dose-Group B | - | - | - | - | 1件: 97 97 💬 |
1491 | MultiStem high dose | 1件: MultiStem MultiStem | - | - | - | 1件: 97 97 💬 |
1492 | MultiStem low dose | 1件: MultiStem MultiStem | - | - | - | 1件: 97 97 💬 |
1493 | Mycophenolat-Natrium | - | - | - | - | 1件: 66 66 💬 |
1494 | Mycophenolate Mofetil (MMF) 3 g/Day | 2件: Mycophenolate mofetil Mycophenolate mofetil, Mycophenolic acid | 2件: Mycophenolate mofetil
Mycophenolate mofetil
,
Mycophenolic acid
💬 | 2件: IMPDH1 IMPDH1, IMPDH2 💬 | 4件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬 | 1件: 35 35 💬 |
1495 | Mycophenolate Mofetil 2 g/Day | 2件: Mycophenolate mofetil Mycophenolate mofetil, Mycophenolic acid | 2件: Mycophenolate mofetil
Mycophenolate mofetil
,
Mycophenolic acid
💬 | 2件: IMPDH1 IMPDH1, IMPDH2 💬 | 4件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬 | 1件: 35 35 💬 |
1496 | Mycophenolate mofetil 2000mg/d | 2件: Mycophenolate mofetil Mycophenolate mofetil, Mycophenolic acid | 2件: Mycophenolate mofetil
Mycophenolate mofetil
,
Mycophenolic acid
💬 | 2件: IMPDH1 IMPDH1, IMPDH2 💬 | 4件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬 | 1件: 53 53 💬 |
1497 | Mycophenolate mofetil orally 1000 mg twice a day (BID) | 2件: Mycophenolate mofetil Mycophenolate mofetil, Mycophenolic acid | 2件: Mycophenolate mofetil
Mycophenolate mofetil
,
Mycophenolic acid
💬 | 2件: IMPDH1 IMPDH1, IMPDH2 💬 | 4件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬 | 1件: 222 222 💬 |
1498 | Mycophenolate mofetil plus lower dose of Prednisone | 3件: Mycophenolate mofetil Mycophenolate mofetil, Mycophenolic acid, Prednisone | 3件: Prednisone
Prednisone
,
Mycophenolate mofetil
,
Mycophenolic acid
💬 | 3件: IMPDH1 IMPDH1, IMPDH2, NR3C1 💬 | 5件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Neuroactive ligand-receptor interaction, Nucleotide metabolism, Purine metabolism 💬 | 1件: 66 66 💬 |
1499 | Mycophenolate mofetil, low dose steroid | 2件: Mycophenolate mofetil Mycophenolate mofetil, Mycophenolic acid | 2件: Mycophenolate mofetil
Mycophenolate mofetil
,
Mycophenolic acid
💬 | 2件: IMPDH1 IMPDH1, IMPDH2 💬 | 4件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬 | 1件: 222 222 💬 |
1500 | Mycophénolate mofétil | - | - | - | - | 1件: 44 44 💬 |
1501 | Myfortic plus low-dose steroid | 1件: Mycophenolic acid Mycophenolic acid | 1件: Mycophenolic acid
Mycophenolic acid
💬 | 2件: IMPDH1 IMPDH1, IMPDH2 💬 | 4件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬 | 1件: 222 222 💬 |
1502 | N,N,N',N'-tetramethyl-10H-phenothiazine-3,7-diaminium bis(methanesulfonate) | 1件: Phenothiazine Phenothiazine | 1件: Phenothiazine
Phenothiazine
💬 | - | - | 1件: 127 127 💬 |
1503 | N,N,N?,N?-tetramethyl-10H-phenothiazine-3,7-diaminium bis(methanesulfonate) | 1件: Phenothiazine Phenothiazine | 1件: Phenothiazine
Phenothiazine
💬 | - | - | 1件: 127 127 💬 |
1504 | N,N,N’,N’-tetramethyl-10H-phenothiazine-3,7-diaminium bis(methanesulfonate) | 1件: Phenothiazine Phenothiazine | 1件: Phenothiazine
Phenothiazine
💬 | - | - | 1件: 127 127 💬 |
1505 | N-(5-hydroxy-2,4- bis(trimethylsilyl)phenyl)-4-oxo- 1,4-dihydroquinoline-3-carboxamide | - | - | - | - | 1件: 299 299 💬 |
1506 | N-(5-hydroxy-2,4-bis(trimethylsilyl)phenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide | - | - | - | - | 1件: 299 299 💬 |
1507 | N-(5-{4-[(3,3-dimethyl-1-azetidinyl)carbonyl]phenyl}[1,2,4]triazolo[1,5-a]pyridin-2-yl)cyclopropanecarboxamide | - | - | - | - | 1件: 49 49 💬 |
1508 | N-Acetyl Cysteine (NAC) | 1件: Cysteine Cysteine | - | - | - | 1件: 90 90 💬 |
1509 | N-acetylcysteine (NAC) | 1件: Acetylcysteine Acetylcysteine | 1件: Acetylcysteine
Acetylcysteine
💬 | - | - | 2件: 51 51, 299 💬 |
1510 | N-Acetylcysteine, (NAC) | 1件: Acetylcysteine Acetylcysteine | 1件: Acetylcysteine
Acetylcysteine
💬 | - | - | 1件: 85 85 💬 |
1511 | N-methyl D-(2,3,4,5,6-pentahydroxy-hexyl)-ammonium | - | - | - | - | 1件: 28 28 💬 |
1512 | N-{4-Chloro-2-[(1-oxido-4-pyridinyl)carbonyl]phenyl}-4-(1,1-dimethylethyl)benzenesulfonamide, sodium | - | - | - | - | 1件: 96 96 💬 |
1513 | N-{4-Chloro-2-[(1-oxido-4-pyridinyl)carbonyl]phenyl}-4-(1,1-dimethylethyl)benzenesulfonamidesodium | - | - | - | - | 1件: 96 96 💬 |
1514 | N. MENINGITIDIS GROUP C (STRAIN C11) OLIGOSACCHARIDE CONJUGATED TO CORYNEBACTERIUM DIPHTHERIAE CRM197 ADSORBED ON ALUMINUM HYDROXIDE | 5件: Aluminium Aluminium, Aluminum hydroxide, Corynebacterium diphtheriae, Corynebacterium diphtheriae CRM197 protein, Hydroxide ion | 1件: Aluminum hydroxide
Aluminum hydroxide
💬 | - | - | 1件: 11 11 💬 |
1515 | N.d. | - | - | - | - | 1件: 97 97 💬 |
1516 | N1,N3-BIS(2-MERCAPTOETHYL) ISOPHTHALAMIDE | - | - | - | - | 2件: 5 5, 17 💬 |
1517 | Nab-sirolimus (also known as ABI-009, nab-rapamycin, albumin-bound rapamycin) | 1件: Sirolimus Sirolimus | 1件: Sirolimus
Sirolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 86 86 💬 |
1518 | NALOXONE HYDROCHLORIDE DIHYDRATE | 1件: Naloxone Naloxone | 1件: Naloxone
Naloxone
💬 | 3件: OPRD1 OPRD1, OPRK1, OPRM1 💬 | 5件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 6 6 💬 |
1519 | NAND (Neoandrographolide) | - | - | - | - | 1件: 97 97 💬 |
1520 | Nandrolone Decanoate | 2件: Nandrolone Nandrolone, Nandrolone decanoate | 2件: Nandrolone decanoate
Nandrolone decanoate
,
Nandrolone
💬 | 1件: AR AR 💬 | 4件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Oocyte meiosis, Pathways in cancer, Prostate cancer 💬 | 2件: 60 60, 85 💬 |
1521 | Nanobody directed towards the human A1 domain of von Willebrand factor | 1件: Von Willebrand factor human Von Willebrand factor human | - | - | - | 1件: 64 64 💬 |
1522 | Nanobubble drink | - | - | - | - | 1件: 46 46 💬 |
1523 | Naproxen (EC-Narosyn) Delayed Release Tables, 375 (Syntex (USA), Inc.) | 1件: Naproxen Naproxen | 1件: Naproxen
Naproxen
💬 | 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 46 46 💬 |
1524 | Naproxen Delayed Release Tables, 375 (Gevena Pharmaceuticals, Inc.) | 1件: Naproxen Naproxen | 1件: Naproxen
Naproxen
💬 | 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 46 46 💬 |
1525 | Natalizumab (NTZ) | 1件: Natalizumab Natalizumab | 1件: Natalizumab
Natalizumab
💬 | 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 💬 |
1526 | National Drug Code: 59762-0074 | - | - | - | - | 1件: 81 81 💬 |
1527 | NATPARA/NATPAR | 1件: Parathyroid hormone Parathyroid hormone | 1件: Parathyroid hormone
Parathyroid hormone
💬 | 2件: PTH1R PTH1R, PTH2R 💬 | 3件: Endocrine and other factor-regulated calcium reabsorption Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬 | 1件: 235 235 💬 |
1528 | NBT-NM108 | - | - | - | - | 1件: 193 193 💬 |
1529 | NBT-NM108 (60 g/day) | - | - | - | - | 1件: 13 13 💬 |
1530 | Nebulization of Amikacin during NIV (RR: 15 cycles/minute) | 1件: Amikacin Amikacin | 1件: Amikacin
Amikacin
💬 | - | - | 1件: 299 299 💬 |
1531 | Nebulization of Amikacin during NIV (RR: 25 cycles/minute) | 1件: Amikacin Amikacin | 1件: Amikacin
Amikacin
💬 | - | - | 1件: 299 299 💬 |
1532 | NeuroVax 300ug/mL Dose for IM Injection | 1件: NeuroVax NeuroVax | - | - | - | 1件: 13 13 💬 |
1533 | Ng-monomethyl-L-arginine (drug) | 3件: Arginine Arginine, L-arginine, Tilarginine | 1件: Arginine
Arginine
💬 | - | - | 1件: 67 67 💬 |
1534 | Nicotine dependence | 1件: Nicotine Nicotine | 1件: Nicotine
Nicotine
💬 | 16件: CHRNA1 CHRNA1, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB1, CHRNB2, CHRNB3, CHRNB4, CHRND, CHRNE, CHRNG 💬 | 8件: Alzheimer disease Alzheimer disease, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Virion - Lyssavirus 💬 | 1件: 13 13 💬 |
1535 | Nicotine Nasal Spray 10 MG/ML (0.5 MG/SPRAY) | 1件: Nicotine Nicotine | 1件: Nicotine
Nicotine
💬 | 16件: CHRNA1 CHRNA1, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB1, CHRNB2, CHRNB3, CHRNB4, CHRND, CHRNE, CHRNG 💬 | 8件: Alzheimer disease Alzheimer disease, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Virion - Lyssavirus 💬 | 1件: 6 6 💬 |
1536 | Nifurtimox 15/20 mg/kg/d 10d + eflornithine 400 mg/kg/d 7d | 2件: Eflornithine Eflornithine, Nifurtimox | 2件: Nifurtimox
Nifurtimox
,
Eflornithine
💬 | 1件: ODC1 ODC1 💬 | 3件: Arginine and proline metabolism Arginine and proline metabolism, Glutathione metabolism, Metabolic pathways 💬 | 1件: 65 65 💬 |
1537 | Nifurtimox-Eflronithine Combination Treatment (NECT) | 1件: Nifurtimox Nifurtimox | 1件: Nifurtimox
Nifurtimox
💬 | - | - | 1件: 65 65 💬 |
1538 | Nintédanib | - | - | - | - | 1件: 227 227 💬 |
1539 | Nitrate-depleted beetroot juice | 1件: Nitrate Nitrate | 1件: Nitric acid
Nitric acid
💬 | - | - | 1件: 67 67 💬 |
1540 | Nitric Oxide generated by the GeNO nitrosyl delivery system | 1件: Nitric Oxide Nitric Oxide | 1件: Nitric oxide
Nitric oxide
💬 | - | - | 1件: 86 86 💬 |
1541 | Nle4,D-Phe7]-a-melanocyte stimulating hormone or NDP-a-MSH | - | - | - | - | 1件: 254 254 💬 |
1542 | Nle4-D-Phe7-alpha-MSH | - | - | - | - | 1件: 254 254 💬 |
1543 | NNC0195-0092 DP 6.7 mg ml 3 ml cartridge | - | - | - | - | 1件: 78 78 💬 |
1544 | Non disponibile | - | - | - | - | 1件: 201 201 💬 |
1545 | Non invasive prenatal diagnosis | - | - | - | - | 3件: 8 8, 113, 206 💬 |
1546 | NON PROPIETRY, THEREFORE N/A | - | - | - | - | 1件: 51 51 💬 |
1547 | Non-biologic anti-rheumatic drugs | - | - | - | - | 1件: 46 46 💬 |
1548 | Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD) | - | - | - | - | 1件: 46 46 💬 |
1549 | Non-Biologic DMARDs | - | - | - | - | 3件: 46 46, 86, 107 💬 |
1550 | Non-biological DMARDs | - | - | - | - | 1件: 46 46 💬 |
1551 | Non-nucleoside reverse transcriptase inhibitors | - | - | - | - | 1件: 265 265 💬 |
1552 | Non-steroidal anti-inflammatory drug | - | - | - | - | 1件: 46 46 💬 |
1553 | Non-steroidal anti-inflammatory drug (NSAID) | - | - | - | - | 1件: 46 46 💬 |
1554 | Non-steroidal anti-inflammatory drugs | - | - | - | - | 1件: 46 46 💬 |
1555 | Non-steroidal anti-inflammatory drugs (NSAIDs) | - | - | - | - | 1件: 107 107 💬 |
1556 | Nonbiologic DMARDs of investigator's choice | - | - | - | - | 1件: 46 46 💬 |
1557 | Norditropin NordiFlex® | - | - | - | - | 1件: 78 78 💬 |
1558 | Norditropin NordiFlex® 10 mg/1.5 ml | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
1559 | Norditropin NordiFlex® 10mg/1.5 ml | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
1560 | Norovirus -specific T-cell (NST) therapy | - | - | - | - | 1件: 65 65 💬 |
1561 | Norucholic acid (NCA) 500 mg | 1件: norUrsodeoxycholic acid norUrsodeoxycholic acid | - | - | - | 1件: 93 93 💬 |
1562 | NorUDCA (Norursodeoxycholic acid) | 1件: norUrsodeoxycholic acid norUrsodeoxycholic acid | - | - | - | 1件: 94 94 💬 |
1563 | Norursodeoxycholic acid, NCA | 1件: norUrsodeoxycholic acid norUrsodeoxycholic acid | - | - | - | 1件: 94 94 💬 |
1564 | Novo Rapid Insulin (Novonordisk) | - | - | - | - | 1件: 299 299 💬 |
1565 | NovoRapid 100 U/ml, solution for injection in a vial. NovoRapid Penfill 100 U/ml, solution for injection in a cartridge. NovoRapid FlexPen 100 U/ml, solution for injection in a pre-filled pen. | - | - | - | - | 1件: 299 299 💬 |
1566 | NPLATE 500 microgramos polvo para solución inyectable | 1件: Romiplostim Romiplostim | 1件: Romiplostim
Romiplostim
💬 | 1件: MPL MPL 💬 | 2件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway 💬 | 1件: 63 63 💬 |
1567 | NR2B NMDA Antagonist CP-101,606 (traxoprodil) | 1件: Ketamine Ketamine | 1件: Ketamine
Ketamine
💬 | 5件: GRIN1 GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬 | 20件: Alcoholism Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1568 | NS-065/NCNP-01 | - | - | - | - | 1件: 113 113 💬 |
1569 | NS-089/NCNP-02 | - | - | - | - | 1件: 113 113 💬 |
1570 | NSAIDs (permitted,not necessary) | - | - | - | - | 1件: 46 46 💬 |
1571 | NurOwn (MSC-NTF cells) | - | - | - | - | 2件: 2 2, 13 💬 |
1572 | NurOwn® (MSC-NTF cells) | - | - | - | - | 1件: 2 2 💬 |
1573 | Nutritional dietary intervention | - | - | - | - | 2件: 96 96, 97 💬 |
1574 | Nutropin AQ [somatropin (DNA origin) injection] | 1件: Somatotropin Somatotropin | - | - | - | 1件: 299 299 💬 |
1575 | NUTROPINAq 10 mg/2 ml (30 UI), solución inyectable | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
1576 | OC oral solution treatment D | - | - | - | - | 1件: 6 6 💬 |
1577 | OCH-NCNP1 | - | - | - | - | 1件: 13 13 💬 |
1578 | Ocrelizumab Dose 1 | 1件: Ocrelizumab Ocrelizumab | 1件: Ocrelizumab
Ocrelizumab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬 |
1579 | Ocrelizumab Dose 2 and Dose 3 | 1件: Ocrelizumab Ocrelizumab | 1件: Ocrelizumab
Ocrelizumab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬 |
1580 | Ocrevus 300 mg, solution à diluer pour perfusion | 1件: Ocrelizumab Ocrelizumab | 1件: Ocrelizumab
Ocrelizumab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬 |
1581 | OCU400 High Dose | - | - | - | - | 1件: 90 90 💬 |
1582 | OCU400 Low Dose | - | - | - | - | 1件: 90 90 💬 |
1583 | OCU400 Mid Dose | - | - | - | - | 1件: 90 90 💬 |
1584 | Oleovit D3 14.400 IU/ml oral drops, solution | - | - | - | - | 1件: 13 13 💬 |
1585 | OligoG DPI | - | - | - | - | 1件: 299 299 💬 |
1586 | Oligomero morfolino fosforodiamidato per skipping dell’esone 45 | - | - | - | - | 1件: 113 113 💬 |
1587 | Oligomero morfolino fosforodiamidato per skipping dell’esone 53 | - | - | - | - | 1件: 113 113 💬 |
1588 | Omadacycline Injection [Nuzyra] | 1件: Omadacycline Omadacycline | 1件: Omadacycline
Omadacycline
💬 | - | - | 1件: 299 299 💬 |
1589 | Omadacycline Oral Tablet [Nuzyra] | 1件: Omadacycline Omadacycline | 1件: Omadacycline
Omadacycline
💬 | - | - | 1件: 299 299 💬 |
1590 | OMNIPAQUE - 300 MG I/ML SOLUZIONE INIETTABILE FLACONE IN POLIPROPILENE DA 50 ML | 1件: Iohexol Iohexol | 1件: Iohexol
Iohexol
💬 | - | - | 1件: 222 222 💬 |
1591 | OMS721 (narsoplimab) | 1件: Narsoplimab Narsoplimab | 1件: Narsoplimab
Narsoplimab
💬 | 1件: MASP2 MASP2 💬 | 3件: Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, Staphylococcus aureus infection 💬 | 2件: 66 66, 222 💬 |
1592 | OMS721 Drug Product 185 mg/mL | - | - | - | - | 1件: 109 109 💬 |
1593 | ON 01910.NA | - | - | - | - | 1件: 36 36 💬 |
1594 | Once a day Trientine | 1件: Triethylenetetramine Triethylenetetramine | - | - | - | 1件: 171 171 💬 |
1595 | Once daily subcutaneous injection of Genotropin | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
1596 | Once-daily insulin detemir | 1件: Insulin detemir Insulin detemir | 1件: Insulin detemir
Insulin detemir
💬 | 1件: INSR INSR 💬 | 22件: AMPK signaling pathway AMPK signaling pathway, Adherens junction, Aldosterone-regulated sodium reabsorption, Alzheimer disease, Diabetic cardiomyopathy, FoxO signaling pathway, HIF-1 signaling pathway, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, MAPK signaling pathway, Non-alcoholic fatty liver disease, Ovarian steroidogenesis, PI3K-Akt signaling pathway, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway, Regulation of lipolysis in adipocytes, Type II diabetes mellitus, cGMP-PKG signaling pathway, mTOR signaling pathway 💬 | 1件: 299 299 💬 |
1597 | Ondansetron hydrochloride dihydrate | 1件: Ondansetron Ondansetron | 1件: Ondansetron
Ondansetron
💬 | 5件: HTR3A HTR3A, HTR3B, HTR3C, HTR3D, HTR3E 💬 | 2件: Serotonergic synapse Serotonergic synapse, Taste transduction 💬 | 2件: 6 6, 97 💬 |
1598 | One additional blood sample during a planned blood test | - | - | - | - | 1件: 266 266 💬 |
1599 | One Alpha Drops | - | - | - | - | 2件: 50 50, 107 💬 |
1600 | One-Alpha drops | 1件: Alfacalcidol Alfacalcidol | 1件: Alfacalcidol
Alfacalcidol
💬 | 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 2件: 50 50, 107 💬 |
1601 | OPC-6535 Tablets (drug) | - | - | - | - | 1件: 97 97 💬 |
1602 | Open label Namilumab | 1件: Namilumab Namilumab | - | - | - | 1件: 84 84 💬 |
1603 | Optimal drug therapy | - | - | - | - | 1件: 6 6 💬 |
1604 | Oral drops solution | - | - | - | - | 1件: 28 28 💬 |
1605 | Oral Methylprednisolone 625 mg/24h x3 days | 1件: Methylprednisolone Methylprednisolone | 1件: Methylprednisolone
Methylprednisolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 13 13 💬 |
1606 | Oral nutritional supplementation | - | - | - | - | 1件: 2 2 💬 |
1607 | Orally disintegrating selegiline (Zelapar) | 1件: Selegiline Selegiline | 1件: Selegiline
Selegiline
💬 | 1件: MAOB MAOB 💬 | 14件: Alcoholism Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 1件: 6 6 💬 |
1608 | Orelabrutinib (High Dose) | 1件: Orelabrutinib Orelabrutinib | 1件: Orelabrutinib
Orelabrutinib
💬 | 1件: BTK BTK 💬 | 7件: B cell receptor signaling pathway B cell receptor signaling pathway, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Platelet activation, Primary immunodeficiency 💬 | 1件: 49 49 💬 |
1609 | Orelabrutinib (Low Dose) | 1件: Orelabrutinib Orelabrutinib | 1件: Orelabrutinib
Orelabrutinib
💬 | 1件: BTK BTK 💬 | 7件: B cell receptor signaling pathway B cell receptor signaling pathway, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Platelet activation, Primary immunodeficiency 💬 | 1件: 49 49 💬 |
1610 | Orelabrutinib( higher dose) | 1件: Orelabrutinib Orelabrutinib | 1件: Orelabrutinib
Orelabrutinib
💬 | 1件: BTK BTK 💬 | 7件: B cell receptor signaling pathway B cell receptor signaling pathway, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Platelet activation, Primary immunodeficiency 💬 | 1件: 63 63 💬 |
1611 | Orelabrutinib( lower dose) | 1件: Orelabrutinib Orelabrutinib | 1件: Orelabrutinib
Orelabrutinib
💬 | 1件: BTK BTK 💬 | 7件: B cell receptor signaling pathway B cell receptor signaling pathway, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Platelet activation, Primary immunodeficiency 💬 | 1件: 63 63 💬 |
1612 | Orencia (trade name) | 1件: Abatacept Abatacept | 1件: Abatacept
Abatacept
💬 | 2件: CD80 CD80, CD86 💬 | 13件: Allograft rejection Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Virion - Adenovirus 💬 | 1件: 50 50 💬 |
1613 | ORENCIA 250 mg polvo para concentrado para sol. para perfusión | 1件: Abatacept Abatacept | 1件: Abatacept
Abatacept
💬 | 2件: CD80 CD80, CD86 💬 | 13件: Allograft rejection Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Virion - Adenovirus 💬 | 1件: 46 46 💬 |
1614 | Originator (legacy) drug | - | - | - | - | 4件: 46 46, 96, 97, 271 💬 |
1615 | ORMONE PARATIROIDEO DA DNA RICOMBINANTE | - | - | - | - | 1件: 235 235 💬 |
1616 | Ortho-cyclen, Ethinyl estradiol/norgestimate, 0.035 mg/0.250 mg | 3件: Estradiol Estradiol, Ethinylestradiol, Norgestimate | 3件: Estradiol
Estradiol
,
Ethinyl estradiol
,
Norgestimate
💬 | 3件: ESR1 ESR1, ESR2, PGR 💬 | 12件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Oocyte meiosis, Pathways in cancer, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬 | 1件: 299 299 💬 |
1617 | Ortho-novum | 1件: Mestranol Mestranol | 1件: Mestranol
Mestranol
💬 | 2件: ESR1 ESR1, ESR2 💬 | 10件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬 | 2件: 46 46, 49 💬 |
1618 | Ortho-Novum 777 | 1件: Mestranol Mestranol | 1件: Mestranol
Mestranol
💬 | 2件: ESR1 ESR1, ESR2 💬 | 10件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬 | 1件: 49 49 💬 |
1619 | Ortho-Novum® 1/35 | 1件: Mestranol Mestranol | 1件: Mestranol
Mestranol
💬 | 2件: ESR1 ESR1, ESR2 💬 | 10件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬 | 1件: 46 46 💬 |
1620 | OSSIDO DI AZOTO | - | - | - | - | 1件: 294 294 💬 |
1621 | Ossido Nitrico | - | - | - | - | 1件: 86 86 💬 |
1622 | OTEZLA - 10 MG + 20 MG + 30 MG COMPRESSA RIVESTITA CON FILM USO ORALE - BLISTER (PVC/ALU) IN UN ASTUCCIO - 4 COMPRESSE DA 10 MG + 4 COMPRESSE DA 20 MG +19 COMPRESSE DA 30 MG | 1件: Apremilast Apremilast | 1件: Apremilast
Apremilast
💬 | 4件: PDE4A PDE4A, PDE4B, PDE4C, PDE4D 💬 | 5件: Metabolic pathways Metabolic pathways, Morphine addiction, Parathyroid hormone synthesis, secretion and action, Purine metabolism, cAMP signaling pathway 💬 | 2件: 56 56, 107 💬 |
1623 | Other disease-modifying therapy | - | - | - | - | 1件: 13 13 💬 |
1624 | OTHER NERVOUS SYSTEM DRUGS | - | - | - | - | 2件: 6 6, 13 💬 |
1625 | Other Non Steroidal Anti-Inflammatory Drugs (NSAIDs) except etodolac | 1件: Etodolac Etodolac | 1件: Etodolac
Etodolac
💬 | 1件: PTGS2 PTGS2 💬 | 22件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 46 46 💬 |
1626 | Other Non-selective NSAIDs | - | - | - | - | 1件: 271 271 💬 |
1627 | Other non-sponsor pancreatic enzyme replacement therapy | - | - | - | - | 1件: 299 299 💬 |
1628 | Other Parkinson's Disease treatments | - | - | - | - | 1件: 6 6 💬 |
1629 | OTL-103 Dispersion for Infusion | - | - | - | - | 1件: 65 65 💬 |
1630 | OTL-200 Dispersion for Infusion | - | - | - | - | 1件: 19 19 💬 |
1631 | Outer membrane vesicles (OMV) from Neisseria meningitidis group B strain NZ98/254measured as amount of total protein containing the PorA P1.4 | - | - | - | - | 1件: 11 11 💬 |
1632 | Over the counter DHA/EPA dietary supplementation | - | - | - | - | 1件: 301 301 💬 |
1633 | OXICODONE DC.IT | - | - | - | - | 1件: 46 46 💬 |
1634 | Oxybutynin and darifenacin | 2件: Darifenacin Darifenacin, Oxybutynin | 2件: Oxybutynin
Oxybutynin
,
Darifenacin
💬 | 5件: CHRM1 CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 💬 | 13件: Alzheimer disease Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1635 | Oxycodone Depot ”Sandoz”, depot tablets | 1件: Oxycodone Oxycodone | 1件: Oxycodone
Oxycodone
💬 | 3件: OPRD1 OPRD1, OPRK1, OPRM1 💬 | 5件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 298 298 💬 |
1636 | Oxycodone naloxone prolonged release tablets | 2件: Naloxone Naloxone, Oxycodone | 2件: Oxycodone
Oxycodone
,
Naloxone
💬 | 3件: OPRD1 OPRD1, OPRK1, OPRM1 💬 | 5件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 226 226 💬 |
1637 | Oxycodone/naloxone prolonged release t | 3件: Manganese citrate Manganese citrate, Naloxone, Oxycodone | 2件: Oxycodone
Oxycodone
,
Naloxone
💬 | 3件: OPRD1 OPRD1, OPRK1, OPRM1 💬 | 5件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 226 226 💬 |
1638 | Oxycodone/Naloxone Prolonged Release tablets | 2件: Naloxone Naloxone, Oxycodone | 2件: Oxycodone
Oxycodone
,
Naloxone
💬 | 3件: OPRD1 OPRD1, OPRK1, OPRM1 💬 | 5件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 6 6 💬 |
1639 | Oxycodone/naloxone prolonged release tablets 10 mg /5 mg | 3件: Manganese citrate Manganese citrate, Naloxone, Oxycodone | 2件: Oxycodone
Oxycodone
,
Naloxone
💬 | 3件: OPRD1 OPRD1, OPRK1, OPRM1 💬 | 5件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 6 6 💬 |
1640 | Oxycodone/naloxone prolonged release tablets 10/5 mg | 3件: Manganese citrate Manganese citrate, Naloxone, Oxycodone | 2件: Oxycodone
Oxycodone
,
Naloxone
💬 | 3件: OPRD1 OPRD1, OPRK1, OPRM1 💬 | 5件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 226 226 💬 |
1641 | Oxycodone/naloxone prolonged release tablets 20 mg /10 mg | 3件: Manganese citrate Manganese citrate, Naloxone, Oxycodone | 2件: Oxycodone
Oxycodone
,
Naloxone
💬 | 3件: OPRD1 OPRD1, OPRK1, OPRM1 💬 | 5件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 6 6 💬 |
1642 | Oxycodone/naloxone prolonged release tablets 20/10 mg | 3件: Manganese citrate Manganese citrate, Naloxone, Oxycodone | 2件: Oxycodone
Oxycodone
,
Naloxone
💬 | 3件: OPRD1 OPRD1, OPRK1, OPRM1 💬 | 5件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 226 226 💬 |
1643 | Oxycodone/naloxone prolonged release tablets 5 mg /2.5 mg | 3件: Manganese citrate Manganese citrate, Naloxone, Oxycodone | 2件: Oxycodone
Oxycodone
,
Naloxone
💬 | 3件: OPRD1 OPRD1, OPRK1, OPRM1 💬 | 5件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 6 6 💬 |
1644 | Oxycodone/naloxone prolonged release tablets 5/2.5 mg | 3件: Manganese citrate Manganese citrate, Naloxone, Oxycodone | 2件: Oxycodone
Oxycodone
,
Naloxone
💬 | 3件: OPRD1 OPRD1, OPRK1, OPRM1 💬 | 5件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 226 226 💬 |
1645 | Oxycodonhydrochlorid ”Lannacher”, depot tablets | - | - | - | - | 1件: 298 298 💬 |
1646 | Oxytocin nasal spray | 1件: Oxytocin Oxytocin | 1件: Oxytocin
Oxytocin
💬 | 1件: OXTR OXTR 💬 | 4件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Oxytocin signaling pathway, cAMP signaling pathway 💬 | 2件: 72 72, 193 💬 |
1647 | P-188 NF | - | - | - | - | 1件: 113 113 💬 |
1648 | P144 DIGNA CREAM | - | - | - | - | 1件: 51 51 💬 |
1649 | P2B001 once daily (pramipexole 0.3 mg / rasagiline 0.75 mg), | 2件: Pramipexole Pramipexole, Rasagiline | 3件: Pramipexole
Pramipexole
,
Rasagiline
,
Rasagiline tartrate
💬 | 4件: DRD2 DRD2, DRD3, DRD4, MAOB 💬 | 18件: Alcoholism Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Gap junction, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1650 | P2B001 once daily (pramipexole 0.6 mg / rasagiline 0.75 mg), | 2件: Pramipexole Pramipexole, Rasagiline | 3件: Pramipexole
Pramipexole
,
Rasagiline
,
Rasagiline tartrate
💬 | 4件: DRD2 DRD2, DRD3, DRD4, MAOB 💬 | 18件: Alcoholism Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Gap junction, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1651 | Palovarotene dose level 1 | 1件: Palovarotene Palovarotene | 1件: Palovarotene
Palovarotene
💬 | 1件: RARG RARG 💬 | - | 1件: 272 272 💬 |
1652 | Palovarotene dose level 2 | 1件: Palovarotene Palovarotene | 1件: Palovarotene
Palovarotene
💬 | 1件: RARG RARG 💬 | - | 1件: 272 272 💬 |
1653 | Palovarotene dose level 3 | 1件: Palovarotene Palovarotene | 1件: Palovarotene
Palovarotene
💬 | 1件: RARG RARG 💬 | - | 1件: 272 272 💬 |
1654 | Palovarotene dose level 4 | 1件: Palovarotene Palovarotene | 1件: Palovarotene
Palovarotene
💬 | 1件: RARG RARG 💬 | - | 1件: 272 272 💬 |
1655 | PANCREATINA (Páncreas Polvo | - | - | - | - | 1件: 299 299 💬 |
1656 | PANCREATINA (Páncreas Polvo) | - | - | - | - | 1件: 299 299 💬 |
1657 | Pancrelipase Delayed Release | 1件: Pancrelipase Pancrelipase | 1件: Pancrelipase
Pancrelipase
💬 | - | - | 1件: 299 299 💬 |
1658 | Pancrelipase Delayed Release Capsule | 1件: Pancrelipase Pancrelipase | 1件: Pancrelipase
Pancrelipase
💬 | - | - | 2件: 298 298, 299 💬 |
1659 | PARACETAMOLO DC.IT FU | - | - | - | - | 1件: 46 46 💬 |
1660 | PARACETAMOLO DOC GENERICI - 1000 MG COMPRESSA 16 COMPRESSE | - | - | - | - | 1件: 19 19 💬 |
1661 | PARACETAMOLO NOVA ARGENTIA - 500 MG COMPRESSE 20 COMPRESSE | - | - | - | - | 1件: 300 300 💬 |
1662 | Part 2 Adult Alogabat High Dose (aged 15-17) | - | - | - | - | 1件: 201 201 💬 |
1663 | Part 2: LJN452 Dose level 1 | - | - | - | - | 1件: 93 93 💬 |
1664 | Part 2: LJN452 Dose level 2 | - | - | - | - | 1件: 93 93 💬 |
1665 | Part B: Dose of GSK2618960 decided from Part A | - | - | - | - | 1件: 13 13 💬 |
1666 | Part C: Dose of GSK2618960 decided from Part A and B | - | - | - | - | 1件: 13 13 💬 |
1667 | Part I- naproxen 1000 mg | 1件: Naproxen Naproxen | 1件: Naproxen
Naproxen
💬 | 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 271 271 💬 |
1668 | Part II- naproxen 1000 mg | 1件: Naproxen Naproxen | 1件: Naproxen
Naproxen
💬 | 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 271 271 💬 |
1669 | Partial Enteral Nutrition | - | - | - | - | 1件: 96 96 💬 |
1670 | PASIREOTIDE DIASPARTATE | 1件: Pasireotide Pasireotide | 1件: Pasireotide
Pasireotide
💬 | 4件: SSTR1 SSTR1, SSTR2, SSTR3, SSTR5 💬 | 4件: Gastric acid secretion Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 75 75 💬 |
1671 | Patient treated with DMARD | - | - | - | - | 1件: 46 46 💬 |
1672 | Patients' existing non-steroidal anti-inflammatory drug (NSAID) at approved doses | - | - | - | - | 1件: 46 46 💬 |
1673 | PD00377 Na-salt | - | - | - | - | 1件: 85 85 💬 |
1674 | Peri-neural Dexamethasone 1 mg | 1件: Dexamethasone Dexamethasone | 1件: Dexamethasone
Dexamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 46 46 💬 |
1675 | Permitted DMARDs | - | - | - | - | 1件: 46 46 💬 |
1676 | Personalized extended interval dosing of natalizumab | 1件: Natalizumab Natalizumab | 1件: Natalizumab
Natalizumab
💬 | 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 💬 |
1677 | PET/CT using PET ligands [F-18]FDG and [F-18]DPA-714 | - | - | - | - | 1件: 85 85 💬 |
1678 | PF-06649751 high dose (15 mg QD) | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1679 | PF-06649751 low dose (1 mg QD) | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1680 | PF-06649751 middle dose 1 (3 mg QD) | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1681 | PF-06649751 middle dose 2 (7 mg QD) | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1682 | Ph. Eur.: (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid | 1件: Propanoic acid Propanoic acid | - | - | - | 1件: 6 6 💬 |
1683 | Ph. Eur.: (2S)-3-(3,4-dihydroxyphenyl)-2hydrazino-2methylprop acid | - | - | - | - | 1件: 6 6 💬 |
1684 | PHA-022121 high dose | - | - | - | - | 1件: 65 65 💬 |
1685 | PHA-022121 low dose | - | - | - | - | 1件: 65 65 💬 |
1686 | PHA-022121 medium dose | - | - | - | - | 1件: 65 65 💬 |
1687 | PHA-022121 selected dose | - | - | - | - | 1件: 65 65 💬 |
1688 | Phase 1: Conventiaonal DMARD | - | - | - | - | 1件: 46 46 💬 |
1689 | Phenylalanine restricted diet | 1件: Phenylalanine Phenylalanine | 1件: Phenylalanine
Phenylalanine
💬 | - | - | 1件: 240 240 💬 |
1690 | PHENYLCYCLOPROPYLAMINE DERIVATIVES AND DUAL LSD1/MAO-B (LYSINE-SPECIFIC DEMETHYLASE 1 AND MONOAMINE OXIDASE-B) INHIBITOR | 1件: Lysine Lysine | 1件: Lysine
Lysine
💬 | - | - | 1件: 13 13 💬 |
1691 | Phenylketonuria-type diet | - | - | - | - | 1件: 240 240 💬 |
1692 | PhEur.: (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid | 1件: Propanoic acid Propanoic acid | - | - | - | 1件: 6 6 💬 |
1693 | PhEur.: (2S)-3-(3,4-dihydroxyphenyl)-2hydrazino-2methylpropanoic acid | - | - | - | - | 1件: 6 6 💬 |
1694 | Physiologic serum nebulized nasally | - | - | - | - | 1件: 299 299 💬 |
1695 | Pilocarpine Nitrate 5% | 2件: Nitrate Nitrate, Pilocarpine | 2件: Pilocarpine
Pilocarpine
,
Nitric acid
💬 | 2件: CHRM2 CHRM2, CHRM3 💬 | 13件: Alzheimer disease Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
1696 | Pimozide 2 mg per day | 1件: Pimozide Pimozide | 1件: Pimozide
Pimozide
💬 | 2件: ADRA2A ADRA2A, DRD2 💬 | 9件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 2 2 💬 |
1697 | Pimozide 2mg/day (current) or 4 mg/day (study initiation) | 1件: Pimozide Pimozide | 1件: Pimozide
Pimozide
💬 | 2件: ADRA2A ADRA2A, DRD2 💬 | 9件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 2 2 💬 |
1698 | Pimozide 4 mg per day | 1件: Pimozide Pimozide | 1件: Pimozide
Pimozide
💬 | 2件: ADRA2A ADRA2A, DRD2 💬 | 9件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 2 2 💬 |
1699 | Pirfenidone and nintedanib | 2件: Nintedanib Nintedanib, Pirfenidone | 2件: Pirfenidone
Pirfenidone
,
Nintedanib
💬 | 14件: CCL2 CCL2, FGFR1, FGFR2, FGFR3, FLT1, FLT4, IL10, IL1A, IL1B, IL6, KDR, PDGFRA, PDGFRB, TNF 💬 | 106件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adherens junction, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, Autoimmune thyroid disease, Bladder cancer, Breast cancer, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Central carbon metabolism in cancer, Chagas disease, Chemokine signaling pathway, Choline metabolism in cancer, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Dilated cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Focal adhesion, FoxO signaling pathway, Gap junction, Gastric cancer, Glioma, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Inflammatory mediator regulation of TRP channels, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, Measles, Melanoma, MicroRNAs in cancer, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Phospholipase D signaling pathway, Prion disease, Prostate cancer, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Rheumatoid arthritis, Salmonella infection, Shigellosis, Signaling pathways regulating pluripotency of stem cells, Sphingolipid signaling pathway, Staphylococcus aureus infection, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Th17 cell differentiation, Thermogenesis, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, VEGF signaling pathway, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 85 85 💬 |
1700 | Pirfenidone or nintedanib | 2件: Nintedanib Nintedanib, Pirfenidone | 2件: Pirfenidone
Pirfenidone
,
Nintedanib
💬 | 14件: CCL2 CCL2, FGFR1, FGFR2, FGFR3, FLT1, FLT4, IL10, IL1A, IL1B, IL6, KDR, PDGFRA, PDGFRB, TNF 💬 | 106件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adherens junction, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, Autoimmune thyroid disease, Bladder cancer, Breast cancer, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Central carbon metabolism in cancer, Chagas disease, Chemokine signaling pathway, Choline metabolism in cancer, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Dilated cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Focal adhesion, FoxO signaling pathway, Gap junction, Gastric cancer, Glioma, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Inflammatory mediator regulation of TRP channels, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, Measles, Melanoma, MicroRNAs in cancer, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Phospholipase D signaling pathway, Prion disease, Prostate cancer, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Rheumatoid arthritis, Salmonella infection, Shigellosis, Signaling pathways regulating pluripotency of stem cells, Sphingolipid signaling pathway, Staphylococcus aureus infection, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Th17 cell differentiation, Thermogenesis, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, VEGF signaling pathway, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 85 85 💬 |
1701 | Pirfenidone, deuterated | 1件: Pirfenidone Pirfenidone | 1件: Pirfenidone
Pirfenidone
💬 | 6件: CCL2 CCL2, IL10, IL1A, IL1B, IL6, TNF 💬 | 84件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, Autoimmune thyroid disease, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease, Chemokine signaling pathway, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Dilated cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Inflammatory mediator regulation of TRP channels, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, Measles, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Staphylococcus aureus infection, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 85 85 💬 |
1702 | PK-Merz® 200mg/500ml inj(Amantadine) , Normal saline 500ml inj | 1件: Amantadine Amantadine | 1件: Amantadine
Amantadine
💬 | 5件: GRIN1 GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬 | 20件: Alcoholism Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1703 | PLA + MTX switched to ABA+ MTX, DB | - | - | - | - | 1件: 46 46 💬 |
1704 | Placental Mesenchymal Stem Cells seeded on a commercially available dural graft extracellular matrix | 1件: Placental Mesenchymal Stem Cells Placental Mesenchymal Stem Cells | - | - | - | 1件: 118 118 💬 |
1705 | Plantain NSP | - | - | - | - | 1件: 96 96 💬 |
1706 | Plasma rico en plaquetas y coagulo de fibrina procesados mediante la tecnología PRGF-System (BTI) | - | - | - | - | 1件: 96 96 💬 |
1707 | Plasma-derived FVIII/VWF concentrate | - | - | - | - | 1件: 288 288 💬 |
1708 | PLASMASAFE - SOLUZIONE PER INFUSIONE 1 SACCA DA 200 ML | - | - | - | - | 1件: 274 274 💬 |
1709 | PLF with NeoFuse | - | - | - | - | 1件: 70 70 💬 |
1710 | PMG1015 Dose 1 | - | - | - | - | 1件: 85 85 💬 |
1711 | PMG1015 Dose 2 | - | - | - | - | 1件: 85 85 💬 |
1712 | PMG1015 Dose 3 | - | - | - | - | 1件: 85 85 💬 |
1713 | PMG1015 Dose 4 | - | - | - | - | 1件: 85 85 💬 |
1714 | PMG1015 Dose 5 | - | - | - | - | 1件: 85 85 💬 |
1715 | PMG1015 Dose 6 | - | - | - | - | 1件: 85 85 💬 |
1716 | PMG1015 Dose 7 | - | - | - | - | 1件: 85 85 💬 |
1717 | PN 200 tablets (500 mg naproxen and 20 mg omeprazole) | 2件: Naproxen Naproxen, Omeprazole | 2件: Naproxen
Naproxen
,
Omeprazole
💬 | 4件: ATP4A ATP4A, ATP4B, PTGS1, PTGS2 💬 | 26件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Collecting duct acid secretion, Gastric acid secretion, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxidative phosphorylation, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 2件: 46 46, 271 💬 |
1718 | PNEUMOVAX – Soluzione iniettabile in siringa preriempita da 0,5 ml | - | - | - | - | 2件: 62 62, 66 💬 |
1719 | POLY(OXY-1,2-ETHANEDIYL), ALPHA-HYDRO-OMEGA-METHOXY, ETHER WITH N-[[[2- | 1件: Diethyl ether Diethyl ether | 1件: Ether
Ether
💬 | - | - | 1件: 235 235 💬 |
1720 | POLY(OXY-1,2-ETHANEDIYL), ALPHA-HYDRO-OMEGA-METHOXY, ETHER WITH N-[[[2-[[6-[[1-[3-[[3-(2,3-DIHYDROXYPROPOXY)PROPYL]AMINO]-3-OXOPROPYL]-2,5-DI | 1件: Diethyl ether Diethyl ether | 1件: Ether
Ether
💬 | - | - | 1件: 235 235 💬 |
1721 | POLY(OXY-1,2-ETHANEDIYL), ALPHA-HYDRO-OMEGA-METHOXY, ETHER WITH N-[[[2-[[6-[[1-[3-[[3-(2,3-DIHYDROXYPROPOXY)PROPYL]AMINO]-3-OXOPROPYL]-2,5-DIOXO-3-PYRROLIDINYL]THIO]HEXYL]AMINO]ETHYL]AMINO]CARBONYL]-2-METHYLALANYL-TERIPARATIDE (2:1) | 2件: Diethyl ether Diethyl ether, Teriparatide | 2件: Ether
Ether
,
Teriparatide
💬 | 1件: PTH1R PTH1R 💬 | 3件: Endocrine and other factor-regulated calcium reabsorption Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬 | 1件: 235 235 💬 |
1722 | Pomalidomide and Dexamethasone | 2件: Dexamethasone Dexamethasone, Pomalidomide | 2件: Dexamethasone
Dexamethasone
,
Pomalidomide
💬 | 3件: IL6 IL6, NR3C1, TNF 💬 | 81件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Dilated cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, Measles, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Neuroactive ligand-receptor interaction, Non-alcoholic fatty liver disease, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 28 28 💬 |
1723 | Pooled Plasma (Human), Solvent/Detergent Treated | - | - | - | - | 1件: 64 64 💬 |
1724 | Posaconazole 100 MG [Noxafil] | 1件: Posaconazole Posaconazole | 1件: Posaconazole
Posaconazole
💬 | - | - | 1件: 299 299 💬 |
1725 | Positron Emission Tomography using [11 Carbon]-3-amino-4-(2-dimethylaminomethylphenylsulfanyl)-benzonitrile ([11C]-DASB) and [18 Fluorine]-altanserin ([18F]-altanserin) | 1件: Activated charcoal Activated charcoal | - | - | - | 1件: 6 6 💬 |
1726 | Post-CPB Drug: Dobutamine Hydrochloride | 1件: Dobutamine Dobutamine | 1件: Dobutamine
Dobutamine
💬 | 1件: ADRB1 ADRB1 💬 | 11件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 58 58 💬 |
1727 | Postoperative 3-month exclusive enteral nutrition | - | - | - | - | 1件: 96 96 💬 |
1728 | Potassium sparing diuretic | 1件: Potassium Potassium | 1件: Potassium
Potassium
💬 | - | - | 1件: 235 235 💬 |
1729 | PRALIA 60 mg Subcutaneous Injection Syringe(denosumab) | 1件: Denosumab Denosumab | 1件: Denosumab
Denosumab
💬 | 1件: TNFSF11 TNFSF11 💬 | 8件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Osteoclast differentiation, Parathyroid hormone synthesis, secretion and action, Prolactin signaling pathway, Rheumatoid arthritis 💬 | 1件: 46 46 💬 |
1730 | PRALIA 60mg Subcutaneous Injection Syringe(denosumab) | 1件: Denosumab Denosumab | 1件: Denosumab
Denosumab
💬 | 1件: TNFSF11 TNFSF11 💬 | 8件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Osteoclast differentiation, Parathyroid hormone synthesis, secretion and action, Prolactin signaling pathway, Rheumatoid arthritis 💬 | 1件: 46 46 💬 |
1731 | PRAMIPEXOLE DIHYDROCHLORIDE | 1件: Pramipexole Pramipexole | 1件: Pramipexole
Pramipexole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1732 | Pramipexole dihydrochloride extended-release tablets | 1件: Pramipexole Pramipexole | 1件: Pramipexole
Pramipexole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1733 | PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE | 1件: Pramipexole Pramipexole | 1件: Pramipexole
Pramipexole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1734 | Pramipexole dihydrochloride monohydrate extended release | 2件: Manganese citrate Manganese citrate, Pramipexole | 1件: Pramipexole
Pramipexole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1735 | Pre and post-CPB Drug: Dobutamine Hydrochloride | 1件: Dobutamine Dobutamine | 1件: Dobutamine
Dobutamine
💬 | 1件: ADRB1 ADRB1 💬 | 11件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 58 58 💬 |
1736 | Precedentemente denominato MEDI2070 e AMG 139 | - | - | - | - | 1件: 96 96 💬 |
1737 | Precision dosing with a dashboard | - | - | - | - | 1件: 96 96 💬 |
1738 | Prednisolone & dipyridamole | 2件: Dipyridamole Dipyridamole, Prednisolone | 2件: Dipyridamole
Dipyridamole
,
Prednisolone
💬 | 3件: NR3C1 NR3C1, PDE4A, PDE5A 💬 | 7件: Metabolic pathways Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action, Purine metabolism, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 46 46 💬 |
1739 | Prednisolone-Dipyridamole | 2件: Dipyridamole Dipyridamole, Prednisolone | 2件: Dipyridamole
Dipyridamole
,
Prednisolone
💬 | 3件: NR3C1 NR3C1, PDE4A, PDE5A 💬 | 7件: Metabolic pathways Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action, Purine metabolism, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 46 46 💬 |
1740 | PREDNISON 5, 20 Léciva por. tablet nob | - | - | - | - | 1件: 50 50 💬 |
1741 | Prednison 5, 20 Léciva por. tablet nob. | - | - | - | - | 1件: 50 50 💬 |
1742 | Prednisone 0,5 mg/kg orally on alternate days | 1件: Prednisone Prednisone | 1件: Prednisone
Prednisone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 222 222 💬 |
1743 | Prednisone discontinuation | 1件: Prednisone Prednisone | 1件: Prednisone
Prednisone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 49 49 💬 |
1744 | PREDNISONE DOC GENERICI - 5 MG COMPRESSE 10 COMPRESSE IN BLISTER PVC-PVDC/ALU | 1件: Prednisone Prednisone | 1件: Prednisone
Prednisone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 19 19 💬 |
1745 | PREDNISONE DOC GENERICI - 5 MG COMPRESSE 30 COMPRESSE IN BLISTER PVC-PVDC/ALU | 1件: Prednisone Prednisone | 1件: Prednisone
Prednisone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 300 300 💬 |
1746 | Prednisone in full dose | 1件: Prednisone Prednisone | 1件: Prednisone
Prednisone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 66 66 💬 |
1747 | Prednisone with daily edasalonexent | 2件: Edasalonexent Edasalonexent, Prednisone | 2件: Prednisone
Prednisone
,
Edasalonexent
💬 | 2件: NR3C1 NR3C1, RELA 💬 | 77件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Acute myeloid leukemia, Adipocytokine signaling pathway, Alcoholic liver disease, Alzheimer disease, Amoebiasis, Antifolate resistance, Apoptosis, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Chronic myeloid leukemia, Cocaine addiction, Coronavirus disease - COVID-19, Cytosolic DNA-sensing pathway, Diabetic cardiomyopathy, Epithelial cell signaling in Helicobacter pylori infection, Epstein-Barr virus infection, Fluid shear stress and atherosclerosis, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Longevity regulating pathway, MAPK signaling pathway, Measles, Mitophagy - animal, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Neuroactive ligand-receptor interaction, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-alcoholic fatty liver disease, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Prolactin signaling pathway, Prostate cancer, RIG-I-like receptor signaling pathway, Ras signaling pathway, Relaxin signaling pathway, Salmonella infection, Shigellosis, Small cell lung cancer, Sphingolipid signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Tuberculosis, Viral carcinogenesis, Yersinia infection, cAMP signaling pathway 💬 | 1件: 113 113 💬 |
1748 | Prednisone, low dose rituximab | 2件: Prednisone Prednisone, Rituximab | 2件: Prednisone
Prednisone
,
Rituximab
💬 | 2件: MS4A1 MS4A1, NR3C1 💬 | 2件: Hematopoietic cell lineage Hematopoietic cell lineage, Neuroactive ligand-receptor interaction 💬 | 1件: 61 61 💬 |
1749 | Prefilled Syringe delivery of Golimumab | 1件: Golimumab Golimumab | 1件: Golimumab
Golimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 97 97 💬 |
1750 | Prescribe N-acetylcysteine tablets | 1件: Acetylcysteine Acetylcysteine | 1件: Acetylcysteine
Acetylcysteine
💬 | - | - | 1件: 90 90 💬 |
1751 | Pridia (Donepezil Hydrochloride) 5mg | 1件: Donepezil Donepezil | 1件: Donepezil
Donepezil
💬 | 1件: ACHE ACHE 💬 | 2件: Cholinergic synapse Cholinergic synapse, Glycerophospholipid metabolism 💬 | 1件: 6 6 💬 |
1752 | PRIM-DJ2727 | - | - | - | - | 2件: 6 6, 97 💬 |
1753 | Primary Cervical Dystonia (Trihexyphenidyl) | 1件: Trihexyphenidyl Trihexyphenidyl | 1件: Trihexyphenidyl
Trihexyphenidyl
💬 | 5件: CHRM1 CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 💬 | 13件: Alzheimer disease Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1754 | Prior Donepezil 5mg | 1件: Donepezil Donepezil | 1件: Donepezil
Donepezil
💬 | 1件: ACHE ACHE 💬 | 2件: Cholinergic synapse Cholinergic synapse, Glycerophospholipid metabolism 💬 | 1件: 6 6 💬 |
1755 | Prior Donzepezil 10mg | - | - | - | - | 1件: 6 6 💬 |
1756 | PRIVIGEN - 100 MG/ML - SOLUZIONE PER INFUSIONE USO ENDOVENOSO FLACONCINO(VETRO) 1 FLACONCINO DA 100 ML | - | - | - | - | 1件: 51 51 💬 |
1757 | PRO045, selected dose | 1件: BMN-045 BMN-045 | - | - | - | 1件: 113 113 💬 |
1758 | Prolastin (drug) | - | - | - | - | 1件: 299 299 💬 |
1759 | Prolotherapy solution of 20% dextrose | 1件: Dextrose, unspecified form Dextrose, unspecified form | - | - | - | 1件: 70 70 💬 |
1760 | Promixin 1 million International Units (IU) Powder for Nebuliser Solution | - | - | - | - | 1件: 299 299 💬 |
1761 | PROMIXIN*NEBUL 30MONOD 1MUI | - | - | - | - | 1件: 299 299 💬 |
1762 | Promixin, 1 million International Units (IU) Powder for Nebuliser Solution | - | - | - | - | 1件: 299 299 💬 |
1763 | Promixin,1 millón de Unidades Internacionales,polvo para solución para inhalación por nebulizador | - | - | - | - | 1件: 299 299 💬 |
1764 | Prophylactic vaccine (tetanus, diphtheria, pertussis, poliomyelitis, influenza, hepatitis A, hepatitis B, tick-borne encephalitis, meningococcal, pneumococcal) | - | - | - | - | 1件: 13 13 💬 |
1765 | Proteína recombinante estimulante de la megacariopoyesis | - | - | - | - | 1件: 63 63 💬 |
1766 | Pulmozyme (dornase alfa) | 1件: Dornase alfa Dornase alfa | 1件: Dornase alfa
Dornase alfa
💬 | - | - | 1件: 299 299 💬 |
1767 | Pulmozyme (Dornase alpha) | 1件: Dornase alfa Dornase alfa | 1件: Dornase alfa
Dornase alfa
💬 | - | - | 1件: 299 299 💬 |
1768 | Puri Nethol | - | - | - | - | 1件: 96 96 💬 |
1769 | Puri-Nethol | - | - | - | - | 3件: 86 86, 96, 97 💬 |
1770 | Puri-Nethol 50 mg | - | - | - | - | 1件: 96 96 💬 |
1771 | PXT002331 - dose 1 | - | - | - | - | 1件: 6 6 💬 |
1772 | PXT002331 - dose 2 | - | - | - | - | 1件: 6 6 💬 |
1773 | PXT3003 Dose 1 | - | - | - | - | 1件: 10 10 💬 |
1774 | PXT3003 Dose 2 | - | - | - | - | 1件: 10 10 💬 |
1775 | PXT3003 Dose 2 (equivalent to twice Dose 1) | - | - | - | - | 1件: 10 10 💬 |
1776 | PXT3003 High Dose | - | - | - | - | 1件: 10 10 💬 |
1777 | PXT3003 Intermediate Dose | - | - | - | - | 1件: 10 10 💬 |
1778 | PXT3003 Low dose | - | - | - | - | 1件: 10 10 💬 |
1779 | Pyruvate, creatine, niacinamide | 2件: Creatine Creatine, Nicotinamide | 1件: Niacinamide
Niacinamide
💬 | - | - | 1件: 5 5 💬 |
1780 | QOL assessment, Neuropsychological | - | - | - | - | 1件: 34 34 💬 |
1781 | QRL-201 - Dose 1 | - | - | - | - | 1件: 2 2 💬 |
1782 | QRL-201 - Dose 2 | - | - | - | - | 1件: 2 2 💬 |
1783 | QRL-201 - Dose 3 | - | - | - | - | 1件: 2 2 💬 |
1784 | QRL-201 - Dose 4 | - | - | - | - | 1件: 2 2 💬 |
1785 | QRL-201 - Dose 5 | - | - | - | - | 1件: 2 2 💬 |
1786 | QRL-201 - Dose 6 | - | - | - | - | 1件: 2 2 💬 |
1787 | QRL-201 - Dose 7 | - | - | - | - | 1件: 2 2 💬 |
1788 | QRL-201- Dose 8 | - | - | - | - | 1件: 2 2 💬 |
1789 | Quercetin (dietary supplement) | 1件: Quercetin Quercetin | - | - | - | 1件: 285 285 💬 |
1790 | R(+) pramipexole dihydrochloride monohydrate | 1件: Pramipexole Pramipexole | 1件: Pramipexole
Pramipexole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 2 2 💬 |
1791 | R-hGH freeze-dried | - | - | - | - | 1件: 78 78 💬 |
1792 | R788 Sodium, R788 Na, R788 | - | - | - | - | 1件: 46 46 💬 |
1793 | R788, fostamatinib disodium hexahydrate (in USPI/FPI) | 1件: Fostamatinib Fostamatinib | 1件: Fostamatinib
Fostamatinib
💬 | 1件: SYK SYK 💬 | 17件: B cell receptor signaling pathway B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Coronavirus disease - COVID-19, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Herpes simplex virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, NF-kappa B signaling pathway, Natural killer cell mediated cytotoxicity, Neutrophil extracellular trap formation, Osteoclast differentiation, PI3K-Akt signaling pathway, Phospholipase D signaling pathway, Platelet activation, Tuberculosis, Viral carcinogenesis 💬 | 1件: 61 61 💬 |
1794 | RA15804589, C19061501-F, DNL788, DN2489, DN0002489 | - | - | - | - | 2件: 2 2, 13 💬 |
1795 | RAAV 2/6 hIDS DONOR | - | - | - | - | 1件: 19 19 💬 |
1796 | RAAV2-ND4 | - | - | - | - | 1件: 302 302 💬 |
1797 | RAAV2.5-CMV-minidystrophin (d3990) | - | - | - | - | 1件: 113 113 💬 |
1798 | RAAV2/2-ND4 VECTOR | - | - | - | - | 1件: 302 302 💬 |
1799 | RAAV2/5-PBGD vector dosage 1 | - | - | - | - | 1件: 254 254 💬 |
1800 | RAAV2/5-PBGD vector dosage 2 | - | - | - | - | 1件: 254 254 💬 |
1801 | RAAV2/5-PBGD vector dosage 3 | - | - | - | - | 1件: 254 254 💬 |
1802 | RAAV2/5-PBGD vector dosage 4 | - | - | - | - | 1件: 254 254 💬 |
1803 | RAAV8-Des-hMTM1 | - | - | - | - | 1件: 111 111 💬 |
1804 | RAAV9-CK8-h-µD5 | 1件: Zildistrogene varoparvovec Zildistrogene varoparvovec | - | - | - | 1件: 113 113 💬 |
1805 | RAAVrh74.MCK.micro-Dystrophin | - | - | - | - | 1件: 113 113 💬 |
1806 | Radiolabelled OligoG CF-5/20 6% Solution for Nebulisation | - | - | - | - | 1件: 299 299 💬 |
1807 | Radiolabelled OligoG CF-5/20 DPI | - | - | - | - | 1件: 299 299 💬 |
1808 | Radiolabelled OligoG CF-5/20 Dry Powder for Inhalation (DPI) | - | - | - | - | 1件: 299 299 💬 |
1809 | Ranolazine PR (prolonged-release) 500 mg 1 tablet bis in die and 750 mg 1 tablet bis in die | 1件: Ranolazine Ranolazine | 1件: Ranolazine
Ranolazine
💬 | - | - | 1件: 58 58 💬 |
1810 | Rapamune 1 mg/ml solución oral | 1件: Sirolimus Sirolimus | 1件: Sirolimus
Sirolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 158 158 💬 |
1811 | Rapid Dose Titration Group of Subcutaneous Treprostinil | 1件: Treprostinil Treprostinil | 1件: Treprostinil
Treprostinil
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 💬 |
1812 | Ravicti high dose | 1件: Glycerol phenylbutyrate Glycerol phenylbutyrate | 1件: Glycerol phenylbutyrate
Glycerol phenylbutyrate
💬 | - | - | 1件: 299 299 💬 |
1813 | Ravicti low dose | 1件: Glycerol phenylbutyrate Glycerol phenylbutyrate | 1件: Glycerol phenylbutyrate
Glycerol phenylbutyrate
💬 | - | - | 1件: 299 299 💬 |
1814 | RAYOS (delayed-release prednisone) | 1件: Prednisone Prednisone | 1件: Prednisone
Prednisone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 46 46 💬 |
1815 | REBIF 44 microgramos solución inyectable | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
1816 | REBIF 44 microgramos solución inyectable en jeringa precargada | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
1817 | Rebif New Formulation + ibuprofen PRN | 1件: Ibuprofen Ibuprofen | 1件: Ibuprofen
Ibuprofen
💬 | 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 13 13 💬 |
1818 | Rebif New Formulation + prophylactic Ibuprofen | 1件: Ibuprofen Ibuprofen | 1件: Ibuprofen
Ibuprofen
💬 | 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 13 13 💬 |
1819 | Rebif New Formulation 44mcg multidose cartridge | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
1820 | Rebif New Formulation Non Titrated | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
1821 | Rebif New Formulation Titrated | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
1822 | Rebif® New Formulation | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
1823 | Rebif® New Formulation (IFN-beta-1a, RNF) | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
1824 | Rebif® new formulation (RNF) | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
1825 | Rebif® New Formulation (RNF) using RebiSmartTM | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
1826 | Recombiant human Desoxyribonuclease ( rhDNase) | 1件: Desoxyribonuclease Desoxyribonuclease | - | - | - | 1件: 299 299 💬 |
1827 | Recombinanat DNA-derived human growth | - | - | - | - | 1件: 78 78 💬 |
1828 | Recombinanat DNA-derived human growth hormone produced in E.coli | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
1829 | Recombinant A Disintegrin and Metalloproteinase Thrombospondin Type-1 Motifs 13 | - | - | - | - | 1件: 64 64 💬 |
1830 | Recombinant A Disintegrin and Metalloproteinase with Thrombospondin Type-1 | - | - | - | - | 1件: 64 64 💬 |
1831 | Recombinant A Disintegrin and Metalloproteinase with Thrombospondin Type-1 Motifs | - | - | - | - | 1件: 64 64 💬 |
1832 | Recombinant A Disintegrin and Metalloproteinase with Thrombospondin Type-1 Motifs 13 | - | - | - | - | 1件: 64 64 💬 |
1833 | Recombinant A Disintegrin And Metalloproteinase with Thrombospondin Type-1 Motifs 13 (rADAMTS13) | - | - | - | - | 1件: 64 64 💬 |
1834 | Recombinant AAV vector serotype 2 containing the human wild type mitochondrial ND4 gene | - | - | - | - | 1件: 302 302 💬 |
1835 | Recombinant AAV vector serotype 2 containing the human wild typemitochondrial ND4 gene | - | - | - | - | 1件: 302 302 💬 |
1836 | Recombinant Adeno-Associated Viral vector, serotype 2 (rAAV2/2) containing the human wild-type mitochondrial NADH Dehydrogenase 4 gene (ND4) | 1件: NADH NADH | - | - | - | 1件: 302 302 💬 |
1837 | Recombinant antihumanized anti-human monoclonal antibody directed against the IL-6R | - | - | - | - | 1件: 107 107 💬 |
1838 | Recombinant DNA-derived human growth hormone | 1件: Somatotropin Somatotropin | - | - | - | 2件: 78 78, 187 💬 |
1839 | Recombinant DNA-derived human growth hormone produced in E.coli | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
1840 | Recombinant form of human nerve growth factor produced in Escherichia Coli. | 2件: Escherichia coli Escherichia coli, Nerve Growth Factor | - | - | - | 1件: 53 53 💬 |
1841 | Recombinant human a-glucosidase conjugated with multiple copies of synthetic bis-mannose-6-phosphate-tetra-mannose glycan (NEOGAA) | 3件: Avalglucosidase alfa Avalglucosidase alfa, Mannose, Phosphate ion | 1件: Avalglucosidase alfa
Avalglucosidase alfa
💬 | 1件: GAA GAA 💬 | 4件: Galactose metabolism Galactose metabolism, Lysosome, Metabolic pathways, Starch and sucrose metabolism 💬 | 1件: 256 256 💬 |
1842 | Recombinant human a-glucosidase conjugated with multiple copies of synthetic bis-mannose-6-phosphate-tetra-mannose glycan Avalglucosidase Alfa (NeoGAA) | 3件: Avalglucosidase alfa Avalglucosidase alfa, Mannose, Phosphate ion | 1件: Avalglucosidase alfa
Avalglucosidase alfa
💬 | 1件: GAA GAA 💬 | 4件: Galactose metabolism Galactose metabolism, Lysosome, Metabolic pathways, Starch and sucrose metabolism 💬 | 1件: 256 256 💬 |
1843 | Recombinant Human Alpha-N-Acetylglucosaminidase (rhNAGLU) | - | - | - | - | 1件: 19 19 💬 |
1844 | Recombinant human Arysulfatase B, recombinant human N-acetylgalactosamine 4-sulfatase | - | - | - | - | 1件: 19 19 💬 |
1845 | Recombinant human brain natriuretic peptide (rhBNP) | - | - | - | - | 1件: 215 215 💬 |
1846 | Recombinant human Cerebral Dopamine Neurotrophic Factor | 1件: Dopamine Dopamine | 1件: Dopamine
Dopamine
💬 | 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1847 | Recombinant human derived macrophage-targeted beta-Glucocerebrosidase | - | - | - | - | 1件: 19 19 💬 |
1848 | Recombinant human derived macrophage-targeted ß-Glucocerebrosidase | - | - | - | - | 1件: 19 19 💬 |
1849 | Recombinant Human DNase (Pulmozyme) | 1件: Dornase alfa Dornase alfa | 1件: Dornase alfa
Dornase alfa
💬 | - | - | 1件: 299 299 💬 |
1850 | Recombinant human heparan N-sulfatase | - | - | - | - | 1件: 19 19 💬 |
1851 | Recombinant human heparan N-sulfatase (rhHNS) | - | - | - | - | 1件: 19 19 💬 |
1852 | Recombinant human heparan N-sulfatase [rhHNS] | - | - | - | - | 1件: 19 19 💬 |
1853 | Recombinant human heparan Nsulfatase (rhHNS) | - | - | - | - | 1件: 19 19 💬 |
1854 | Recombinant human N-acetylgalactosamine 4-sulfatase | - | - | - | - | 1件: 19 19 💬 |
1855 | Recombinant human N-acetylgalactosamine 6-sulfatase, BMN 110 | - | - | - | - | 1件: 19 19 💬 |
1856 | Recombinant human N-acetylgalactosamine 6-sulfatase, BMN 110 drug substance | - | - | - | - | 1件: 19 19 💬 |
1857 | Recombinant human N-acetylgalactosamine-6-sulfatase | 1件: Elosulfase alfa Elosulfase alfa | 1件: Elosulfase alfa
Elosulfase alfa
💬 | 1件: GALNS GALNS 💬 | 3件: Glycosaminoglycan degradation Glycosaminoglycan degradation, Lysosome, Metabolic pathways 💬 | 1件: 19 19 💬 |
1858 | Recombinant human N-acetylgalactosamine-6-sulfatase (rhGALNS) | 1件: Elosulfase alfa Elosulfase alfa | 1件: Elosulfase alfa
Elosulfase alfa
💬 | 1件: GALNS GALNS 💬 | 3件: Glycosaminoglycan degradation Glycosaminoglycan degradation, Lysosome, Metabolic pathways 💬 | 1件: 19 19 💬 |
1859 | Recombinant human N-acetylgalactosamine-6-sulfatase, BMN 110 | 1件: Elosulfase alfa Elosulfase alfa | 1件: Elosulfase alfa
Elosulfase alfa
💬 | 1件: GALNS GALNS 💬 | 3件: Glycosaminoglycan degradation Glycosaminoglycan degradation, Lysosome, Metabolic pathways 💬 | 1件: 19 19 💬 |
1860 | Recombinant human N-acetylgalactosamine-6-sulfatase, BMN 110 drug substance | 1件: Elosulfase alfa Elosulfase alfa | 1件: Elosulfase alfa
Elosulfase alfa
💬 | 1件: GALNS GALNS 💬 | 3件: Glycosaminoglycan degradation Glycosaminoglycan degradation, Lysosome, Metabolic pathways 💬 | 1件: 19 19 💬 |
1861 | Recombinant human Nacetylgalactosamine- | - | - | - | - | 1件: 19 19 💬 |
1862 | Recombinant Human Nerve Growth Factor (rhNGF) | 2件: Cenegermin Cenegermin, Nerve Growth Factor | 1件: Cenegermin
Cenegermin
💬 | 1件: NGFR NGFR 💬 | 9件: Apoptosis - multiple species Apoptosis - multiple species, Cytokine-cytokine receptor interaction, MAPK signaling pathway, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Rap1 signaling pathway, Ras signaling pathway, Transcriptional misregulation in cancer, Virion - Lyssavirus 💬 | 2件: 53 53, 90 💬 |
1863 | Recombinant human porphobilinogen deaminase (Porphozym) | 1件: Porphobilinogen Porphobilinogen | - | - | - | 1件: 254 254 💬 |
1864 | Recombinant humanised anti-human monoclonal antibody directed against the IL-6R | - | - | - | - | 1件: 46 46 💬 |
1865 | Recombinant humanized anti-human monoclonal antibody directed against the IL-6R | - | - | - | - | 3件: 46 46, 51, 107 💬 |
1866 | RECOMBINANT NEISSERIA | - | - | - | - | 1件: 11 11 💬 |
1867 | RECOMBINANT NEISSERIA MENINGITIDIS GROUP B FHBP FUSION PROTEIN PRODUCED IN E.COLI CELLS BY RECOMBINANT DNA TECHNOLOGY ADSORBED ON ALUMINIUM HYDROXIDE | 5件: Aluminium Aluminium, Aluminum hydroxide, Hydroxide ion, Iron polymaltose, Lactobacillus casei | 2件: Aluminum hydroxide
Aluminum hydroxide
,
Lactobacillus casei
💬 | - | - | 1件: 11 11 💬 |
1868 | RECOMBINANT NEISSERIA MENINGITIDIS GROUP B NADA PROTEIN | - | - | - | - | 1件: 11 11 💬 |
1869 | RECOMBINANT NEISSERIA MENINGITIDIS GROUP B NHBA FUSION PROTEIN | 2件: Iron polymaltose Iron polymaltose, Lactobacillus casei | 1件: Lactobacillus casei
Lactobacillus casei
💬 | - | - | 2件: 11 11, 13 💬 |
1870 | Recombinant porcine coagulation factor VIII (B domain deleted) | 1件: Beroctocog alfa Beroctocog alfa | - | - | - | 1件: 288 288 💬 |
1871 | Recombinant porcine coagulation factor VIII (B-domain deleted) | 1件: Beroctocog alfa Beroctocog alfa | - | - | - | 1件: 288 288 💬 |
1872 | Recombinant-methionyl human glial cell line-derived neurotrophic factor | - | - | - | - | 1件: 6 6 💬 |
1873 | Rectal dialysis | - | - | - | - | 1件: 97 97 💬 |
1874 | REF CRUZADA PEI Nº 12-088 | - | - | - | - | 1件: 274 274 💬 |
1875 | REGE pro dressing | - | - | - | - | 1件: 36 36 💬 |
1876 | Regular Novolin R | - | - | - | - | 1件: 6 6 💬 |
1877 | Remicade (anti tumor necrosis factor inhibitor) | 1件: Infliximab Infliximab | 1件: Infliximab
Infliximab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 40 40 💬 |
1878 | REMICADE 100 mg polvo para concentrado para solución para perfusión | 1件: Infliximab Infliximab | 1件: Infliximab
Infliximab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 2件: 46 46, 271 💬 |
1879 | REVATIO - 0.8 MG/ML - SOLUZIONE INIETTABILE - USO ENDOVENOSO - FLACONCINO(VETRO) 1 FLACONCINO DA 20 ML | 1件: Sildenafil Sildenafil | 1件: Sildenafil
Sildenafil
💬 | 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 294 294 💬 |
1880 | RhASA - Dose Level 1 | - | - | - | - | 1件: 19 19 💬 |
1881 | RhASA - Dose Level 2 | - | - | - | - | 1件: 19 19 💬 |
1882 | RhASA - Dose Level 3 | - | - | - | - | 1件: 19 19 💬 |
1883 | Rheumatoid Arthritis With Disease-Modifying Drugs (DMARDs) | - | - | - | - | 1件: 46 46 💬 |
1884 | RhGH Norditropin® pen (34 µg/kg) | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
1885 | RhNGF 180 µg/ml eye drops solution | 1件: Cenegermin Cenegermin | 1件: Cenegermin
Cenegermin
💬 | 1件: NGFR NGFR 💬 | 9件: Apoptosis - multiple species Apoptosis - multiple species, Cytokine-cytokine receptor interaction, MAPK signaling pathway, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Rap1 signaling pathway, Ras signaling pathway, Transcriptional misregulation in cancer, Virion - Lyssavirus 💬 | 1件: 90 90 💬 |
1886 | RhNGF 60 µg/ml eye drops solution | 1件: Cenegermin Cenegermin | 1件: Cenegermin
Cenegermin
💬 | 1件: NGFR NGFR 💬 | 9件: Apoptosis - multiple species Apoptosis - multiple species, Cytokine-cytokine receptor interaction, MAPK signaling pathway, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Rap1 signaling pathway, Ras signaling pathway, Transcriptional misregulation in cancer, Virion - Lyssavirus 💬 | 1件: 90 90 💬 |
1887 | Rice/turkey free diet (R/TFD) group | 2件: Rice Rice, Turkey | - | - | - | 1件: 53 53 💬 |
1888 | Rifampin 300mg BID + istradefylline 40mg Day 8 only | 2件: Istradefylline Istradefylline, Rifampicin | 2件: Rifampin
Rifampin
,
Istradefylline
💬 | 1件: ADORA2A ADORA2A 💬 | 7件: Alcoholism Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1889 | Rifaximin Delayed Release (DR) | 1件: Rifaximin Rifaximin | 1件: Rifaximin
Rifaximin
💬 | - | - | 1件: 96 96 💬 |
1890 | Rifaximin delayed release 400 mg film coated tablet | 1件: Rifaximin Rifaximin | 1件: Rifaximin
Rifaximin
💬 | - | - | 1件: 96 96 💬 |
1891 | Rifaximin delayed release tablets | 1件: Rifaximin Rifaximin | 1件: Rifaximin
Rifaximin
💬 | - | - | 1件: 96 96 💬 |
1892 | Riluzole 100mg/day | 1件: Riluzole Riluzole | 1件: Riluzole
Riluzole
💬 | 14件: GRIA1 GRIA1, GRIA2, GRIA3, GRIA4, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬 | 23件: Alcoholism Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term depression, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Retrograde endocannabinoid signaling, Spinocerebellar ataxia, Systemic lupus erythematosus, Transcriptional misregulation in cancer, cAMP signaling pathway 💬 | 1件: 2 2 💬 |
1893 | Risedronato sódico 2.5mg | - | - | - | - | 1件: 274 274 💬 |
1894 | Risedronato sódico 5mg | - | - | - | - | 1件: 274 274 💬 |
1895 | Ritonavir (Norvir) | 1件: Ritonavir Ritonavir | 1件: Ritonavir
Ritonavir
💬 | - | - | 1件: 265 265 💬 |
1896 | Rituxan (INN: Rituximab), brand name in the United States | 1件: Rituximab Rituximab | 1件: Rituximab
Rituximab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 46 46 💬 |
1897 | Rituxan (INN: Rituximab), brand name in the US | 1件: Rituximab Rituximab | 1件: Rituximab
Rituximab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 46 46 💬 |
1898 | Rituximab (MABTHERA® or RITUXAN®). | 1件: Rituximab Rituximab | 1件: Rituximab
Rituximab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 2件: 35 35, 61 💬 |
1899 | Rivenprost (drug) | 1件: Rivenprost Rivenprost | - | - | - | 1件: 97 97 💬 |
1900 | RO7248824/F03-01 (Diluent for RO7248824/F02-01 | - | - | - | - | 1件: 201 201 💬 |
1901 | RoActemra 20 mg/ml concentrado para solución para perfusión | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
1902 | ROACTEMRA 20 mg/ml, concentrado para solución para perfusión | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 3件: 46 46, 107, 271 💬 |
1903 | Rob 803 (9-Chloro-2,3-dimethyl-6-(N,N-dimethylaminoethylamino-2-oxoethyl)-6H-indolo[2,3-b] quinoxali | - | - | - | - | 1件: 46 46 💬 |
1904 | Roflumilast 500 Ug ORAL TABLET [Daliresp] | 1件: Roflumilast Roflumilast | 1件: Roflumilast
Roflumilast
💬 | 4件: PDE4A PDE4A, PDE4B, PDE4C, PDE4D 💬 | 5件: Metabolic pathways Metabolic pathways, Morphine addiction, Parathyroid hormone synthesis, secretion and action, Purine metabolism, cAMP signaling pathway 💬 | 1件: 97 97 💬 |
1905 | Rokan (r) Novo 120 mg | - | - | - | - | 1件: 18 18 💬 |
1906 | Romiplostim plus dexamethasone | 2件: Dexamethasone Dexamethasone, Romiplostim | 2件: Dexamethasone
Dexamethasone
,
Romiplostim
💬 | 2件: MPL MPL, NR3C1 💬 | 3件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction 💬 | 1件: 63 63 💬 |
1907 | ROP+L-Dopa | 1件: Levodopa Levodopa | 1件: Levodopa
Levodopa
💬 | 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1908 | Ropinirole/L-dopa | 2件: Levodopa Levodopa, Ropinirole | 2件: Levodopa
Levodopa
,
Ropinirole
💬 | 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1909 | Ropivacaine plus normal saline | 1件: Ropivacaine Ropivacaine | 1件: Ropivacaine
Ropivacaine
💬 | 5件: SCN1A SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | 3件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬 | 1件: 70 70 💬 |
1910 | Rotigotine Nasal Spray | 1件: Rotigotine Rotigotine | 1件: Rotigotine
Rotigotine
💬 | 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1911 | S(-)-3-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxopyridin-1(2H)-yl]-N,4-dimethylbenzamide | - | - | - | - | 1件: 46 46 💬 |
1912 | SA001 High dose | - | - | - | - | 1件: 53 53 💬 |
1913 | SA001 Low dose | - | - | - | - | 1件: 53 53 💬 |
1914 | SA001 Mid dose | - | - | - | - | 1件: 53 53 💬 |
1915 | Safinimide 50-100 mg/day | - | - | - | - | 1件: 6 6 💬 |
1916 | SAIZEN - 1 FLACONCINO POLV. 8 MG + 1 CARTUCCIA. SOLV. INSERITI IN UN DISPOSITIVO PER LA RICOSTITUZIONE | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
1917 | Salbutamol Only Product in Oral Dose Form | 1件: Salbutamol Salbutamol | 1件: Albuterol
Albuterol
💬 | 1件: ADRB2 ADRB2 💬 | 9件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 111 111 💬 |
1918 | Salbutamol-ratiopharm® N metered-dose aerosol inhaler | 1件: Salbutamol Salbutamol | 1件: Albuterol
Albuterol
💬 | 1件: ADRB2 ADRB2 💬 | 9件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 299 299 💬 |
1919 | Salbutamol-ratiopharm® N metereddose aerosol inhaler | 1件: Salbutamol Salbutamol | 1件: Albuterol
Albuterol
💬 | 1件: ADRB2 ADRB2 💬 | 9件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 299 299 💬 |
1920 | Saline 0.9% NaCl | - | - | - | - | 1件: 235 235 💬 |
1921 | Saline Intranasal Delivery | - | - | - | - | 1件: 6 6 💬 |
1922 | Saline Nasal Mist | - | - | - | - | 1件: 127 127 💬 |
1923 | Sandimmun Neoral | 1件: Cyclosporine Cyclosporine | 1件: Cyclosporine
Cyclosporine
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 3件: 60 60, 97, 226 💬 |
1924 | SANDIMMUN NEORAL - 10 MG CAPSULE MOLLI 50 CAPSULE | 1件: Cyclosporine Cyclosporine | 1件: Cyclosporine
Cyclosporine
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 60 60 💬 |
1925 | SANDIMMUN NEORAL - 100 MG CAPSULE MOLLI 30 CAPSULE | 1件: Cyclosporine Cyclosporine | 1件: Cyclosporine
Cyclosporine
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 60 60 💬 |
1926 | SANDIMMUN NEORAL - 25 MG CAPSULE MOLLI 50 CAPSULE | 1件: Cyclosporine Cyclosporine | 1件: Cyclosporine
Cyclosporine
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 60 60 💬 |
1927 | SANDIMMUN NEORAL - 50 MG CAPSULE MOLLI 50 CAPSULE | 1件: Cyclosporine Cyclosporine | 1件: Cyclosporine
Cyclosporine
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 60 60 💬 |
1928 | SANDIMMUN NEORAL*30CPS 100MG | 1件: Cyclosporine Cyclosporine | 1件: Cyclosporine
Cyclosporine
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 46 46 💬 |
1929 | SANDIMMUN NEORAL*50CPS 25MG | 1件: Cyclosporine Cyclosporine | 1件: Cyclosporine
Cyclosporine
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 46 46 💬 |
1930 | SAPROPTERIN DIHYDROCHLORIDE | 1件: Sapropterin Sapropterin | 1件: Sapropterin
Sapropterin
💬 | - | - | 1件: 240 240 💬 |
1931 | Sapropterin dihydrochloride (6R-BH4) | 1件: Sapropterin Sapropterin | 1件: Sapropterin
Sapropterin
💬 | - | - | 1件: 86 86 💬 |
1932 | Sapropterin dihydrochloride, 6R-BH4, tetrahydrobiopterin | 1件: Sapropterin Sapropterin | 1件: Sapropterin
Sapropterin
💬 | - | - | 1件: 240 240 💬 |
1933 | Sapropterin Dihydrocholoride | 1件: Sapropterin Sapropterin | 1件: Sapropterin
Sapropterin
💬 | - | - | 1件: 240 240 💬 |
1934 | Sapropterin, sapropterin dihydrochloride | 1件: Sapropterin Sapropterin | 1件: Sapropterin
Sapropterin
💬 | - | - | 1件: 240 240 💬 |
1935 | Saproterin dihydrochloride | - | - | - | - | 1件: 240 240 💬 |
1936 | SARACATINIB DIFUMARATE | 1件: Saracatinib Saracatinib | 1件: Saracatinib
Saracatinib
💬 | 2件: ABL1 ABL1, SRC 💬 | 49件: Adherens junction Adherens junction, Axon guidance, Bacterial invasion of epithelial cells, Bladder cancer, C-type lectin receptor signaling pathway, Cell cycle, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endocytosis, Epithelial cell signaling in Helicobacter pylori infection, ErbB signaling pathway, Estrogen signaling pathway, Fluid shear stress and atherosclerosis, Focal adhesion, GABAergic synapse, Gap junction, GnRH signaling pathway, Hepatitis B, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Inflammatory mediator regulation of TRP channels, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, MicroRNAs in cancer, Mitophagy - animal, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Oxytocin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Platelet activation, Prolactin signaling pathway, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Shigellosis, Thyroid hormone signaling pathway, Tight junction, Tuberculosis, VEGF signaling pathway, Viral carcinogenesis, Viral myocarditis, Yersinia infection 💬 | 1件: 272 272 💬 |
1937 | Sativex Oromucosal Spray (non-marketed) | 2件: Cannabidiol Cannabidiol, Dronabinol | 2件: Dronabinol
Dronabinol
,
Cannabidiol
💬 | 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 13 13 💬 |
1938 | Satralizumab (120 mg/PFS with NSD) | 1件: Satralizumab Satralizumab | 1件: Satralizumab
Satralizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 13 13 💬 |
1939 | SB-A6P-HRL Donor Vector | - | - | - | - | 1件: 19 19 💬 |
1940 | SC0062 high dose | - | - | - | - | 1件: 66 66 💬 |
1941 | SC0062 low dose | - | - | - | - | 1件: 66 66 💬 |
1942 | SC0062 medium dose | - | - | - | - | 1件: 66 66 💬 |
1943 | Scopolamine, atropine, edaravone and dexmedetomidine | 4件: Atropine Atropine, Dexmedetomidine, Edaravone, Scopolamine | 4件: Atropine
Atropine
,
Scopolamine
,
Dexmedetomidine
,
Edaravone
💬 | 8件: ADRA2A ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 💬 | 14件: Alzheimer disease Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 2 2 💬 |
1944 | SD-101 dermal cream (3%) | - | - | - | - | 1件: 36 36 💬 |
1945 | SD-101 Dermal Cream (6%) | - | - | - | - | 1件: 36 36 💬 |
1946 | Secukinumab 150 mg (2 injections per dose | 1件: Secukinumab Secukinumab | 1件: Secukinumab
Secukinumab
💬 | 1件: IL17A IL17A 💬 | 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 269 269 💬 |
1947 | See D.3.9.3 'Other descriptive name' below | - | - | - | - | 1件: 46 46 💬 |
1948 | See Intervention Description) | - | - | - | - | 1件: 13 13 💬 |
1949 | Selective Nerve Root Block | - | - | - | - | 1件: 70 70 💬 |
1950 | Selexipag, ACT-293987 (NS-304) | 1件: Selexipag Selexipag | 1件: Selexipag
Selexipag
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 💬 |
1951 | Selumetinib (AZD6244 hyd sulfate) 50mg/dose | 2件: Selumetinib Selumetinib, Sulfate ion | 1件: Selumetinib
Selumetinib
💬 | 2件: MAP2K1 MAP2K1, MAP2K2 💬 | 89件: Acute myeloid leukemia Acute myeloid leukemia, Alcoholism, Alzheimer disease, Apelin signaling pathway, Apoptosis, Autophagy - animal, B cell receptor signaling pathway, Bladder cancer, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, Colorectal cancer, Cushing syndrome, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Focal adhesion, FoxO signaling pathway, Gap junction, Gastric cancer, Glioma, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Influenza A, Insulin signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Long-term depression, Long-term potentiation, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-small cell lung cancer, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Serotonergic synapse, Signaling pathways regulating pluripotency of stem cells, Sphingolipid signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Thyroid cancer, Thyroid hormone signaling pathway, Toll-like receptor signaling pathway, VEGF signaling pathway, Vascular smooth muscle contraction, Yersinia infection, cAMP signaling pathway, cGMP-PKG signaling pathway, mTOR signaling pathway 💬 | 1件: 34 34 💬 |
1952 | Semi-vegetarian diet | - | - | - | - | 1件: 97 97 💬 |
1953 | SEN0014196 (High Dose) | - | - | - | - | 1件: 8 8 💬 |
1954 | SEN0014196 (Low Dose) | - | - | - | - | 1件: 8 8 💬 |
1955 | Sezione * D.3.6.2.1 - valore: 400mg alla settimana 0, in seguito 200mg ogni due settimane | - | - | - | - | 1件: 96 96 💬 |
1956 | Short Chain Fatty Acids (SCFA) Dietary Supplement | - | - | - | - | 1件: 46 46 💬 |
1957 | Sialic acid, N-acetylneuraminic acid | - | - | - | - | 1件: 30 30 💬 |
1958 | SIMPONI 50 mg solución inyectable en pluma precargada | 1件: Golimumab Golimumab | 1件: Golimumab
Golimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1959 | Simvastatin treatment for 28 days | 1件: Simvastatin Simvastatin | 1件: Simvastatin
Simvastatin
💬 | 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 299 299 💬 |
1960 | Simvastatine Sandoz 40mg deelbare filmomhulde tabletten | 1件: Simvastatin Simvastatin | 1件: Simvastatin
Simvastatin
💬 | 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 13 13 💬 |
1961 | SINEMET - 100 MG + 25 MG COMPRESSE 50 COMPRESSE DIVISIBILI | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1962 | Single Dose | - | - | - | - | 2件: 38 38, 162 💬 |
1963 | Single dose C2N-8E12 | - | - | - | - | 1件: 5 5 💬 |
1964 | Single dose reduced | - | - | - | - | 1件: 2 2 💬 |
1965 | Single dose standard | - | - | - | - | 1件: 2 2 💬 |
1966 | Single dose-group A | - | - | - | - | 1件: 97 97 💬 |
1967 | Single intravenous (IV) dose of human Low Density Lipoprotein Receptor (LDLR) Gene Therapy | - | - | - | - | 1件: 79 79 💬 |
1968 | Sirolimus (study drug)+ACE inhibitor + statin | 1件: Sirolimus Sirolimus | 1件: Sirolimus
Sirolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 66 66 💬 |
1969 | Slow Dose Titration Group of Subcutaneous Treprostinil | 1件: Treprostinil Treprostinil | 1件: Treprostinil
Treprostinil
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 💬 |
1970 | Smartject Device delivery of Golimumab | 1件: Golimumab Golimumab | 1件: Golimumab
Golimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 97 97 💬 |
1971 | SMOFKABIVEN - EMULSIONE PER INFUSIONE SENZA ELETTROLITI 1 SACCA BIOFINE MULTICOMPARTIMENTATE DA 493 ML | 2件: Medium-chain triglycerides Medium-chain triglycerides, Sodium glycerophosphate | 1件: Sodium glycerophosphate
Sodium glycerophosphate
💬 | - | - | 1件: 66 66 💬 |
1972 | Sobetirome (NV1205) | 1件: Sobetirome Sobetirome | 1件: Sobetirome
Sobetirome
💬 | 1件: THRB THRB 💬 | 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Thyroid hormone signaling pathway 💬 | 1件: 20 20 💬 |
1973 | SoC: cyclophosphamide, bortezomib, and Dexamethasone (CyBorD) | 3件: Bortezomib Bortezomib, Cyclophosphamide, Dexamethasone | 4件: Cyclophosphamide
Cyclophosphamide
,
Dexamethasone
,
Bortezomib
,
Cyclophosphamide
💬 | 2件: NR3C1 NR3C1, PSMB5 💬 | 9件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Neuroactive ligand-receptor interaction, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬 | 1件: 28 28 💬 |
1974 | SODIO ASCORBATO DC.IT | - | - | - | - | 1件: 10 10 💬 |
1975 | Sodium chloride (NaCl) | 2件: Chloride ion Chloride ion, Sodium chloride | 1件: Sodium chloride
Sodium chloride
💬 | - | - | 1件: 67 67 💬 |
1976 | Sodium Nitrate | 2件: Nitrate Nitrate, Sodium nitrate | 1件: Nitric acid
Nitric acid
💬 | - | - | 2件: 58 58, 113 💬 |
1977 | Sodium Nitrate - double dose | 2件: Nitrate Nitrate, Sodium nitrate | 1件: Nitric acid
Nitric acid
💬 | - | - | 1件: 113 113 💬 |
1978 | SODIUM NITRITE | 1件: Nitrite Nitrite | - | - | - | 1件: 86 86 💬 |
1979 | Sodium Nitrite Inhalation Solution | 1件: Nitrite Nitrite | - | - | - | 1件: 86 86 💬 |
1980 | SODIUM NITROPRUSSIDE | 1件: Nitroprusside Nitroprusside | - | - | - | 1件: 51 51 💬 |
1981 | Sodium phenylbutyrate (NaPB) | 1件: Phenylbutyric acid Phenylbutyric acid | - | - | - | 1件: 3 3 💬 |
1982 | Sodium tanshinone IIA sulfonate diluted with 5% glucose solution,20mg sildenafil citrate by mouth | 2件: Dextrose, unspecified form Dextrose, unspecified form, Sildenafil | 1件: Sildenafil
Sildenafil
💬 | 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
1983 | Sodium-[o-[(2,6-dichlorophenyl)-amino]- phenyl]-acetate | 1件: Acetate Acetate | - | - | - | 1件: 46 46 💬 |
1984 | Sodium-[o-[(2,6-dichlorophenyl)-amino]-phenyl]-acetate | 1件: Acetate Acetate | - | - | - | 1件: 46 46 💬 |
1985 | SOLIRIS 300 mg concentrado para solución para perfusión | 1件: Eculizumab Eculizumab | 1件: Eculizumab
Eculizumab
💬 | 1件: C5 C5 💬 | 11件: Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬 | 1件: 109 109 💬 |
1986 | SOLU MEDROL - 125 MG/2 ML POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE 1 FLACONE A DOPPIA CAMERA DA 125 MG/2 ML | - | - | - | - | 3件: 13 13, 14, 53 💬 |
1987 | SOLU MEDROL - 40 MG/ML POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE 1 FLACONE A DOPPIA CAMERA DA 40 MG/ML | - | - | - | - | 1件: 56 56 💬 |
1988 | SOLU MEDROL - 500 MG/8 ML POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE 1 FLACONE DI POLVERE DA 500 MG+ FIALA SOLVENTE DA 8 ML | - | - | - | - | 1件: 56 56 💬 |
1989 | Solucion de Cloruro de Sodio | - | - | - | - | 1件: 228 228 💬 |
1990 | Solucion de cloruro de sodio Sodium Chloride Solution | 2件: Chloride ion Chloride ion, Sodium chloride | 1件: Sodium chloride
Sodium chloride
💬 | - | - | 1件: 228 228 💬 |
1991 | Solution de chlorhydrate de dopamine anaérobie | 1件: Dopamine Dopamine | 1件: Dopamine
Dopamine
💬 | 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1992 | Soluzione di levodopa/carbidopa | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1993 | Solvente Cloruro de Sodio Sodium Chloride Solvent | 2件: Chloride ion Chloride ion, Sodium chloride | 1件: Sodium chloride
Sodium chloride
💬 | - | - | 1件: 228 228 💬 |
1994 | Solvente de Cloruro de Sodio | - | - | - | - | 1件: 228 228 💬 |
1995 | Somatropin (DNA origin) | 1件: Somatotropin Somatotropin | - | - | - | 1件: 19 19 💬 |
1996 | Somatropin (INN) recombinant DNA orgin, Escherichia coli | 2件: Escherichia coli Escherichia coli, Somatotropin | - | - | - | 1件: 78 78 💬 |
1997 | Somatropin (recombinant DNA origin produced in E. coli) | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
1998 | SOMATROPIN (recombinant DNA-derived human growth hormone) | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
1999 | Somatropin - GH naïve pediatric cohort | 1件: Somatotropin Somatotropin | - | - | - | 1件: 193 193 💬 |
2000 | SPD476 is a polymeric matrix formulation that displays both delayed- and extended-release of mesalazine | 1件: Mesalazine Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
2001 | SPECT : 123 I-FP-CIT (DATSCAN) and 123I-ADAM | 1件: Ioflupane I-123 Ioflupane I-123 | - | - | - | 1件: 2 2 💬 |
2002 | SPH3127 Tablets with Dose A | - | - | - | - | 1件: 97 97 💬 |
2003 | SPH3127 Tablets with Dose B | - | - | - | - | 1件: 97 97 💬 |
2004 | SPI-62 dose 2 | - | - | - | - | 1件: 75 75 💬 |
2005 | SPI-62 dose 3 | - | - | - | - | 1件: 75 75 💬 |
2006 | SPI-62 dose 4 | - | - | - | - | 1件: 75 75 💬 |
2007 | SPI-62 dose1 | - | - | - | - | 1件: 75 75 💬 |
2008 | Spironolactone (drug) | 1件: Spironolactone Spironolactone | 1件: Spironolactone
Spironolactone
💬 | 1件: NR3C2 NR3C2 💬 | 1件: Aldosterone-regulated sodium reabsorption Aldosterone-regulated sodium reabsorption 💬 | 1件: 210 210 💬 |
2009 | Stable weekly dose of methotrexate | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
2010 | Standard care Hyaluronic acid eye drops | 1件: Hyaluronic acid Hyaluronic acid | 1件: Hyaluronic acid
Hyaluronic acid
💬 | - | - | 1件: 53 53 💬 |
2011 | Standard DMARDs (Disease Modifying Anti Rheumatic Drugs) | - | - | - | - | 1件: 46 46 💬 |
2012 | Standard dose of HCQ | - | - | - | - | 1件: 49 49 💬 |
2013 | Standard dose of rituximab | 1件: Rituximab Rituximab | 1件: Rituximab
Rituximab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 49 49 💬 |
2014 | Standard Dose YPT-01 | - | - | - | - | 1件: 299 299 💬 |
2015 | Standard interval dosing | - | - | - | - | 1件: 13 13 💬 |
2016 | Standard MS DMT | - | - | - | - | 1件: 13 13 💬 |
2017 | Standard MS DMTs | - | - | - | - | 1件: 13 13 💬 |
2018 | Standard Nutritional Supplement + PERT | - | - | - | - | 1件: 299 299 💬 |
2019 | Standard therapy (without eltrombopag): HD-DXM | 1件: Eltrombopag Eltrombopag | - | - | - | 1件: 63 63 💬 |
2020 | Standard treatment with a conventional drug | - | - | - | - | 1件: 13 13 💬 |
2021 | Standard Vitamin D3 Supplementation | 1件: Cholecalciferol Cholecalciferol | 1件: Cholecalciferol
Cholecalciferol
💬 | 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 60 60 💬 |
2022 | Standard-dose vitamin D (400IU per day) | 1件: Vitamin D Vitamin D | - | - | - | 1件: 274 274 💬 |
2023 | STELARA - 90 MG - SOLUZIONE INIETTABILE IN SIRINGHE PRERIEMPITE - USO SOTTOCUTANEO - SIRINGA PRERIEMPITA(VETRO) 1 ML(90MG/ML) 1 SIRINGA PRERIEMPITA DA 1 ML | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 96 96 💬 |
2024 | Sterile Normal Saline (0.9% NaCl) | - | - | - | - | 2件: 62 62, 254 💬 |
2025 | STERILE PYROGEN-FREE ISOTONIC NACL SOLUTE (0.9% W / V) | - | - | - | - | 1件: 299 299 💬 |
2026 | Steroid Drug | - | - | - | - | 2件: 46 46, 49 💬 |
2027 | STK-001 - Multiple Ascending Doses | 1件: Zorevunersen Zorevunersen | - | - | - | 1件: 140 140 💬 |
2028 | STK-001 - Single Ascending Doses | 1件: Zorevunersen Zorevunersen | - | - | - | 1件: 140 140 💬 |
2029 | Study Drug | - | - | - | - | 2件: 6 6, 13 💬 |
2030 | STW5-II (Iberogast N, BAY98-7410) | - | - | - | - | 1件: 97 97 💬 |
2031 | Sub-Study: Nintedanib | 1件: Nintedanib Nintedanib | 1件: Nintedanib
Nintedanib
💬 | 8件: FGFR1 FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 | 34件: Adherens junction Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, Choline metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, Gap junction, Gastric cancer, Glioma, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Rheumatoid arthritis, Signaling pathways regulating pluripotency of stem cells, Thermogenesis, Transcriptional misregulation in cancer, VEGF signaling pathway 💬 | 1件: 85 85 💬 |
2032 | Sublingual nitroglycerine | 1件: Nitroglycerin Nitroglycerin | 1件: Nitroglycerin
Nitroglycerin
💬 | - | - | 1件: 46 46 💬 |
2033 | Subtenon injection of Wharton jelly derived mesenchymal stem cell exosomes | - | - | - | - | 1件: 90 90 💬 |
2034 | Subtenon injection of Wharton jelly derived mesenchymal stem cells | - | - | - | - | 1件: 90 90 💬 |
2035 | Sulfate d'hydroxychloroquine | 2件: Hydroxychloroquine Hydroxychloroquine, Sulfate ion | 1件: Hydroxychloroquine
Hydroxychloroquine
💬 | - | - | 1件: 53 53 💬 |
2036 | Sulfato de amikacina | 1件: Amikacin Amikacin | 1件: Amikacin
Amikacin
💬 | - | - | 1件: 299 299 💬 |
2037 | Sulindac (HLX-0201), dose strength 1 | 1件: Sulindac Sulindac | 1件: Sulindac
Sulindac
💬 | 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 206 206 💬 |
2038 | Sulindac (HLX-0201), dose strength 2 | 1件: Sulindac Sulindac | 1件: Sulindac
Sulindac
💬 | 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 206 206 💬 |
2039 | Sulphsalazine, Pentasa, Asacol, Colazide, Depentum | - | - | - | - | 1件: 97 97 💬 |
2040 | SUNPG1622 I dose | - | - | - | - | 1件: 271 271 💬 |
2041 | Supplement nutritional supporting | - | - | - | - | 1件: 291 291 💬 |
2042 | Supplementation with vitamin D2/D3 | 1件: Ergocalciferol Ergocalciferol | 1件: Ergocalciferol
Ergocalciferol
💬 | 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 299 299 💬 |
2043 | Supressi. T-Diet plus Range | - | - | - | - | 1件: 6 6 💬 |
2044 | Surgical infusion of AAV-GAD into the subthalamic nucleus | - | - | - | - | 1件: 6 6 💬 |
2045 | Survival of Motor Neuron 2 (SMN2) Splicing Modulator Antisense Oligonucleotide | - | - | - | - | 1件: 3 3 💬 |
2046 | Suspension de microbiote fécal | - | - | - | - | 1件: 97 97 💬 |
2047 | Suspension of adipose derived autologous adult stem cells | - | - | - | - | 1件: 96 96 💬 |
2048 | Sustained-release oral dalfampridine | 1件: Dalfampridine Dalfampridine | 1件: Dalfampridine
Dalfampridine
💬 | 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 1件: 13 13 💬 |
2049 | Symbiotic Formula with DHA and antioxidants | - | - | - | - | 1件: 299 299 💬 |
2050 | Symptomatic treatment (Converting Enzyme inhibitor, Angiotensin II, Anti-renin, Aldosterone antagonist diuretic, Beta blocker, Calcium inhibitor, statin) | 3件: Aldosterone Aldosterone, Angiotensin II, Calcium | 3件: Angiotensin II
Angiotensin II
,
Angiotensin II
,
Aldosterone
💬 | 3件: AGTR1 AGTR1, AGTR2, NR3C2 💬 | 17件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Aldosterone-regulated sodium reabsorption, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 222 222 💬 |
2051 | Synacthen Depot | 1件: Tetracosactide Tetracosactide | 1件: Cosyntropin
Cosyntropin
💬 | 1件: MC2R MC2R 💬 | 5件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 3件: 83 83, 145, 222 💬 |
2052 | Synacthen Depot 1mg | 1件: Tetracosactide Tetracosactide | 1件: Cosyntropin
Cosyntropin
💬 | 1件: MC2R MC2R 💬 | 5件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 222 222 💬 |
2053 | Synthetic DMARD(s) | - | - | - | - | 1件: 46 46 💬 |
2054 | Syntocinon 40 IU/ml nasal spray | 1件: Oxytocin Oxytocin | 1件: Oxytocin
Oxytocin
💬 | 1件: OXTR OXTR 💬 | 4件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Oxytocin signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2055 | Syntocinon nasal spray | 1件: Oxytocin Oxytocin | 1件: Oxytocin
Oxytocin
💬 | 1件: OXTR OXTR 💬 | 4件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Oxytocin signaling pathway, cAMP signaling pathway 💬 | 1件: 193 193 💬 |
2056 | Systemic non-biological treatments | - | - | - | - | 2件: 46 46, 271 💬 |
2057 | T Cell-Depleted Donor Lymphocyte Infusion | - | - | - | - | 1件: 60 60 💬 |
2058 | T-Cell Depleted & CD34+Select/w/StemCell Enriched Product | - | - | - | - | 1件: 65 65 💬 |
2059 | Tacrolimus capsule (low-dose) | 1件: Tacrolimus Tacrolimus | 2件: Tacrolimus
Tacrolimus
,
Tacrolimus
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 227 227 💬 |
2060 | Tailored diet | - | - | - | - | 1件: 66 66 💬 |
2061 | Tamoxifen 40 mg daily for one year | 1件: Tamoxifen Tamoxifen | 1件: Tamoxifen
Tamoxifen
💬 | 2件: ESR1 ESR1, ESR2 💬 | 10件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬 | 1件: 2 2 💬 |
2062 | Tapering or discontinuation of etanercept | 1件: Etanercept Etanercept | 1件: Etanercept
Etanercept
💬 | 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 271 271 💬 |
2063 | Target Sequencing by NGS ( Next-generation sequencing) | - | - | - | - | 1件: 65 65 💬 |
2064 | Targeted synthetic DMARD class | - | - | - | - | 1件: 46 46 💬 |
2065 | TAS5315 high dose | - | - | - | - | 1件: 46 46 💬 |
2066 | TAS5315 low dose | - | - | - | - | 1件: 46 46 💬 |
2067 | Tauroursoursodeoxycholic acid, brand name Tudcabil | - | - | - | - | 1件: 97 97 💬 |
2068 | TCH346 (dibenz[b,f]oxepin-10-ylmethyl-prop-2-ynyl-amine, hydrogen maleate salt) | 1件: Hydrogen Hydrogen | - | - | - | 1件: 6 6 💬 |
2069 | TD-1473 Dose A | - | - | - | - | 1件: 97 97 💬 |
2070 | TD-1473 Dose B | - | - | - | - | 1件: 97 97 💬 |
2071 | TD-1473 Dose C | - | - | - | - | 1件: 97 97 💬 |
2072 | Tears Naturale Forte | - | - | - | - | 1件: 53 53 💬 |
2073 | Tecifdera (dimethyl fumarate) | 1件: Dimethyl fumarate Dimethyl fumarate | 1件: Dimethyl fumarate
Dimethyl fumarate
💬 | 1件: KEAP1 KEAP1 💬 | 6件: Chemical carcinogenesis - reactive oxygen species Chemical carcinogenesis - reactive oxygen species, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Parkinson disease, Pathways in cancer, Ubiquitin mediated proteolysis 💬 | 1件: 13 13 💬 |
2074 | Teduglutide 0.05 dose | 1件: Teduglutide Teduglutide | 1件: Teduglutide
Teduglutide
💬 | 1件: GLP2R GLP2R 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 96 96 💬 |
2075 | Teduglutide 0.1 mg dose | 1件: Teduglutide Teduglutide | 1件: Teduglutide
Teduglutide
💬 | 1件: GLP2R GLP2R 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 96 96 💬 |
2076 | Tenofovir DF | 1件: Tenofovir Tenofovir | 1件: Tenofovir
Tenofovir
💬 | - | - | 1件: 265 265 💬 |
2077 | Tenofovir disoproxil | 2件: Tenofovir Tenofovir, Tenofovir disoproxil | 1件: Tenofovir
Tenofovir
💬 | - | - | 2件: 93 93, 265 💬 |
2078 | Tenofovir Disoproxil Fumarate | 2件: Tenofovir Tenofovir, Tenofovir disoproxil | 1件: Tenofovir
Tenofovir
💬 | - | - | 1件: 265 265 💬 |
2079 | Testosterone decanoate | 2件: Testosterone Testosterone, Testosterone decanoate | 2件: Testosterone
Testosterone
,
Testosterone decanoate
💬 | 1件: AR AR 💬 | 4件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Oocyte meiosis, Pathways in cancer, Prostate cancer 💬 | 1件: 113 113 💬 |
2080 | Tetanus diphtheria toxoid vaccine (Td) | 1件: Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) | - | - | - | 1件: 13 13 💬 |
2081 | Tetanus diphtheria toxoids vaccine | - | - | - | - | 1件: 13 13 💬 |
2082 | Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed) | 3件: Clostridium tetani toxoid antigen (formaldehyde inactivated) Clostridium tetani toxoid antigen (formaldehyde inactivated), Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated), Pertussis vaccine | 1件: Pertussis vaccine
Pertussis vaccine
💬 | - | - | 1件: 46 46 💬 |
2083 | Tetanus, diphtheria, and acellular pertussis vaccine | 1件: Pertussis vaccine Pertussis vaccine | 1件: Pertussis vaccine
Pertussis vaccine
💬 | - | - | 1件: 13 13 💬 |
2084 | Tetrahydro-6,6,9-tri methyl-3-penthyl-6 H-dibenzo[ b,d ]pyran-1-ol | - | - | - | - | 1件: 298 298 💬 |
2085 | TETRAHYDROCANNABINOL Botanical Drug Substance (THC BDS) | 1件: Dronabinol Dronabinol | 1件: Dronabinol
Dronabinol
💬 | 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 13 13 💬 |
2086 | TEV-48574 Dose Regimen A | - | - | - | - | 2件: 96 96, 97 💬 |
2087 | TEV-48574 Dose Regiment B | - | - | - | - | 2件: 96 96, 97 💬 |
2088 | Thalidomide (drug) | 1件: Thalidomide Thalidomide | 1件: Thalidomide
Thalidomide
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 2 2 💬 |
2089 | The 0.5 mL dose of vaccine contains 25 micrograms of each of the following 23 pneumococcal polysaccharide | - | - | - | - | 1件: 222 222 💬 |
2090 | The generic name is warfarin and many producers will be involved | 1件: Warfarin Warfarin | 1件: Warfarin
Warfarin
💬 | 2件: NQO1 NQO1, VKORC1 💬 | 7件: Biosynthesis of cofactors Biosynthesis of cofactors, Chemical carcinogenesis - reactive oxygen species, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Metabolic pathways, Pathways in cancer, Ubiquinone and other terpenoid-quinone biosynthesis 💬 | 1件: 49 49 💬 |
2091 | The investigational medicinal product (IMP) may be labelled as either PF-04236921 106 mg/vial, Clonal SC lyophilized form” or PF-04236921 Powder for Injection, 106 mg/vial”. Supplies labelled with either nomenclature are equivalent. | - | - | - | - | 1件: 96 96 💬 |
2092 | The investigational medicinal product (IMP) will be labeled as PF-04236921 106 mg/vial, Clonal SC lyophilized form, which is equivalent to PF-04236921 Powder for Injection, 106 mg/vial as described in the enclosed CTA | - | - | - | - | 1件: 96 96 💬 |
2093 | The investigational medicinal product (IMP) will be labeled as PF-04236921 106 mg/vial, Clonal SC lyophilized form, which is equivalent to PF-04236921 Powder for Injection, 106 mg/vial as described in the enclosed CTA. | - | - | - | - | 1件: 96 96 💬 |
2094 | The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: | - | - | - | - | 1件: 86 86 💬 |
2095 | The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care: | - | - | - | - | 1件: 86 86 💬 |
2096 | Therapy with disease-modifying anti rheumatic drugs (DMARD) | - | - | - | - | 1件: 46 46 💬 |
2097 | There is no recommended INN | - | - | - | - | 1件: 65 65 💬 |
2098 | Thiotepa--escalated dose | 1件: Thiotepa Thiotepa | 1件: Thiotepa
Thiotepa
💬 | - | - | 4件: 19 19, 20, 65, 284 💬 |
2099 | Thiotepa--single daily dose | 1件: Thiotepa Thiotepa | 1件: Thiotepa
Thiotepa
💬 | - | - | 4件: 19 19, 20, 65, 284 💬 |
2100 | THN102 Dosage A | - | - | - | - | 1件: 6 6 💬 |
2101 | THN102 Dosage B | - | - | - | - | 1件: 6 6 💬 |
2102 | THN102 Dosage C | - | - | - | - | 1件: 6 6 💬 |
2103 | Thymosin Beta 4 eye drops | 1件: Thymosin beta-4 Thymosin beta-4 | - | - | - | 1件: 53 53 💬 |
2104 | Tiamin DAK | - | - | - | - | 1件: 93 93 💬 |
2105 | Time delay treatment of botulinum toxin | - | - | - | - | 1件: 149 149 💬 |
2106 | Timolol nasal spray | 1件: Timolol Timolol | 2件: Timolol
Timolol
,
Timolol
💬 | 2件: ADRB1 ADRB1, ADRB2 💬 | 11件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 227 227 💬 |
2107 | Tiotropium bromide-low dose-2.5mcg | 1件: Tiotropium Tiotropium | - | - | - | 1件: 299 299 💬 |
2108 | TNF-a antagonists, non-TNFs, DMARD non-biologics | - | - | - | - | 2件: 46 46, 271 💬 |
2109 | To be determined | - | - | - | - | 2件: 96 96, 113 💬 |
2110 | TOBI 300 mg / 5 mL nebuliser solution | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
2111 | TOBI 300 mg/5 ml Nebuliser Solution | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
2112 | TOBI 300 mg/5 ml solución para inhalación por nebulizador | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
2113 | TOBI 300 mg/5 ml, solution pour inhalation par nébuliseur | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
2114 | TOBI 300mg/ 5ml solución para inhalación con nebulizador | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
2115 | TOBI 300mg/5mL Nebuliser Solution | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
2116 | Tobi 300mg/5ml Nebuliser solution. | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
2117 | Tobi 300mg/5ml Solución para inhalación por nebulizador. | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
2118 | Tobi Nebcinal | - | - | - | - | 1件: 299 299 💬 |
2119 | TOBI Podhaler 28 mg inhalációs por, kemény kapszula | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
2120 | TOBI*NEBUL 56F 1D 300MG/5ML | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
2121 | TOBI™ Podhaler™ 112 mg inhaled twice daily | - | - | - | - | 1件: 299 299 💬 |
2122 | Tobramycin dry powder | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
2123 | Tobramycin Inhalation Powder TIP delivered by the T-326 Inhaler | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
2124 | Tobramycin inhalation solution using a PARI LC® Plus nebulizer. | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
2125 | Tobramycin nebulized nasally | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
2126 | Tobramycin Steri-Neb 300 mg/5 ml, inhalation solution | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
2127 | Tocilizumab SC 162 mg/0.9 ml disposable auto-injector (AI) | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
2128 | Tocilizumab SC 162 mg/0.9 ml pre-filled syringe with safety device (PFS) | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
2129 | Tocilizumab SC 162 mg/0.9 ml prefilled syringe with safety device (PFS) | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 51 51 💬 |
2130 | Tofacitinib 5 mg twice daily | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 84 84 💬 |
2131 | Tofacitinib citrate (Proposed commercial formulation - debossed) | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 2件: 46 46, 97 💬 |
2132 | Tofacitinib citrate (Proposed commercial formulation debossed) | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 💬 |
2133 | Tofacitinib citrate (Proposed commercial formulation – debossed) | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 2件: 46 46, 97 💬 |
2134 | Tofacitinib citrate (Proposed commercial formulation- debossed) | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 💬 |
2135 | Tofacitinib citrate (Proposed commercialFormulation - debossed) | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 97 97 💬 |
2136 | Tolerogenic dendritic cells | - | - | - | - | 2件: 46 46, 96 💬 |
2137 | Tolerogenic dendritic cells (tolDC) | - | - | - | - | 1件: 13 13 💬 |
2138 | Tolerogenic Dendritic cells loaded with myelin peptides | 1件: Myelin basic protein Myelin basic protein | - | - | - | 1件: 13 13 💬 |
2139 | Top down treatment if patient at high risk | - | - | - | - | 2件: 96 96, 97 💬 |
2140 | Top-down | - | - | - | - | 1件: 96 96 💬 |
2141 | Topical AmphiMatrix with nitroglycerin (MQX-503) | 1件: Nitroglycerin Nitroglycerin | 1件: Nitroglycerin
Nitroglycerin
💬 | - | - | 1件: 51 51 💬 |
2142 | Topical organogel with nitroglycerin | 1件: Nitroglycerin Nitroglycerin | 1件: Nitroglycerin
Nitroglycerin
💬 | - | - | 1件: 51 51 💬 |
2143 | Topiramate (drug) | 1件: Topiramate Topiramate | 1件: Topiramate
Topiramate
💬 | 36件: CA2 CA2, CA4, CACNA1C, CACNA1D, CACNA1F, CACNA1S, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIA1, GRIA2, GRIA3, GRIA4, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | 53件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Arrhythmogenic right ventricular cardiomyopathy, Bile secretion, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Circadian entrainment, Cocaine addiction, Collecting duct acid secretion, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy, Dopaminergic synapse, GABAergic synapse, Gastric acid secretion, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Huntington disease, Hypertrophic cardiomyopathy, Insulin secretion, Long-term depression, Long-term potentiation, MAPK signaling pathway, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Nitrogen metabolism, Oxytocin signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Prion disease, Proximal tubule bicarbonate reclamation, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Spinocerebellar ataxia, Taste transduction, Tight junction, Transcriptional misregulation in cancer, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 6 6 💬 |
2144 | Total Dietary Replacement | - | - | - | - | 1件: 265 265 💬 |
2145 | TP05 Coating D | - | - | - | - | 1件: 97 97 💬 |
2146 | TPN-101, 400 mg/day | - | - | - | - | 2件: 2 2, 127 💬 |
2147 | TPN171H single dose | - | - | - | - | 1件: 86 86 💬 |
2148 | Trade name depends on the source of the product | - | - | - | - | 1件: 76 76 💬 |
2149 | Trade name depends on the source of the product’ | - | - | - | - | 1件: 76 76 💬 |
2150 | Trade Name Xarelto | 1件: Rivaroxaban Rivaroxaban | 1件: Rivaroxaban
Rivaroxaban
💬 | 1件: F10 F10 💬 | 1件: Complement and coagulation cascades Complement and coagulation cascades 💬 | 1件: 49 49 💬 |
2151 | Traditional antirheumatic drugs | - | - | - | - | 1件: 46 46 💬 |
2152 | Trancopal Dolo | - | - | - | - | 1件: 13 13 💬 |
2153 | TransCon PTH high-dose pen | - | - | - | - | 1件: 235 235 💬 |
2154 | TransCon PTH low-dose pen | - | - | - | - | 1件: 235 235 💬 |
2155 | TransCon PTH mid-dose pen | - | - | - | - | 1件: 235 235 💬 |
2156 | Transdermal nicotine | 1件: Nicotine Nicotine | 1件: Nicotine
Nicotine
💬 | 16件: CHRNA1 CHRNA1, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB1, CHRNB2, CHRNB3, CHRNB4, CHRND, CHRNE, CHRNG 💬 | 8件: Alzheimer disease Alzheimer disease, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Virion - Lyssavirus 💬 | 1件: 6 6 💬 |
2157 | Treatment D | - | - | - | - | 1件: 34 34 💬 |
2158 | Treatment defined only by active substance | - | - | - | - | 1件: 50 50 💬 |
2159 | Treatment with systemic therapy (doxycycline) | 1件: Doxycycline Doxycycline | 2件: Doxycycline
Doxycycline
,
Doxycycline
💬 | - | - | 1件: 162 162 💬 |
2160 | Treprosinil Diethanolamine | - | - | - | - | 1件: 86 86 💬 |
2161 | Treprostinil dietanolamina | 1件: Treprostinil Treprostinil | 1件: Treprostinil
Treprostinil
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 💬 |
2162 | Treprostinil diethanolamine | 1件: Treprostinil Treprostinil | 1件: Treprostinil
Treprostinil
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 2件: 51 51, 86 💬 |
2163 | Treprostinil Diolamine | 1件: Treprostinil Treprostinil | 1件: Treprostinil
Treprostinil
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 💬 |
2164 | Triamcinolone Acetonide and normal saline solution | 1件: Triamcinolone Triamcinolone | 1件: Triamcinolone
Triamcinolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 70 70 💬 |
2165 | Trientine Dihydrochloride | 1件: Triethylenetetramine Triethylenetetramine | - | - | - | 2件: 58 58, 171 💬 |
2166 | Trientine dihydrochloride 300mg capsules | 1件: Triethylenetetramine Triethylenetetramine | - | - | - | 1件: 171 171 💬 |
2167 | Triethylenetetramine dihydrochloride | 1件: Triethylenetetramine Triethylenetetramine | - | - | - | 1件: 171 171 💬 |
2168 | Triethylinetetramine dihydrochloride | - | - | - | - | 1件: 58 58 💬 |
2169 | Triheptanoin 1g/kg/day | 1件: Triheptanoin Triheptanoin | 1件: Triheptanoin
Triheptanoin
💬 | - | - | 1件: 8 8 💬 |
2170 | Trimetazidine Dihydrochloride | 1件: Trimetazidine Trimetazidine | 1件: Trimetazidine
Trimetazidine
💬 | - | - | 2件: 2 2, 58 💬 |
2171 | Trimetazidine Dihydrochloride 20mg | 1件: Trimetazidine Trimetazidine | 1件: Trimetazidine
Trimetazidine
💬 | - | - | 1件: 58 58 💬 |
2172 | Triterpene dry extract from birch cork | - | - | - | - | 1件: 36 36 💬 |
2173 | Trivalent chromium versus synthetic and/ or biological DMARDs | 1件: Chromium Chromium | - | - | - | 1件: 46 46 💬 |
2174 | Trulicity 0,75 mg injekcný roztok naplnený v injekcnom pere | 1件: Dulaglutide Dulaglutide | 1件: Dulaglutide
Dulaglutide
💬 | 1件: GLP1R GLP1R 💬 | 3件: Insulin secretion Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 13 13 💬 |
2175 | Trulicity 0,75 mg injekcný roztok naplnený v injekcnom pere. | 1件: Dulaglutide Dulaglutide | 1件: Dulaglutide
Dulaglutide
💬 | 1件: GLP1R GLP1R 💬 | 3件: Insulin secretion Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 13 13 💬 |
2176 | Tryptophan (TRP) depletion | 1件: Tryptophan Tryptophan | 1件: Tryptophan
Tryptophan
💬 | - | - | 1件: 6 6 💬 |
2177 | Tumor Necrosis Factor Inhibitor (etanercept, infliximab, adalimumab, and golimumab) | 4件: Adalimumab Adalimumab, Etanercept, Golimumab, Infliximab | 4件: Etanercept
Etanercept
,
Adalimumab
,
Infliximab
,
Golimumab
💬 | 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
2178 | Tumor Necrosis Factor Inhibitors | - | - | - | - | 1件: 46 46 💬 |
2179 | TVP-1012 (1 mg/day) with levodopa | 1件: Levodopa Levodopa | 1件: Levodopa
Levodopa
💬 | 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2180 | Twice-daily dosage with 0.5% cyclosporine-A eyedrops | 1件: Cyclosporine Cyclosporine | 1件: Cyclosporine
Cyclosporine
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 90 90 💬 |
2181 | TYSABRI 300 mg concentrado para solución para perfusión | 1件: Natalizumab Natalizumab | 1件: Natalizumab
Natalizumab
💬 | 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 💬 |
2182 | TYSABRI 300 mg solution à diluer pour perfusion | 1件: Natalizumab Natalizumab | 1件: Natalizumab
Natalizumab
💬 | 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 💬 |
2183 | Tysabri ® (Natalizumab) | 1件: Natalizumab Natalizumab | 1件: Natalizumab
Natalizumab
💬 | 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 💬 |
2184 | Tysabri® (natalizumab) | 1件: Natalizumab Natalizumab | 1件: Natalizumab
Natalizumab
💬 | 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 💬 |
2185 | UC-MSC+DMARDS | - | - | - | - | 1件: 46 46 💬 |
2186 | Ultra-high-caloric carbohydrate-rich diet | - | - | - | - | 1件: 2 2 💬 |
2187 | Ultra-high-caloric fatty diet | - | - | - | - | 1件: 2 2 💬 |
2188 | Ultrasound-guided Suprascapular Nerve Block | - | - | - | - | 1件: 149 149 💬 |
2189 | Umbilical Cord Derived Mesenchymal Stem Cell (UC -MSC) Transplantation | - | - | - | - | 2件: 93 93, 296 💬 |
2190 | Umbilical cord derived Mesenchymal Stem Cells | - | - | - | - | 1件: 13 13 💬 |
2191 | Umbilical Cord-Derived Mesenchymal Stem Cells (UC-MSCs) | 1件: Human Umbilical Cord Mesenchymal Stem Cells Human Umbilical Cord Mesenchymal Stem Cells | - | - | - | 1件: 46 46 💬 |
2192 | Unrelated BM with T cell depletion | - | - | - | - | 1件: 65 65 💬 |
2193 | Upadacitinib - Direct compression-yellow | 1件: Upadacitinib Upadacitinib | 1件: Upadacitinib
Upadacitinib
💬 | 1件: JAK1 JAK1 💬 | 27件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 97 97 💬 |
2194 | Upadacitinib -Direct compression-yellow | 1件: Upadacitinib Upadacitinib | 1件: Upadacitinib
Upadacitinib
💬 | 1件: JAK1 JAK1 💬 | 27件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 97 97 💬 |
2195 | Ursodeoxycholic acid+Low Dose Glucocorticoid(Methylprednisolone) | 2件: Methylprednisolone Methylprednisolone, Ursodeoxycholic acid | 2件: Methylprednisolone
Methylprednisolone
,
Ursodiol
💬 | 2件: NR1H4 NR1H4, NR3C1 💬 | 2件: Bile secretion Bile secretion, Neuroactive ligand-receptor interaction 💬 | 1件: 93 93 💬 |
2196 | Use of lipid-lowering drugs. | - | - | - | - | 1件: 265 265 💬 |
2197 | Ustekinumab Dose Based on BSA and Body Weight | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 97 97 💬 |
2198 | Ustekinumab IV - Nonresponder - Ustekinumab 90mg SC (MP) | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 96 96 💬 |
2199 | Usual dopaminergic per os treatment | - | - | - | - | 1件: 6 6 💬 |
2200 | UT-15C (treprostinil diethanolamine) | 1件: Treprostinil Treprostinil | 1件: Treprostinil
Treprostinil
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 💬 |
2201 | UT-15C SR (treprostinil diethanolamine) | 1件: Treprostinil Treprostinil | 1件: Treprostinil
Treprostinil
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 💬 |
2202 | Vaccine Vivotif + Vaccine Dukoral | 6件: Recombinant Cholera Toxin B Subunit Recombinant Cholera Toxin B Subunit, Typhoid Vaccine Live, Vibrio cholerae Inaba 48 classical biotype, heat inactivated, Vibrio cholerae Inaba 6973 El Tor biotype, formalin inactivated, Vibrio cholerae Ogawa 50 classical biotype, formalin inactivated, Vibrio cholerae Ogawa 50 classical biotype, heat inactivated | - | - | - | 1件: 97 97 💬 |
2203 | Vaccine Vivotif + Vaccine Dukoral + oats | 7件: Oat Oat, Recombinant Cholera Toxin B Subunit, Typhoid Vaccine Live, Vibrio cholerae Inaba 48 classical biotype, heat inactivated, Vibrio cholerae Inaba 6973 El Tor biotype, formalin inactivated, Vibrio cholerae Ogawa 50 classical biotype, formalin inactivated, Vibrio cholerae Ogawa 50 classical biotype, heat inactivated | - | - | - | 1件: 97 97 💬 |
2204 | VACCINO CONTRO IL MEMINGOCOCCO DI GRUPPO B | - | - | - | - | 3件: 61 61, 62, 66 💬 |
2205 | Vamorolone 0.25 mg/day/day | 1件: Vamorolone Vamorolone | 1件: Vamorolone
Vamorolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 113 113 💬 |
2206 | Vamorolone 0.25 mg/kg/day | 1件: Vamorolone Vamorolone | 1件: Vamorolone
Vamorolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 113 113 💬 |
2207 | Vamorolone 0.75 mg/day/day | 1件: Vamorolone Vamorolone | 1件: Vamorolone
Vamorolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 113 113 💬 |
2208 | Vamorolone 0.75 mg/kg/day | 1件: Vamorolone Vamorolone | 1件: Vamorolone
Vamorolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 113 113 💬 |
2209 | Vamorolone 2.0 mg/day/day | 1件: Vamorolone Vamorolone | 1件: Vamorolone
Vamorolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 113 113 💬 |
2210 | Vamorolone 2.0 mg/kg/day | 1件: Vamorolone Vamorolone | 1件: Vamorolone
Vamorolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 113 113 💬 |
2211 | Vamorolone 4% suspension for oral dosing | 1件: Vamorolone Vamorolone | 1件: Vamorolone
Vamorolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 97 97 💬 |
2212 | Vamorolone 6.0 mg/day/day | 1件: Vamorolone Vamorolone | 1件: Vamorolone
Vamorolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 113 113 💬 |
2213 | Vamorolone 6.0 mg/kg/day | 1件: Vamorolone Vamorolone | 1件: Vamorolone
Vamorolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 113 113 💬 |
2214 | Varenicline Nasal Spray | 1件: Varenicline Varenicline | 1件: Varenicline
Varenicline
💬 | 2件: CHRNA4 CHRNA4, CHRNB2 💬 | 4件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Cholinergic synapse, Neuroactive ligand-receptor interaction, Nicotine addiction 💬 | 1件: 53 53 💬 |
2215 | Variation of behaviors of Parkinson's disease | - | - | - | - | 1件: 6 6 💬 |
2216 | VAY736 higher dose | - | - | - | - | 1件: 53 53 💬 |
2217 | VAY736 lower dose | - | - | - | - | 1件: 53 53 💬 |
2218 | Vector viral adenoasociado de serotipo 9 que contiene el gen de la sulfamidasa humana | - | - | - | - | 1件: 19 19 💬 |
2219 | Vectra DA MBDA Test | - | - | - | - | 1件: 46 46 💬 |
2220 | Vehicle eye drops | - | - | - | - | 1件: 90 90 💬 |
2221 | Vehicle of ADX-102 Topical Dermal Cream | - | - | - | - | 1件: 160 160 💬 |
2222 | Venetoclax MTD with Dexamethasone | 2件: Dexamethasone Dexamethasone, Venetoclax | 2件: Dexamethasone
Dexamethasone
,
Venetoclax
💬 | 2件: BCL2 BCL2, NR3C1 💬 | 44件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Amyotrophic lateral sclerosis, Apoptosis, Apoptosis - multiple species, Autophagy - animal, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Colorectal cancer, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Epstein-Barr virus infection, Estrogen signaling pathway, Fluid shear stress and atherosclerosis, Focal adhesion, Gastric cancer, HIF-1 signaling pathway, Hedgehog signaling pathway, Hepatitis B, Herpes simplex virus 1 infection, Human immunodeficiency virus 1 infection, JAK-STAT signaling pathway, Lipid and atherosclerosis, Measles, MicroRNAs in cancer, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Necroptosis, Neuroactive ligand-receptor interaction, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platinum drug resistance, Prostate cancer, Protein processing in endoplasmic reticulum, Salmonella infection, Shigellosis, Small cell lung cancer, Sphingolipid signaling pathway, Toxoplasmosis, Tuberculosis, p53 signaling pathway 💬 | 1件: 28 28 💬 |
2223 | Verde de Indocianina (Indocyanine Green) | 1件: Indocyanine green Indocyanine green | 1件: Indocyanine green
Indocyanine green
💬 | - | - | 1件: 235 235 💬 |
2224 | Verum arm receiving Vitamin D oil | 1件: Vitamin D Vitamin D | - | - | - | 1件: 13 13 💬 |
2225 | Vidofludimus calcium dihydrate | 2件: Calcium Calcium, Vidofludimus | - | - | - | 1件: 97 97 💬 |
2226 | Vigabatrin: Vigabatrin new ST formulation then Sabril® | 1件: Vigabatrin Vigabatrin | 1件: Vigabatrin
Vigabatrin
💬 | 1件: ABAT ABAT 💬 | 7件: Alanine, aspartate and glutamate metabolism Alanine, aspartate and glutamate metabolism, Butanoate metabolism, GABAergic synapse, Metabolic pathways, Propanoate metabolism, Valine, leucine and isoleucine degradation, beta-Alanine metabolism 💬 | 1件: 145 145 💬 |
2227 | Vinblastine, vincristine, prednisone, daunorubicin | 4件: Daunorubicin Daunorubicin, Prednisone, Vinblastine, Vincristine | 4件: Prednisone
Prednisone
,
Daunorubicin
,
Vinblastine
,
Vincristine
💬 | 12件: NR3C1 NR3C1, TOP2A, TOP2B, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 | 12件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Gap junction, Huntington disease, Neuroactive ligand-receptor interaction, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Platinum drug resistance, Prion disease, Salmonella infection 💬 | 1件: 65 65 💬 |
2228 | Viokase 16 (pancrelipase) + Nexium | 2件: Esomeprazole Esomeprazole, Pancrelipase | 2件: Pancrelipase
Pancrelipase
,
Esomeprazole
💬 | 2件: ATP4A ATP4A, ATP4B 💬 | 4件: Collecting duct acid secretion Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬 | 1件: 298 298 💬 |
2229 | Viral load driven treatment interruption | - | - | - | - | 1件: 265 265 💬 |
2230 | Visilizumab (Nuvion) | 1件: Visilizumab Visilizumab | 1件: Visilizumab
Visilizumab
💬 | 3件: CD3D CD3D, CD3E, CD3G 💬 | 11件: Chagas disease Chagas disease, Epstein-Barr virus infection, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬 | 1件: 97 97 💬 |
2231 | Visilizumab (Nuvion® | 1件: Visilizumab Visilizumab | 1件: Visilizumab
Visilizumab
💬 | 3件: CD3D CD3D, CD3E, CD3G 💬 | 11件: Chagas disease Chagas disease, Epstein-Barr virus infection, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬 | 1件: 97 97 💬 |
2232 | Vit D | - | - | - | - | 1件: 227 227 💬 |
2233 | Vitamin D | 2件: Cholecalciferol Cholecalciferol, Vitamin D | 1件: Cholecalciferol
Cholecalciferol
💬 | 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 20件: 13 13, 19, 41, 43, 44, 46, 49, 50, 68, 93, 95, 96, 97, 179, 222, 228, 235, 274, 298, 299 💬 |
2234 | Vitamin D 100ug | 1件: Vitamin D Vitamin D | - | - | - | 1件: 298 298 💬 |
2235 | Vitamin D 10ug | 1件: Vitamin D Vitamin D | - | - | - | 1件: 298 298 💬 |
2236 | Vitamin D 2 | 1件: Vitamin D Vitamin D | - | - | - | 1件: 46 46 💬 |
2237 | Vitamin D 25(OH)D | 1件: Vitamin D Vitamin D | - | - | - | 1件: 49 49 💬 |
2238 | Vitamin D drops | 1件: Vitamin D Vitamin D | - | - | - | 2件: 96 96, 97 💬 |
2239 | Vitamin D in arm B | 1件: Vitamin D Vitamin D | - | - | - | 1件: 46 46 💬 |
2240 | Vitamin D Oil | 1件: Vitamin D Vitamin D | - | - | - | 1件: 299 299 💬 |
2241 | Vitamin D Powder | 1件: Vitamin D Vitamin D | - | - | - | 1件: 299 299 💬 |
2242 | Vitamin D2 | 1件: Ergocalciferol Ergocalciferol | 1件: Ergocalciferol
Ergocalciferol
💬 | 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 3件: 49 49, 84, 299 💬 |
2243 | Vitamin D2 ( calciferol ) | 2件: Ergocalciferol Ergocalciferol, Vitamin D | 1件: Ergocalciferol
Ergocalciferol
💬 | 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 49 49 💬 |
2244 | Vitamin D3 | 1件: Cholecalciferol Cholecalciferol | 1件: Cholecalciferol
Cholecalciferol
💬 | 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 12件: 6 6, 13, 20, 46, 49, 51, 53, 60, 65, 96, 97, 299 💬 |
2245 | Vitamin D3 - high dose | 1件: Cholecalciferol Cholecalciferol | 1件: Cholecalciferol
Cholecalciferol
💬 | 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 6 6 💬 |
2246 | Vitamin D3 3000 UI daily | 1件: Cholecalciferol Cholecalciferol | 1件: Cholecalciferol
Cholecalciferol
💬 | 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 96 96 💬 |
2247 | Vitamin D3 400 IU | 1件: Cholecalciferol Cholecalciferol | 1件: Cholecalciferol
Cholecalciferol
💬 | 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 49 49 💬 |
2248 | Vitamin D3 4000 UI daily | 1件: Cholecalciferol Cholecalciferol | 1件: Cholecalciferol
Cholecalciferol
💬 | 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 96 96 💬 |
2249 | Vitamin D3 6000 IU | 1件: Cholecalciferol Cholecalciferol | 1件: Cholecalciferol
Cholecalciferol
💬 | 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 49 49 💬 |
2250 | Vitamin D3 800 UI/day then 800 UI/day | 1件: Cholecalciferol Cholecalciferol | 1件: Cholecalciferol
Cholecalciferol
💬 | 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 96 96 💬 |
2251 | Vitamin D3: 3000 or 4000 UI/day then 2,000 UI/day | 1件: Cholecalciferol Cholecalciferol | 1件: Cholecalciferol
Cholecalciferol
💬 | 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 96 96 💬 |
2252 | Vitamin K supplementation, dose #1 | 1件: Phylloquinone Phylloquinone | - | - | - | 1件: 299 299 💬 |
2253 | Vitamin K supplementation, dose #2 | 1件: Phylloquinone Phylloquinone | - | - | - | 1件: 299 299 💬 |
2254 | Vitamina D e calcio | 1件: Calcium Calcium | - | - | - | 1件: 274 274 💬 |
2255 | VITAMINA D3 KERN PHARMA SOLUCIÓN OLEOSA | - | - | - | - | 1件: 13 13 💬 |
2256 | VTX002 is not biologic | - | - | - | - | 1件: 97 97 💬 |
2257 | VWF SD-35-DH | - | - | - | - | 1件: 288 288 💬 |
2258 | VX-121/TEZ/D-IVA | - | - | - | - | 1件: 299 299 💬 |
2259 | VX-121/tezacaftor/deutivacaftor | 2件: Deutivacaftor Deutivacaftor, Tezacaftor | 2件: Tezacaftor
Tezacaftor
,
Deutivacaftor
💬 | 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
2260 | Weancare-domus | - | - | - | - | 1件: 6 6 💬 |
2261 | Wharton's jelly derived mesenchymal stem cell | - | - | - | - | 1件: 90 90 💬 |
2262 | WHARTON’S JELLY DERIVED MESENCHYMAL STEM CELLS | - | - | - | - | 1件: 36 36 💬 |
2263 | WHARTON’S JELLY-DERIVED MESENCHYMAL STEM CELLS | - | - | - | - | 1件: 2 2 💬 |
2264 | Wheat/milk free diet (W/MFD) group | 1件: Wheat Wheat | 1件: Wheat
Wheat
💬 | - | - | 1件: 53 53 💬 |
2265 | Withhold IS (B cell depletion therapy) | - | - | - | - | 7件: 13 13, 35, 46, 49, 50, 51, 107 💬 |
2266 | YONDELIS 0,25 mg polvo para concentrado para solución para perfusión | 1件: Trabectedin Trabectedin | 1件: Trabectedin
Trabectedin
💬 | - | - | 1件: 159 159 💬 |
2267 | YONDELIS 1 mg polvo para concentrado para solución para perfusión | 1件: Trabectedin Trabectedin | 1件: Trabectedin
Trabectedin
💬 | - | - | 1件: 159 159 💬 |
2268 | YRA-1909 high dose | - | - | - | - | 1件: 46 46 💬 |
2269 | YRA-1909 low dose | - | - | - | - | 1件: 46 46 💬 |
2270 | YRA-1909 mid dose | - | - | - | - | 1件: 46 46 💬 |
2271 | Z102 (Prednisolone and Dipyridamole). | 2件: Dipyridamole Dipyridamole, Prednisolone | 2件: Dipyridamole
Dipyridamole
,
Prednisolone
💬 | 3件: NR3C1 NR3C1, PDE4A, PDE5A 💬 | 7件: Metabolic pathways Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action, Purine metabolism, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 46 46 💬 |
2272 | ZGN-440 sterile diluent | - | - | - | - | 1件: 193 193 💬 |
2273 | Zhibo dihuang pills | 1件: Rehmannia glutinosa root Rehmannia glutinosa root | - | - | - | 1件: 76 76 💬 |
2274 | Zinc acetate (20mg/d) | 3件: Acetate Acetate, Zinc, Zinc acetate | 1件: Zinc acetate
Zinc acetate
💬 | - | - | 1件: 299 299 💬 |
2275 | ZINC ACETATE DIHYDRATE | 2件: Acetate Acetate, Zinc acetate | 1件: Zinc acetate
Zinc acetate
💬 | - | - | 1件: 171 171 💬 |
2276 | Zink Natur-Drogeriet | - | - | - | - | 1件: 171 171 💬 |
2277 | ZN-d5 | - | - | - | - | 1件: 28 28 💬 |
2278 | Zofran - no intubation | - | - | - | - | 1件: 98 98 💬 |
2279 | Zolpidem first dose | 1件: Zolpidem Zolpidem | 1件: Zolpidem
Zolpidem
💬 | 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 1件: 6 6 💬 |
2280 | Zolpidem second dose | 1件: Zolpidem Zolpidem | 1件: Zolpidem
Zolpidem
💬 | 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 1件: 6 6 💬 |
2281 | ZX008 - 0.2 mg/kg/day | - | - | - | - | 1件: 140 140 💬 |
2282 | ZX008 - 0.8 mg/kg/day | - | - | - | - | 1件: 140 140 💬 |
2283 | ZX008 0.2 or 0.8 mg/kg/day | - | - | - | - | 1件: 144 144 💬 |
2284 | ZX008 0.2 to 0.8 mg/kg/day | - | - | - | - | 2件: 140 140, 144 💬 |
2285 | ÁCIDO GADOBÉNICO | - | - | - | - | 1件: 96 96 💬 |
2286 | Ácido risedrónico | - | - | - | - | 1件: 274 274 💬 |